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Os-
teoar-
thritis (OA) is a 
disabling joint disease 
with a high prevalence and 
incidence [1]. The numbers of patients 
which are prone to develop osteoarthritis is 
expected to increase due to an ageing population 
in combination with an obesity epidemic [1]. Next to this, 
older people have an enhanced wish for (joint) mobility compared 
to earlier days. To this day, OA treatment includes pain medication 
and lifestyle changes like weight loss and regular exercise. These treatments 
are symptomatic treatments which are not able to durably cure the disease [409]. 
If these conservative measures fail, the fi nal treatment option is joint replacement. 
Unfortunately, joint prostheses have a limited lifespan and as a result they do not 
provide a fi nal solution for OA. For this thesis we studied the working mechanisms 
and effi cacy of two biological treatments as a long term disease modifying osteoar-
thritis drug (DMOAD). As a fi rst treatment we used platelet-rich plasma releasate 
(PRPr) a preparation of bioactive factors indirectly derived from cells. The second 
treatment was cell therapy using bone marrow-derived cells. We hypothesized 
that by using and stimulating one’s own biological repair mechanisms, it would be 
possible to break or slow down the vicious circle of cartilage degeneration that is 
characteristic for OA. 
In chapter 2 we evaluated the potential of PRPr that was isolated by means of 
centrifugation from patients own blood. [111]. Platelets are small cell fragments 
derived from megakaryocytes, containing many bioactive factors. These can 
potentially reduce the effects of infl ammatory mediators on osteoarthritic chon-
drocytes. PRPr inhibited multiple interleukin-1 beta (IL-1 beta) induced effects 
in OA chondrocytes. Addition of PRPr to chondrocytes benefi cially affected 
genes involved in the formation and degradation of extracellular matrix, as well 
as genes related to infl ammation. PRPr diminished IL-1 beta induced inhibition 
of collagen type II (COL2A1) and aggrecan (ACAN) gene expression. These 
are two important genes involved in cartilage matrix formation [410]. PRPr also 
reduced IL-1 beta induced increase of a disintegrin and metalloproteinase 
with thrombospondin motifs (ADAMTS)4 and prostaglandin-endoperoxide 
synthase (PTGS)2 gene expression. The products of these genes are involved 
in cartilage matrix degradation and infl ammation respectively. In order to fi nd 
a possible pathway through which PRPr exerts these effects, we studied the 
effects of PRPr on nuclear factor kappa B (NFkB) activation. NFkB is a protein 
family that controls apoptosis, infl ammation and other immune responses, 
and is thus involved in many pathologic OA processes [96,116,117]. PRPr 
fully counteracted IL-1 beta induced nuclear factor kappa B (NFkB) activation 
back to control levels with no IL-1 beta. 
This study demonstrated the capacity of a combination of bioactive factors 
to alter pathologic processes in OA chondrocytes. This could potentially 
improve the application of PRP in a clinical setting, for instance the timing or 
frequency of administration. A limitation of this study was the use of a single 
pro-infl ammatory factor to induce infl ammation on a single cell-type in a short 
term in vitro model. OA pathophysiology on the other hand, is a complex 
interplay of many factors and tissues with a dynamic and chronic time course 
[82]. Therefore, further in vivo studies are needed to show long term benefi cial 
PRP effects on diseased cartilage or joints as a whole. Next to the limitations 
of our model, another drawback of the use of PRP as an OA treatment is the 
fact that injected biological compounds are known to reside in the joint for 
a limited time-span only [411]. We searched for a way to provide a durable 
presence of disease modifying factors in the joint. Since mesenchymal stem 
cells (MSCs) are able to secrete a broad panel of immunomodulatory factors 
and growth factors, we further focussed on this source of biological treatment 
as a durable DMOAD.
Friedenstein et al. were the fi rst to describe colony-forming cells with osteogenic 
capacities derived from bone marrow [41]. Since then, a vast amount of research 
has been conducted concerning these multi-potent bone marrow-derived cells 
which were later denominated mesenchymal stem cells (MSCs) by Caplan et al. 
[412]. More recently, progenitor cells with a high resemblance to bone marrow-derived 
MSCs have been isolated from many other musculoskeletal tissues and adipose tissue. 
In Chapter 3 we re- viewed the natural presence and characteristics of progenitor cells in various other tissues 
found in the joint, including adipose tissue, periosteum, perichondrium, tendons, ligaments, muscle, cartilage, bone 
and synovial membrane or -fl uid. Cells from these various tissues are generally isolated by mincing the tissue followed 
by enzymatic digestion. In general, these cells have small dissimilarities from one another, but generally are very comparable 
to bone marrow-derived MSCs. Cell yields from these tissues and proliferation capacities of these cells appear to be within the 
same order of magnitude. Furthermore, cells derived from the various musculoskeletal tissues have all been shown to have a multi-
lineage differentiation potential, although they in general do show some preference for differentiating towards the tissue they were originally 
derived from.
Regenerative capacities of local stem cells are based on at least two features. Firstly they have the ability to differentiate into mature tissue 
cells, thereby contributing to new tissue formation [42]. A second, more recently discovered feature of stem cells is the secretion of 
trophic factors that may be responsible for other mechanisms of stem cell-mediated tissue repair [43]. These trophic factors can alter the 
diseased micro-environment towards an anti-infl ammatory and regenerative state. Moreover, these factors are capable of stimulating locally 
present progenitor cells to repair OA damage or by attracting circulating endogenous progenitor cells, thereby further contributing to tissue 
repair [238]. Overall, we concluded that musculoskeletal stem cells derived from various sources posses a huge capacity for application in 
regenerative medicine. Better characterization of musculoskeletal stem cells and more knowledge about lineage differentiation is required to fully 
understand the potential of each individual source of cells for each of the different applications. In this respect, not only differentiation into mature 
tissue cells, but also the secretion of trophic factors and the infl uence of host microenvironment on cell fate and function deserve more study. By 
far, the most knowledge has been gathered concerning bone marrow-derived MSCs. These cells have already been used in more than 100 clinical 
trials [413] without reports of serious adverse side effects. Since one of the main aims of this thesis was to direct our studies towards clinical translation, 
this is the cell-type we chose for our further research.  
Various pre- clinical and some initial clinical studies have already been performed applying intra-articularly injected MSCs to OA joints 
[54,55,237]. Animal studies have shown benefi cial effects of MSCs on cartilage morphology and histology in various OA models 
[47,54,55]. Interestingly, studies using cell tracking in cartilage repair show only limited cartilage formation by chondrogenic differentia-
tion of the injected MSCs [54,55]. Instead, the applied cells are mostly retrieved from other articular structures, such as 
the synovium. Apparently, the intra-articularly injected MSCs only occasionally differentiate into chondrocytes to actively 
produce extracellular matrix. This implies a different OA modifying mechanism, such as the previously mentioned 
paracrine effects of MSCs by secreting bioactive factors. Paracrine effects of MSCs have already been 
demonstrated in other applications including cardiovascular regenerative medicine and organ transplanta-
tion. In these fi elds, factors secreted by MSCs have been shown to increase ventricular function after 
ischemic myocardial injury and to reduce the occurence and severeness of graft versus host 
disease, respectively [414,415]. Whether factors secreted by MSCs are also capable of 
infl uencing osteoarthritic environments was not known. Therefore, in chapter 4, 
we studied the infl uence of MSC-derived factors on OA cartilage and 
synovial explants in vitro. We prepared MSC-conditioned 
medium by stimulating primary human 
MSCs, to se-
crete bioactive factors, with 
tumor necr oduced 
IL-6, hepatocyte growth factor (HGF), tissue inhibitor of MMP (TIMP)2 and transforming gr
and displayed a high enzymatic indoleamine 2,3-dioxygenase (IDO) activity. IDO is an immunomodulatory enzyme with an 
anti-infl ammatory function. Selection of this panel of factors as study targets was based on the fact that they are known to be secreted 
by MSCs at high levels and their known involvement in general infl ammation processes or joint metabolism [250,252]. Synovial explants 
exposed to MSC-conditioned medium showed decreased expression of the infl ammation- or matrix degradation-related genes interleukin-1 
oteinase (MMP)1 and MMP13. On the other hand, the anti-infl ammation-related gene suppressor of cytokine signalling 
(SOCS)1 was upregulated. In cartilage, expression of the anti-infl ammation-related gene IL-1 receptor antagonist (IL-1RA) was upregulated. IL-1RA 
is a competitive non-functional binder to the IL-1 receptor and is already clinically used as a drug (Anakinra) to treat rheumatoid arthritis [416]. In ad-
dition, genes related to matrix degradation (ADAMTS5) as well as matrix formation (COL2A1) were downregulated. Additionally, MSC-conditioned 
medium reduced nitric oxide (NO) production in cartilage explants and the presence of the inhibitor of nuclear factor kappa B a
increased in synoviocytes and chondrocytes tr otein inhibiting the activation of NFkB, a 
protein family controlling apoptosis, infl ammation and other immune responses. Based on these results, we concluded that MSCs in an 
infl ammatory environment secrete factors which cause multiple anti-infl ammatory effects and infl uence genes involved in matrix turnover 
in OA synovium and cartilage explants. 
A limitation of our study, as in our PRP studies, was the use of a short term in vitro culture model to evaluate the 
paracrine effects of MSCs. We did use a more complex in vitro model than the one used in chapter 2 by 
performing experiments on cartilage and synovium as well as a pilot experiment where we combined both 
tissues in the same model. In this way, we resembled more closely the in vivo situation. Nevertheless, 
further in vivo studies are needed to demonstrate the effi cacy of MSC injection as a treatment for 
OA. Next to the use of an in vitro model, another limitation of our study was the need to stimulate 
MSCs with supra-physiological concentrations of infl ammatory factors in order to initiate an 
immunomodulatory function. Whether the level of infl ammatory and catabolic factors in OA 
joints in-vivo is suffi cient to elicit a regenerative response in MSCs remains to be elucidated, 
although we recently investigated in-vitro effects of bioactive factors in synovial fl uid of 
OA patients on MSC immunomodulation. In this study, we found that synovial fl uid 
upregulated the expression of genes in MSCs with an anti-infl ammatory function and 
that synovial fl uid stimulated MSCs to condition medium in a way that suppressed lym-
phocyte proliferation in vitro [417]. MSC-conditioned medium undoubtedly contained 
many more factors than the ones we have measured in chapter 4. The whole panel 
of bio-active factors probably worked in concert to achieve the anti-osteoarthritic 
effects observed in this study. Several anti-infl ammatory effects could be caused 
by the direct secretion of anti-infl ammatory factors by MSCs, or by their infl uence 
on macrophages and the subsequent effect on their secretion of immunomodula-
tory factors [418]. Next to these MSC-secreted bioactive factors, it has more 
recently been shown that the regenerative potential of MSCs might be related 
to cellular transfer of mitochondria and other cytosolic elements [419,420]. 
The anti-osteoarthritic effect of this aspect has to be further studied using 
different in-vitro models. Since we observed clear paracrine effects of MSCs 
and given that intra-articularly injected MSCs have been shown to survive in 
an intra-articular environment for up to at least four to six weeks [54,55], we 
believe that they could provide the ultimate long term delivery of a cocktail of 
OA modifying elements.
Osteoarthritis 
(OA) is a disabling 
joint disease with a 
high prevalence and 
incidence [1]. The numbers 
of patients which are prone 
to develop osteoarthritis is 
expected to increase due 
to an ageing population 
in combination with an 
obesity epidemic [1]. Next 
to this, older people have 
an enhanced wish for 
(joint) mobility compared to 
earlier days. To this day, 
OA treatment includes 
pain medication and 
lifestyle changes like weight 
loss and regular exercise. 
These treatments are 
symptomatic treatments 
which are not able 
to durably cure the 
disease [409]. If these 
conservative measures fail, 
the fi nal treatment option 
is joint replacement. 
Unfortunately, joint 
prostheses have a limited 
lifespan and as a result they 
do not provide a fi nal solution 
for OA. For this thesis 
we studied the working 
mechanisms and effi cacy of 
two biological treatments as a 
long term disease modifying 
osteoarthritis drug (DMOAD). 
As a fi rst treatment we used 
platelet-rich plasma releasate 
(PRPr) a preparation of bioac-
tive factors indirectly derived 
from cells. The second 
treatment was cell therapy 
using bone marrow-derived 
cells. We hypothesized that by 
using and stimulating one’s own 
biological repair mechanisms, it 
would be possible to break or 
slow down the vicious circle of 
cartilage degeneration that is 
characteristic for OA. 
In chapter 2 we evaluated the 
potential of PRPr that was isolated 
by means of centrifugation from 
patients own blood. [111]. Platelets 
are small cell fragments derived 
from megakaryocytes, containing 
many bioactive factors. These can 
potentially reduce the effects of 
infl ammatory mediators on osteoar-
thritic chondrocytes. PRPr inhibited multiple 
interleukin-1 beta (IL-1 beta) induced effects 
in OA chondrocytes. Addition of PRPr to 
chondrocytes benefi cially affected genes 
involved in the formation and degradation of 
extracellular matrix, as well as genes related 
to infl ammation. PRPr diminished IL-1 beta 
induced inhibition of collagen type II (COL2A1) 
and aggrecan (ACAN) gene expression. These 
are two important genes involved in cartilage 
matrix formation [410]. PRPr also reduced IL-1 
beta induced increase of a disintegrin and metal-
loproteinase with thrombospondin motifs (ADAMTS)4 
and prostaglandin-endoperoxide synthase (PTGS)2 
gene expression. The products of these genes are 
involved in cartilage matrix degradation and infl ammation 
respectively. In order to fi nd a possible pathway through 
which PRPr exerts these effects, we studied the effects of 
PRPr on nuclear factor kappa B (NFkB) activation. NFkB is a 
protein family that controls apoptosis, infl ammation and other immune 
responses, and is thus involved in many pathologic OA processes 
[96,116,117]. PRPr fully counteracted IL-1 beta induced nuclear factor kappa 
B (NFkB) activation back to control levels with no IL-1 beta. 
This study demonstrated the capacity of a combination of bioactive factors 
to alter pathologic processes in OA chondrocytes. This could potentially 
improve the application of PRP in a clinical setting, for instance the 
timing or frequency of administration. A limitation of this study 
was the use of a single pro-infl ammatory factor to 
induce infl ammation on a single cell-type in a short 
term in vitro model. OA pathophysiology on 
the other hand, is a complex interplay 
of many factors and tissues 
with a dynamic and chronic 
time course [82]. Therefore, 
further in vivo studies are 
needed to show long 
term benefi cial PRP 
effects on diseased 
cartilage or joints as 
a whole. Next to 
the limitations 
of our model, 
another 
drawback of 
the use of 
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ing factors in 
the joint. Since 
mesenchymal 
stem cells (MSCs) 
are able to 
secrete a broad panel of 
immunomodulatory factors and growth 
factors, we further focussed on this source 
of biological treatment as a durable DMOAD.
Friedenstein et al. were the fi rst to describe 
colony-forming cells with osteogenic capacities 
derived from bone marrow [41]. Since then, a vast 
amount of research has been conducted concerning 
these multi-potent bone marrow-derived cells which 
were later denominated mesenchymal stem cells (MSCs) 
by Caplan et al. [412]. More recently, progenitor cells with a high 
resemblance to bone marrow-derived MSCs have been isolated from many other 
musculoskeletal tissues and adipose tissue. In Chapter 3 we reviewed the natural presence 
and characteristics of progenitor cells in various other tissues found in the joint, including adipose 
tissue, periosteum, perichondrium, tendons, ligaments, muscle, cartilage, bone and synovial membrane 
or -fl uid. Cells from these various tissues are generally isolated by mincing the tissue followed by enzymatic 
digestion. In general, these cells have small dissimilarities from one another, but generally are very comparable to 
bone marrow-derived MSCs. Cell yields from these tissues and proliferation capacities of these cells appear to be 
within the same order of magnitude. Furthermore, cells derived from the various musculoskeletal tissues have all been 
shown to have a multi-lineage differentiation potential, although they in general do show some preference for differentiating 
towards the tissue they were originally derived from.
Regenerative capacities of local stem cells are based on at least two features. Firstly they have the ability to differentiate into 
mature tissue cells, thereby contributing to new tissue formation [42]. A second, more recently discovered feature of stem cells is the secretion 
of trophic factors that may be responsible for other mechanisms of stem cell-mediated tissue repair [43]. These trophic factors can alter 
the diseased micro-environment towards an anti-infl ammatory and regenerative state. Moreover, these factors are capable 
of stimulating locally present progenitor cells to repair OA damage or by attracting circulating 
endogenous progenitor cells, thereby further contributing to tissue repair [238]. 
Overall, we concluded that musculoskeletal stem cells derived 
from various sources posses a huge capacity 
for application in regenerative 
medicine. Better characterization of 
musculoskeletal stem cells and more 
knowledge about lineage differentiation 
is required to fully understand the 
potential of each individual source of 
cells for each of the different applications. 
In this respect, not only differentiation into 
mature tissue cells, but also the secretion 
of trophic factors and the infl uence of host 
microenvironment on cell fate and function 
deserve more study. By far, the most 
knowledge has been gathered concerning bone 
marrow-derived MSCs. These cells have already 
been used in more than 100 clinical trials [413] 
without reports of serious adverse side effects. Since 
one of the main aims of this thesis was to direct our 
studies towards clinical translation, this is the 
cell-type we chose for our further research.  
Various pre-clinical and some initial clinical studies 
have already been performed applying intra-
articularly injected MSCs to OA joints [54,55,237]. Animal 
studies have shown benefi cial effects of MSCs on cartilage 
morphology and histology in various OA models 
[47,54,55]. Interestingly, studies using cell tracking in 
cartilage repair show only limited cartilage formation by 
chondrogenic differentiation of the injected MSCs [54,55]. 
Instead, the applied cells are mostly retrieved from 
other articular structures, such as the synovium. 
Apparently, the intra-articularly injected MSCs 
only occasionally differentiate into chondrocytes 
to actively produce extracellular matrix. This implies 
a different OA modifying mechanism, such as the 
previously mentioned paracrine effects of MSCs 
by secreting bioactive factors. Paracrine effects of 
MSCs have already been demonstrated in other 
applications including cardiovascular regenerative 
medicine and organ transplantation. In these fi elds, factors 
secreted by MSCs have been shown to increase ventricular 
function after ischemic myocardial injury and to reduce the 
occurence and severeness of graft versus host disease, respectively 
[414,415]. Whether factors secreted by MSCs are also capable of 
infl uencing osteoarthritic environments was not known. Therefore, in chapter 
4, we studied the infl uence of MSC-derived factors on OA cartilage and synovial 
explants in vitro. We prepared MSC-conditioned medium by stimulating primary human MSCs, to 
secrete bioactive factors, with tumor necr on  
produced IL-6, hepatocyte growth factor (HGF), tissue inhibitor of MMP (TIMP)2 and transforming gr
a high enzymatic indoleamine 2,3-dioxygenase (IDO) activity. IDO is an immunomodulatory enzyme with an anti-infl ammatory function. Selection of 
this panel of factors as study targets was based on the fact that they are known to be secreted by MSCs at high levels and their known involvement in 
general infl ammation processes or joint metabolism [250,252]. Synovial explants exposed to MSC-conditioned medium showed decreased expression of the infl am-
mation- or matrix degradation-r oteinase (MMP)1 and MMP13. On the other hand, the anti-infl ammation-related 
gene suppressor of cytokine signalling (SOCS)1 was upregulated. In cartilage, expression of the anti-infl ammation-related gene IL-1 receptor antagonist (IL-1RA) 
was upregulated. IL-1RA is a competitive non-functional binder to the IL-1 receptor and is already clinically used as a drug (Anakinra) to treat rheumatoid arthritis [416]. 
In addition, genes related to matrix degradation (ADAMTS5) as well as matrix formation (COL2A1) were downregulated. Additionally, MSC-conditioned medium reduced 
nitric oxide (NO) production in cartilage explants and the pr s increased in synoviocytes and chondrocytes treated with 
otein inhibiting the activation of NFkB, a protein family controlling apoptosis, infl ammation and other immune responses. Based on these results, we 
concluded that MSCs in an infl ammatory environment secrete factors which cause multiple anti-infl ammatory effects and infl uence genes involved in 
matrix turnover in OA synovium and cartilage explants. 
A limitation of our study, as in our PRP studies, was the use of a short term in vitro culture model to evaluate the paracrine effects of MSCs. We did use 
a more complex in vitro model than the one used in chapter 2 by performing experiments on cartilage and synovium as well as a pilot experiment where we combined both tissues in the same model. In this way, we 
resembled more closely the in vivo situation. Nevertheless, further in vivo studies are needed to demonstrate the effi cacy of MSC injection as a treatment for OA. Next to the use of an in vitro model, 
another limitation of our study was the need to stimulate MSCs with supra-physiological concentrations of infl ammatory factors in order to 
initiate an immunomodulatory function. Whether the level of infl ammatory and catabolic 
factors in OA joints in-vivo is suffi cient to elicit a regenerative response in MSCs remains to be 
elucidated, although we recently investigated in-vitro effects of bioactive factors in synovial fl uid 
of OA patients on MSC immunomodulation. In this study, we found that 
synovial fl uid upregulated the expression of genes in MSCs with 
an anti-infl ammatory function and that synovial 
fl uid stimulated MSCs to condition 
medium in a way 
that suppressed 
lymphocyte 
proliferation in vitro [417]. 
MSC-conditioned medium 
undoubtedly contained many 
more factors than the ones we 
have measured in chapter 4. The 
whole panel of bio-active factors 
probably worked in concert to 
achieve the anti-osteoarthritic 
effects observed in this study. 
Several anti-infl ammatory 
effects could be caused 
by the direct secretion of 
anti-infl ammatory factors 
by MSCs, or by their 
infl uence on macrophages 
and the subsequent effect 
on their secretion of 
immunomodulatory factors 
[418]. Next to these 
MSC-secreted bioactive 
factors, it has more 
recently been shown 
that the regenerative 
potential of MSCs 
might be related to 
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Osteoarthritis (OA) is a disabling joint disease affecting over 10% of individuals aged 60 
years or older [1]. In a study from 2007, prevalence of OA in the Netherlands was esti-
mated to be around 650,000 patients [2]. OA involves the entire joint and is character-
ized by inflammation and catabolic processes, leading to progressive cartilage damage 
[3]. Current treatments include pain medication, lifestyle changes such as weight loss 
and regular exercise, and ultimately joint replacement. Pain medication and lifestyle 
changes are symptomatic treatments which are not able to cure the disease. Joint 
replacement is a good option for many OA patients, but unfortunately joint prosthe-
ses have a limited lifespan and as a result they do not provide a final solution for OA. 
Regenerative medicine therapies are promising approaches to modify the pathologic 
processes associated with OA and other musculoskeletal diseases [4]. Regenerative 
medicine aims at replacing or regenerating human cells, tissues or organs to restore or 
establish normal function. This goal can be achieved by replacing damaged tissue or 
by stimulating the body’s own repair mechanisms to heal tissues or organs with poor 
self-repair capacity. Regarding regenerative medicine, a lot can be learned from other 
organisms. Probably the most striking example of musculoskeletal regeneration is the 
regrowth of an entire limb, after it has been traumatically amputated, in a salamander 
[5]. This classic example unfortunately doesn’t apply to humans, but growth factors and 
stem cells are indispensable in physiological tissue homeostasis and regeneration after 
musculoskeletal tissue injury
In this thesis we studied the efficacy and working mechanisms of biological treatments 
for OA. Two biological treatments that are currently under extensive investigation are 
platelet-rich plasma (PRP), a preparation of concentrated, platelet-derived bio-active 
factors isolated from blood, and mesenchymal stem cells (MSCs). Both these treat-
ments have possibilities to influence the degenerative joint environment characteristic of 
OA. Therefore, the aim of this thesis is to evaluate and improve the effects of biological 
treatments to inhibit progressive joint damage. To this aim, we studied the effects of 
PRP and MSCs on multiple inflammatory, anabolic and catabolic processes throughout 
the joint in in vitro models as well as small animal models.
Osteoarthritis 
Osteoarthritis (OA) represents the most widespread cause of physical morbidity and 
impaired quality of life throughout the industrialized world [6]. The disease causes pain 
and joint stiffness that can severely impair daily activities. OA is a chronic and progres-
sive disease of the joint with multifactorial etiology that amongst others can involve age, 
preceding trauma, obesity, female gender and genetic predisposition [7]. Many simul-
taneous processes take place in OA, including cartilage breakdown, subchondral bone 








direct cell-cell contact or via the cellular secretion of bioactive factors. Many of these 
processes are not only reactive to the degenerative joint environment, but they result in 
degradation products or compounds which induce further inflammatory and catabolic 
effects by itself [8]. Thereby, these processes contribute to a vicious degenerative circle, 
which characterizes progressive joint damage [9,10].
Cartilage
Articular cartilage limits friction and allows for efficient load bearing and distribution 
in synovial joints. Cartilage contains one cell-type, the chondrocyte, which produces 
the extracellular matrix (ECM). Chondrocytes account for approximately 5% of the wet 
weight of cartilage, the ECM for 25% and water for the remaining 70% [11]. The most 
abundant protein in the ECM is collagen type II, which represents around 60-80% of 
the dry weight of cartilage, followed by approximately 20-30% of glycosaminoglycans 
(GAGs). The collagen molecules form an organized network, defining the shape and 
tensile strength of the cartilage. The hydrophilic proteoglycans are intertwined in this 
collagen network and are responsible for the high water content of articular cartilage. 
Cartilage is avascular, aneural and lacks lymphatic drainage [12]. These factors con-
tribute to the fact that natural repair mechanisms are underprovided, giving cartilage a 
very limited intrinsic regenerative capacity [13]. As a result, cartilage lesions are prone 
to progress to OA and the cartilage damage in OA progresses over time [14,15]. Mac-
roscopically, cartilage degeneration is displayed as fibrillations and fissures in the ar-
ticular surface and partial or complete erosion of the tissue. Cartilage breakdown at the 
molecular level is mediated by the presence of inflammatory and catabolic mediators, 
together with a diminished synthetic function of chondrocytes, a reduced responsive-
ness to anabolic growth factors or even chondrocyte death [16,17,18]. 
Bone
Bone alterations present as osteophyte formation and subchondral bone sclerosis in 
late stage OA. Osteophytes are abnormal outgrowths of bone occurring in joints. The 
formation of osteophytes is not completely understood, but their presence is classi-
cally related to joint degeneration [19]. The involvement of the subchondral bone in 
the pathogenesis of osteoarthritis has become more evident during the last decade 
[10]. The underlying bone undergoes dynamic changes, leading to loss of bone in early 
stages and increased bone formation in late stages of the disease [20]. Although the 
interaction of cartilage and bone is not fully elucidated, it has been demonstrated that 
both mechanical interactions as well as the exchange of bioactive factors play a role 
[21]. 
Synovium
Synovium is a thin membrane lining the inside of the joint which produces synovial 
fluid, the “lubricant” of the joint. Next to this, synovium contains high numbers of mac-






by, the synovium is primarily involved in joint inflammation. Inflammation manifests as 
an elevation of inflammatory cytokines in synovial fluid and increased synovial thick-
ness resulting from synovial hyperplasia together with infiltration of inflammatory cells 
[22,23,24]. The synovium produces multiple inflammatory and catabolic factors in the 
joint, including interleukin-1 and tumor necrosis factor alpha [25]. Factors secreted by 
osteoarthritic synovium have been shown to reduce chondrogenic differentiation of 
MSCs [26]. In cartilage explants, these factors increase GAG breakdown and diminish 
GAG production [25,27]. In later stages of OA the synovium can become fibrotic [23], 
contributing to stiffening of the joint. 
Osteoarthritis therapies
Current OA therapies
Current treatments for OA mainly aim at treating symptoms of the disease, not at a du-
rable way of modifying osteoarthritic pathologic processes. Therapeutic options include 
life-style changes, physical therapy, a variety of pain medications and ultimately surgical 
intervention like joint replacement. Hyaluronic acid, glucosamine sulfate and chondroi-
tin sulfate have more recently been postulated as symptom relieving pharmaceuticals 
which might also have structural OA modifying effects, but efficacy of these drugs on 
pain reduction as well as on structural alterations remain debated [28]. 
Platelet-rich plasma
Due to the complexity and dynamic character of OA, biological treatments appear very 
appealing. Biological treatments can likewise provide a high complexity and versatility 
in effects, thereby engaging in many different processes simultaneously. Platelet-rich 
plasma (PRP) is blood plasma enriched with platelets. Platelets are irregularly shaped 
cell fragments derived from precursor megakaryocytes, and contain many growth fac-
tors. Thereby, PRP is an autologous preparation of concentrated bioactive factors, 
which can be easily derived from blood by centrifugation. Previous animal studies and 
some preliminary clinical studies have evaluated the efficacy of single growth factors in 
modifying OA processes [29,30,31,32]. PRP on the other hand, provides a multitude 
of growth factors which could orchestrate together to interfere with and adjust many 
pathological processes simultaneously. The growth factors in PRP encompass vascular 
endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and transform-
ing growth factor-beta (TGF-beta) [33]. Initial clinical studies show promising effects of 
intra-articular PRP injections as an OA treatment, although these studies were very pre-
liminary and not randomized double blind placebo-controlled trials [34,35,36]. Next to 
this, the basic fundamental evidence for PRP as an OA treatment is rather limited. Some 
studies have shown anabolic effects of PRP on cell proliferation [37,38], but possible 








not studied. Further insight in the working mechanism and anti-osteoarthritic effects is 
warranted for additional optimization and broad clinical application.
Mesenchymal stem cells
Mesenchymal stem cells (MSCs) represent another biological therapeutic option which 
is considered a promising alternative for an OA modifying treatment [39]. Stem cells play 
a vital role in physiological tissue homeostasis and regeneration after tissue injury [40]. 
MSCs were initially found in the bone marrow [41], but at present cells with a high re-
semblance to these MSCs have been found in many musculoskeletal and other tissues, 
such as fat tissue. MSCs have the potential to differentiate into multiple lineages, such 
as the adipogenic, osteogenic and chondrogenic lineage [42]. Thereby, they provide a 
very suitable source of cartilage forming cells. Next to this differentiation potential, more 
recent studies have indicated the capacity of MSCs to alter their microenvironment via 
secretion of so-called trophic factors, which might play an even more important role in 
tissue repair [43,44]. These factors could possibly counteract inflammatory and catabol-
ic aspects of OA and attract endogenous repair cells. MSCs are able to survive in vivo 
and secrete trophic factors for a longer period of time, which could be advantageous 
over PRP which provides only a short term delivery of growth factors to the joint. By 
providing a more durable presence of growth factors, a long term modification of patho-
logic OA processes is possible. Next to the advantage of duration of therapeutic effi-
cacy, MSCs are normally present in healthy and diseased joints. Moreover, they are able 
to react to the joint environment as shown before by the increased presence of MSCs 
in synovium and synovial fluid after mechanical joint injury in an animal OA model as 
well as a clinical study concerning intra-articular ligament injury [45,46]. This indicates 
that MSCs respond to stimuli after articular damage and suggests that the increased 
intra-articular presence of MSCs is part of a natural healing process. The administration 
of additional MSCs in an osteoarthritic joint could be a therapy for OA, mimicking and 
enhancing this healing process and thereby provide a natural, long term and tailor made 
treatment for OA. Animal studies have indicated some positive effects of intra-articularly 
injected MSCs on cartilage morphology in various joint damage models [47,48,49,50,5
1,52,53,54,55,56,57]. Even some clinical studies report the feasibility and safety of this 
therapy, although in these initial studies nothing could be said about efficacy [58,59]. In 
order to further optimize this therapy and to be able to translate it to a broad clinical OA 
setting, more insight in the fate and function of the MSCs and their effects on multiple 






Evaluating cell fate and function of MSC therapy
Cell tracking is an invaluable tool for determining the efficacy and safety of cell based 
regenerative therapies. By using different techniques, cell-tracking could give insight 
into the distribution, survival and even function of applied cells. Intra-articularly applied 
cells are found up to four weeks after injection, but their numbers dramatically decrease 
in this time-period [50,51,56]. Unraveling their survival and working mechanism gives 
tremendous options for further optimization of cell-based therapies. Many modalities 
for cell visualization exist, including histology, optical imaging and magnetic resonance 
imaging (MRI) [60,61]. Cell labeling using superparamagnetic iron oxide (SPIO) particles 
allows in vivo cell tracking using MRI. This technique has the main advantage that only 
clinically applied compounds are used for cell labeling, and it has already entered the 
clinical arena in non-orthopedic fields [62,63,64]. Before implementing this approach to 
an orthopedic application, it has to be tailored to intra-articular use in terms of safety 








and cell traceability. Relevant safety issues include the influence of SPIO on cell viability, 
cell differentiation and MSC secretion profile. Regarding cell traceability it is important 
to ensure accurate intra-articular visualization and distinction from other joint structures, 
together with quantification of labeled cells. If we would know where the cells go to in 
the joint and what they exactly do, we could improve for instance the mode or timing of 
intra-articular application. This way, these techniques could be used to further optimize 
cellular therapies by evaluating adjustments to increase cell survival or functionality. 
Optimizing cellular OA therapies
Several aspects of MSCs as a regenerative therapy are already known from other fields, 
which could hamper the use of MSCs as a durable, disease modifying osteoarthritic 
drug (DMOAD). Isolating and culturing MSCs is a costly and time-consuming proce-
dure requiring special expertise and facilities. This aspect is a slight drawback in an 
experimental setting, but is a huge shortcoming in order to accomplish broad clinical 
application once therapeutic efficacy has been established. By using allogeneic MSCs, 
cells from one single, well-characterized donor could be used for multiple patients. This 
would considerably reduce the total costs per patient, realizing a higher cost-effec-
tiveness of the therapy. Another option would be to use freshly isolated bone marrow 
mononuclear cells, the cell fraction from bone marrow containing MSCs [65,66]. This 
cell fraction can be isolated in a one-step procedure, in that way making costly culturing 
procedures redundant. 
Next to the cell-type being used, the mode of application could also be used to optimize 
cell therapies. Cells injected intravenously have been shown to be removed from the 
body within 24h, while MSC administered in tissues like muscle, spine, and fat pads 
remain present locally up to several weeks [67]. The joint is known to be an immune 
privileged and sealed-off compartment, which likely beneficially affects cell survival and 
their retention [68]. Still, expectedly, improving cell survival will increase the duration of 
advantageous therapeutic effects. Cell encapsulation in alginate beads could be a way 
to protect cells from the host immune system, but at the same time allow them to fulfill 
their regenerative role. This enables an increase in longevity and intra-articular presence 
of the cells and thereby an increase in durability of therapeutic efficacy. Evaluating these 
effects on joint integrity and various osteoarthritic processes is a necessary feed-back 






Aim and outline of this thesis
The aim of this thesis was to elucidate the effects of PRP and MSCs on multiple OA 
related processes. Additionally, we aimed to develop a method to track cells in vivo to 
evaluate their fate in future studies. 
In chapter 2 we studied the capacity of an autologous preparation of bioactive factors 
to reduce the effects of an inflammatory mediator on osteoarthritic chondrocytes. The 
growth factor preparation we used was platelet-rich plasma releasate, which contains 
many growth factors. Platelets are small cell fragments derived from megakaryocytes 
and can be isolated from blood by means of centrifugation. In chapter 3 we reviewed 









the presence and characteristics of mesencymal progenitor cells in various musculo-
skeletal tissues. These cells provide a renewable cell source for physiological tissue 
homeostasis and regeneration after musculoskeletal tissue injury. The progenitor cells 
from different musculoskeletal tissues have small dissimilarities from one another, but in 
general are very alike the bone marrow derived MSCs further discussed in this thesis. 
In chapter 4 we determined at which level MSCs were able to secrete a panel of fac-
tors and whether the total of MSC-secreted factors was able to exert anti-inflammatory 
and anti-catabolic effects on osteoarthritic cartilage and synovium in-vitro. In chapter 
5 we determined the effects of MSCs, as well as freshly isolated bone marrow mono-
nuclear cells, on several OA aspects in a rat OA model in-vivo. We used these differ-
ent cell-types in order to enhance clinical translatability, and evaluated their effects on 
pain, structural damage and inflammation. In chapter 6 we compared ferucarbotran to 
ferumoxides, both superparamagnetic iron oxides (SPIOs), for cell labeling in order to 
track them with magnetic resonance imaging (MRI). Both SPIOs have different physical 
properties and different techniques for labeling non-phagocytic cells, resulting in differ-
ent amounts of endocytosed SPIO. We selected the best technique and SPIO based 
on these studies and in chapter 7 we determined several aspects regarding safety and 
MRI traceability in order to use this technique in-vivo in an intra-articular environment. 
Since limited cell survival might be one of the aspects compromising long term effects 
of cell therapies, we studied a method to increase their longevity after intra-articular 
application. In chapter 8 we encapsulated MSCs in alginate beads to see if this would 
enable a long-lasting interplay between MSCs and an inflammatory environment. The 
alginate beads are permeable to small soluble factors as secreted by MSCs and dis-
eased tissues, yet they can protect MSCs from hostile interactions with the immune 
system. In chapter 9 and 10 we discuss and summarize the findings of this thesis and 
elaborate on directions for future studies in order to translate MSC application towards 
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Background: Platelet-rich plasma (PRP) has recently been postulated as a treatment for 
osteoarthritis (OA). Although anabolic effects of PRP on chondrocytes are well docu-
mented, no reports are known addressing effects on cartilage degeneration. Since OA 
is characterized by a catabolic and inflammatory joint environment, we studied whether 
PRP was able to counteract the effects of such an environment on human osteoarthritic 
chondrocytes. 
Methods: Human OA chondrocytes were cultured in the presence of IL-1 beta to mimic 
an osteoarthritic environment. Medium was supplemented with 0%, 1% or 10% PRP 
releasate ([PRPr] the active releasate of PRP). After 48 hours, gene expression of col-
lagen type II alpha 1 (COL2A1), aggrecan (ACAN), a disintegrin and metalloproteinase 
with thrombospondin motifs (ADAMTS)4, ADAMTS5, matrix metalloproteinase (MMP)13 
and prostaglandin-endoperoxide synthase (PTGS)2 was analyzed. Additionally, glycos-
aminoglycan (GAG) content, nitric oxide (NO) production and nuclear factor kappa B 
(NFkB) activation were studied.
Results: PRPr diminished IL-1 beta induced inhibition of COL2A1 and ACAN gene 
expression. PRPr also reduced IL-1 beta induced increase of ADAMTS4 and PTGS2 
gene expression. ADAMTS5 gene expression and GAG content were not influenced 
by IL1-beta or additional PRPr. MMP13 gene expression and NO production were 
upregulated by IL-1 beta but not affected by added PRPr. Finally, PRPr reduced IL-1 
beta induced NFkB activation to control levels containing no IL-1 beta.
Conclusion: PRPr diminished multiple inflammatory IL-1 beta mediated effects on 
human osteoarthritic chondrocytes, including inhibition of NFkB activation. NFkB acti-
vation is a major pathway involved in the pathogenesis of OA. These results encourage 














































Articular cartilage provides a low friction and efficient load bearing joint surface. Car-
tilage is an avascular and aneural tissue without lymphatic drainage, and has a very 
limited intrinsic regenerative capacity[13]. Osteoarthritis (OA) is a degenerative joint 
disease, characterized by an imbalance of anabolic and catabolic processes in syno-
vial joints[69]. This imbalance results in progressive cartilage damage and ultimately 
patient disability. In order to stimulate repair processes by endogenous cells, platelet-
rich plasma (PRP) has recently been under extensive investigation[70,71,72]. PRP is 
a plasma preparation that can be obtained from whole blood, having an increased 
platelet concentration above baseline[73]. Platelets contain various organelles, includ-
ing α granules. These granules hold numerous growth factors and other bioactive pro-
teins, including vascular endothelial growth factor (VEGF), platelet-derived growth factor 
(PDGF) and transforming growth factor-beta (TGF-beta ), many of which play a pivotal 
role in hemostasis or tissue healing[33]. Upon activation, platelets are triggered to re-
lease these growth factors to the injured site to stimulate various healing processes. 
PRP can be produced by centrifugation of autologous blood, making PRP a highly 
concentrated, natural and autologous treatment option for a variety of regenerative 
medicine fields[74]. Several pre-clinical and clinical studies using PRP as a treatment for 
OA have been performed, reporting promising results[75,76,77,78]. Unfortunately, no 
randomized controlled clinical trials regarding this subject have been reported, thereby 
limiting the level of current evidence of benefit for PRP-based treatment of OA. Eluci-
dating the working mechanisms of PRP in a standardized in vitro environment could 
provide tools to further optimize these therapies. Several studies have previously de-
scribed the effects of PRP on chondrocytes in an in vitro model[37,38,79,80,81]. These 
studies did not evaluate PRP primarily as a treatment option, but mainly as a culture 
additive in standard in vitro conditions. They describe without exception a stimulating 
effect of PRP on cell proliferation, although the effects on the maintenance of a chon-
drogenic phenotype were less concordant. However, to evaluate PRP as a therapy for 
OA, the in vitro environment has to simulate the in vivo situation. The joint environment 
in OA has shifted towards the catabolic side at the moment patients require medical 
care. Therefore, the emphasis may well be better directed toward understanding not 
only the anabolic effects, but also the effects of PRP on prevention of degeneration in 
an osteoarthritic environment. Interleukin (IL)-1 beta is one of the most potent inflam-
matory factors in osteoarthritic joints. This cytokine has been described to induce the 
production of destructive proteases together with the inhibition of extracellular matrix 
formation[82,83]. Treating cells with IL-1 beta has been reported to be a useful model to 
reproduce the mechanisms involved in degenerative arthropathies[84]. IL-1 beta exerts 
its effects through a diverse spectrum of signaling cascades, including nuclear factor 
kappa B (NFkB) activation[84,85]. NFkB is normally located in an inactivated state in the 
cytosol bound to IκB, an inhibitory protein. Upon activation NFkB translocates to the 






other immune responses[86]. In order to determine the effects of PRP in a standardized 
inflammatory environment, we studied the capacity of PRP releasate ([PRPr] the active 
releasate of PRP) to counteract IL-1 beta induced effects on genes involved in matrix 
formation and degradation in osteoarthritic chondrocytes, including NFkB as a possible 
pathway through which these effects occurred.
Materials and methods 
PRP releasate preparation
Anticoagulated whole blood from three healthy male donors was acquired (Sanquin 
Blood Supply Foundation, Amsterdam, the Netherlands) after informed consent. Whole 
blood was further processed within two hours after collection. PRP was prepared by 
means of a GPS® III System (kindly provided by Biomet Nederland BV, Dordrecht, the 
Netherlands) according to the manufacturer’s protocol. Clotting upon addition of 22.8 
mM CaCl2 1:10 (v/v) activated platelets to release their growth factors. Supernatant 
was collected and designated PRP releasate (PRPr). Baseline platelet, white blood cell 
and red blood cell concentrations of whole blood, PRP and PRPr were measured on 
a clinical Sysmex XE-2100 automated hematology system (Sysmex Europe, Norder-
stedt, Germany). PRPr was subsequently stored in aliquots of 1.5 ml at -80◦C for further 
experiments and growth factor analyses. Cryopreservation has been reported before 
to maintain the ability of PRPr to influence chondrocyte behavior[37]. Baseline VEGF, 
PDGF-AA, PDGF-AB/BB in PRPr were measured by means of a MILLIPLEX (Millipore 
BV, Amsterdam, the Netherlands) and TGF-beta 1 using the human TGF-ß1 Immuno-
assay Quantikine® (R&D Systems, Abingdon, UK). Two dilutions of the samples were 
measured for growth factor analyses. The measurements that were best in the range of 
the standard are reported. 
Chondrocyte culture with PRP releasate
Human OA cartilage from six donors was obtained from patients undergoing total knee 
replacement surgery (after implicit consent, as approved by the local ethical commit-
tee; MEC-2004-322). Full thickness cartilage was harvested, treated with 0.2% pro-
tease (Sigma-Aldrich,Zwijndrecht, Netherlands) in physiological saline solution for 90 
minutes and subsequently digested overnight in standard culture medium (DMEM con-
taining 10% FCS, 50 µg/mL gentamicine and 1.5 µg/mL fungizone) supplemented with 
0.15% collagenase B (Roche Diagnostics, Mannheim, Germany). Following digestion, 
cells were washed twice with physiologic saline and the harvested cell number was 
determined using a hemocytometer. Alginate beads were prepared as described previ-
ously[87]. In short, chondrocytes were suspended in 1.2% low viscosity alginate (Kel-
tone LV; Kelco, Surrey, UK) at a concentration of four million cells/ml. Beads were cre-













































solution. Chondrocytes in alginate beads were cultured in standard culture medium 
as described above, supplemented with 1x10-4 M ascorbic acid-2-phosphate (Sigma-
Aldrich, St. Louis, MO). After pre-culturing chondrocytes in alginate beads for 3 weeks 
to allow extracellular matrix formation, beads were washed three times with serum-
free DMEM. Subsequently, beads were placed in serum free culture medium (DMEM 
containing ITS+1 1:100 (v/v), 50 µg/ml gentamicin, 1.5 µg/ml fungizone and 1x10-4 M 
ascorbic acid-2-phosphate) with or without 10ng/ml IL-1 beta and the addition of PRPr 
at concentrations of 0, 1 and 10% (v/v). After 48 hours of culture, beads were harvested 
for gene expression analyses. 48 hours of culture has been described previously as a 
suitable time point to study the effects of IL-1 beta and various treatments on chondro-
cyte behavior[84,88]. Additionally, beads were harvested for glycosaminoglycan (GAG) 
and DNA analyses and medium was harvested for nitric oxide and GAG analysis. 
Gene expression analysis
Alginate beads were dissolved in 55 mM sodium citric acid and spun down at 350G 
for 8 minutes at a temperature of 4 ◦C. Cell pellets were resuspended in RNA-BeeTM 
(TEL-TEST, Friendswood, TX). RNA was extracted with chloroform and purified from 
the supernatant using the RNAeasy Micro Kit (Qiagen, Hilden, Germany), according 
to the manufacturer’s guidelines with on-column DNA digestion. Nucleic acid content 
was determined spectrophotometrically (NanoDrop ND1000; Isogen Life Science, IJs-
selstein, The Netherlands). Complementary DNA (cDNA) synthesis was performed using 
a RevertAid™First Strand cDNASynthesis Kit (MBI Fermentas, St. Leon-Rot, Germany), 
and polymerase chain reactions (PCRs) were performed using TaqMan® Universal PCR 
MasterMix (Applied Biosystems, Capelle a/d IJssel, the Netherlands) as described ear-
lier[89]. RT-PCR primers for collagen type II alpha 1 (COL2A1), aggrecan (ACAN), a dis-
integrin and metalloproteinase with thrombospondin motifs (ADAMTS)4, ADAMTS5 and 
matrix metalloproteinase (MMP)13 are reported by Uitterlinden et al[90]. Prostaglandin-
endoperoxide synthase (PTGS)2 gene expression was determined using a commercial 
assay-on-demand set (Hs01573474.g1, Applied Biosystems, Capelle a/d IJssel, the 
Netherlands). GAPDH, HPRT and beta 2-microglobulin were compared as housekeep-
ing genes. Relative expression levels, normalized to GAPDH as the most stably ex-
pressed of the three reference genes (data not shown), were calculated using the 2-ΔΔCt 
method[91]. 
Glycosaminoglycan and DNA assay
Glycosaminoglycan (GAG) analysis was performed by a dimethylmethylene blue (DMB) 
assay. Alginate beads were digested overnight at 60 ◦C in papain buffer (250 µg/ml 
papain in 50 mM EDTA and 5 mM L-cysteine). Glycosaminoglycan (GAG) amount in 
the digest was quantified using a modified dimethylmethylene blue (DMB) assay[92], 
based on the original description by Farndale et al.[93]. The metachromatic reaction 
of GAG with DMB was monitored using a spectrophotometer, and the ratio A530 : 






C (Sigma-Aldrich, Zwijndrecht, the Netherlands) as a standard. The amount of DNA in 
each papain-digested sample was determined using ethidium bromide with calf thymus 
DNA (Sigma-Aldrich, Zwijndrecht, the Netherlands) as a standard. 
Nitric oxide assay
Nitric oxide (NO) production was determined by quantifying its derived product, nitrite, 
in medium using a spectrophotometric method based upon the Griess reaction[94]. 
Briefly, 100 µl of culture medium was mixed with 100 µl of Griess reagent (0.5% sulpha-
nilamide, 0.05% naphtyl ethylenediamine dihydrochloride, 2.5% H3PO4). A serial dilution 
of sodium nitrite (NaNO 2, Fluka, Buchs, Switzerland) was used as a standard. The ab-
sorption was measured at 540 nm.
NFkB 
To evaluate the involvement of NFkB activation in the working mechanism of PRPr, 
freshly isolated chondrocytes were seeded in monolayer at a density of 20,000 cells/
cm2. Cells were precultured in basal medium in 48-well plates until subconfluency. A 
preliminary study revealed one hour of IL-1 beta incubation to be the optimal moment 
to evaluate NFkB activation (data not shown), confirming a previous study by Largo et 
al.[85]. Cells were cultured for one hour in the presence or absence of IL-1 beta and 
PRPr at concentrations of 0, 1 and 10% (v/v) and subsequently fixed in formalin 4%. 
All conditions were simultaneously fixed per donor. Fixation was followed by incubation 
with NFkB-p65 Antibody (Ab-276) 1:100 (Signalway Antibody, Leusden, the Nether-
lands) and goat-anti rabbit AP 1:20 (Sigma, St. Louis, MO, USA). Freshly prepared new 
fuchsin was used as substrate to achieve staining. Negative controls were performed 
using an IgG isotype control. Staining was performed synchronously for all conditions 
per donor. The percentage of positive cells was determined by two independent observ-
ers by scoring three times 100 cells/well. All separate values from both observers were 
used for statistical analysis. 
Statistical analysis 
Experiments were performed in triplicate samples for all three PRPr donors on two 
separate chondrocyte donors each (six chondrocyte donors in total). NFkB immuno-
histochemistry was performed for all three PRPr donors on single chondrocyte donors. 
Statistical analysis was performed using a mixed model ANOVA, in which treatment 
was considered a fixed factor and donor a random factor. The effects of IL-1 beta and 

















































































































































































































































































































































































































































































Baseline platelet concentration and growth factor analyses
Whole blood samples contained physiological values of platelets, white blood cells and 
red blood cells for all three donors. PRP contained on average 6.04 – 7.75 times more 
platelets than whole blood (Table 1). White blood cells increased in a comparable man-
ner (5.87 – 7.24 fold increase), while red blood cell counts decreased. After activating 
the PRP by clotting, platelet numbers were decreased to 0.15 – 0.83 times the baseline 
value of whole blood levels. Next to this, the clotting procedure decreased white blood 
cells to 0.48 – 1.27 times baseline and red blood cell count to 0.03 – 0.07 times base-
line whole blood level. The growth factors PDGF-AA, PDGF-AB/BB, TGF-beta 1 were 
abundantly present in PRPr from all three donors (values listed in Table 1). VEGF was 
found in a lower amount on average and was below detection level in one donor. 
PRPr diminishes  IL-1 beta effects on chondrocyte gene expression 
The addition of the inflammatory cytokine IL-1 beta diminished expression of COL2A1 
and ACAN in chondrocytes, while it increased expression of ADAMTS4, MMP13 and 
PTGS2 (Fig. 1, P<0.03 for all genes). Upon addition of 10% PRPr, COL2A1gene ex-
pression increased compared to IL-1 beta only treated samples (P=0.003) as well as 
ACAN (P=0.001), while ADAMTS4 expression was reduced (P=0.001) as was PTGS2 
(P=0.004). The addition of 1% PRPr to our cultures revealed a trend towards normal-
izing COL2A1 and ADAMTS4 expression, although these results did not reach statistical 
significance. MMP13 expression was not changed by PRPr, whereas ADAMTS5 was 
not influenced by the presence of IL-1 beta or additional PRPr. 
Without the addition of IL-1 beta to our cultures, PRPr did not significantly affect COL2A1 
gene expression compared to the control containing no PRPr, while ACAN showed a 
significant downregulation after the addition of 1% and 10% PRPr (P ≤ 0.003 for both). 
ADAMTS4 and MMP13 were significantly upregulated by 10% PRPr (P ≤ 0.002 for 
both), whereas ADAMTS5 was downregulated by 10% PRPr (P = 0.002).  PTGS2 was 
not influenced by PRPr in the absence of IL-1 beta. 
PRPr effects on GAG and NO production 
Neither IL-1 beta nor simultaneous addition of PRPr showed an effect on amount of 
GAG per cell in our experiments (Fig. 2). Next to this, no effects were seen on GAG 
release in the medium, DNA content per bead or total GAG per bead (data not shown). 
Moreover, PRPr did not alter any of these parameters in the absence of IL-1 beta (data 
not shown). We also determined the effect of PRPr on nitric oxide (NO) production in 
IL-1 beta treated chondrocyte cultures. PRPr was unable to counteract the IL-1 beta 
induced production of this inflammatory mediator (Fig. 3). In the absence of IL-1 beta, 














































Figure 1. Effects of PRPr on OA chondrocyte gene expression.
PRPr reduced IL-1 beta effects on COL2A1, ACAN, ADAMTS4 and PTGS2 gene expression. No PRPr 
effects were seen on ADAMTS5 or MMP13 in the presence of IL-1 beta. Without the addition of IL-1 
beta, PRPr downregulated ACAN gene expression and ADAMTS5, while ADAMTS4 and MMP13 were 
upregulated. PRPr did not alter COL2A1 or PTGS2 gene expression in the absence of IL-1 beta. Gene 
expression was normalized to GAPDH. Data are presented as means ± standard deviations for 6 
experiments.  * indicates P<0.05 compared to control without IL-1 beta, # indicates P<0.05 compared 






PRPr reduces IL-1 beta induced NFkB activation
In order to determine a possible mechanism through which PRPr exerts its effects, 
we studied the effect of PRPr on NFkB activation using immunohistochemistry. This 
revealed NFkB activation in our IL-1 beta treated chondrocytes, which was reduced 
by PRPr (Fig 3A-C). Manually scoring these cells showed IL-1 beta to cause a marked 
increase in NFkB activated chondrocytes (Fig 3D, P=0.001). This activation was down-
regulated by PRPr (P<0.001 for both doses) in a dose dependent manner. The highest 
concentration of PRPr (10%) reduced the amount of NFkB activated chondrocytes back 
to control levels.
Discussion
In this study we tested our hypothesis that PRPr has anti-inflammatory properties and 
influences gene expression of extracellular matrix forming and degrading proteins in an 
OA mimicking environment. The osteoarthritic and inflammatory environment was creat-
ed through addition of IL-1 beta, one of the key players in OA pathogenesis[82,83,84,95], 
to chondrocytes in culture. Exposure of chondrocytes to the inflammatory cytokine IL-1 
beta resulted in marked changes in the expression of genes involved in matrix formation 
and degradation as well as inflammation, many of which were reduced by the addition 
of PRPr. PRPr ameliorated the IL-1 beta induced changes on chondrocyte gene expres-
sion of COL2A1, ACAN, ADAMTS4 and PTGS2. The inhibition of NFkB activation was 
found to be a possible mechanism through which PRPr exerted these effects.
Figure 2: Influence PRPr on GAG/DNA and NO in the presence of IL1-beta. 
No effects on GAG per cell were found by IL-1 beta or additional PRPr. IL-1 beta increased NO release 
by chondrocytes, additional PRPr did not alter this. Data are shown relative to control as means ± 













































Various research groups have studied the use of PRP mainly as a culture supplement 
for chondrocytes. A consistent finding in their reports is that PRP increases cell prolif-
eration[37,38,79,80,81]. In contrast, some describe an increased gene expression or 
synthesis of COL2A1 and ACAN upon PRP addition[37,38], while others mention PRP 
to decrease these parameters[79,80,81]. We consider these contradicting reports and 
our own results using PRP in the absence of IL-1 beta to hinder a clear statement re-
garding the use of PRP as a culture supplement for chondrocytes. A major difference 
between these previous reports and the focus of our current study is the fact that we did 
not evaluate PRPr as a culture additive, but aimed at establishing the potential of PRP 
as a possible treatment for OA. For this application, PRP should preferably restore the 
anabolic-catabolic imbalance found in OA joints. By applying PRPr to OA chondrocytes 
in a standardized IL-1 beta mediated inflammatory and catabolic environment, our re-
sults indicated consistent anti-inflammatory effects of PRP.
Figure 3: Impact of PRPr on NFkB activation in the presence of IL1-beta. 
NFkB immunohistochemistry showing IL-1 beta treated chondrocytes in the absence of PRPr (A) and 
the presence of 10% PRPr (B). (C) represents IgG control. Dotted arrows in (A) resemble negative cells, 
whereas solid arrows in (B) indicate NFkB activated cells. IL-1 beta induced NFkB activation, which 
was dose-dependently reduced by PRPr (D). Data are presented as means ± standard deviations for 3 
experiments. Magnification (A-C): 200 x.  * indicates P<0.05 compared to control without IL-1 beta, # 






PRP inhibited the translocation of NFkB to the nucleus. NFkB is present as an inactive, 
inhibitor-bound complex in almost all mammalian cells and gets translocated into the 
nucleus upon activation [96]. NFkB regulates more than 150 genes, including those 
involved in inflammation and other immune responses[97]. In chondrocytes, NFkB has 
been reported to inhibit COL2A1 gene expression and to regulate MMP-1, MMP-3, 
MMP13, IL-8 and MCP-1 expression[96]. Several pharmacologic agents act as NFkB 
inhibitors, including non-steroidal anti-inflammatory drugs, glucocorticoids and protea-
some inhibitors[98,99,100]. NFkB inhibition by PRP has been recently reported in a 
human immortalized chondrocyte cell line[101]. We were able to confirm the latter result 
using primary human osteoarthritic chondrocytes, thereby providing a link towards clini-
cal application.
NO production is increased in OA joints, and has been described to inhibit collagen and 
GAG synthesis, while inducing chondrocyte apoptosis and the production of metal-
loproteinases[102,103,104,105,106]. Vuolteenaho et al. previously reported that both 
TGF-beta  and an NFkB inhibitor decreased IL-1 beta induced NO production by im-
mortalized murine chondrocytes[107]. IL-1 beta induced an evident increase in NFkB 
activation and NO production in our experiments, but PRPr only counteracted the first 
effect. TGF-beta was abundantly present in our PRPr, and the amount of TGF-beta  in 
the condition where we used 10% PRPr exceeded those used by Vuolteenaho et al. 
The different origin of our cells or the heterogeneity and multitude of growth factors 
present in PRP, affecting many regulatory pathways, could be possible explanations for 
the fact that we did not observe an inhibitory effect of PRPr on NO production. Although 
PRP could be a promising autologous treatment option with many applications, this 
heterogeneity and multitude of growth factors in PRP substantially limits the ability to 
understand and investigate the effects of PRP. This could also explain the different PRP 
mediated effects we observed in an environment with versus without IL-1 beta. 
A limitation of our study is the use of a short term in vitro model to study PRP as a possi-
ble OA treatment.  In our model we did not detect catabolic effects of IL-1 beta on GAG 
content at a protein level, although we observed clear downregulation of ACAN gene 
expression and upregulation of the aggrecanase gene ADAMTS4 indicating IL-1 beta 
did evoke inflammatory effects. Previous studies from our group did reveal an IL-1 beta 
effect on GAG content of constructs of immature bovine chondrocytes in alginate[108]. 
These bovine chondrocytes had a substantial higher GAG turnover than the human 
cells used in this present study. This difference could be due to the fact that we used 
human osteoarthritic chondrocytes from relatively aged donors. The lower overall GAG 
turnover of human chondrocytes in our culture model could be masking IL-1 beta and 
PRP effects after 48 hours.  Furthermore since PRP derived growth factors may not all 
have their optimal effect in an in vitro model, further in vivo studies are needed to show 













































The use of PRP as a highly concentrated autologous source of growth factors has 
gained wide acceptance in various applications, such as orthopaedic surgery, otolar-
yngology and plastic surgery[109]. Due to the biological nature of these PRP products, 
inter-donor variability in the amount of platelets and growth factors is known to occur 
[33,71]. This was also seen in our PRP preparations, especially in the variation of VEGF 
concentration. Anitua et al. reported this finding before and mentioned a correlation 
between VEGF and platelet concentration[110], which is in line with our findings. De-
spite these variations, we found consistent anti-inflammatory effects of PRPr from three 
donors on OA chondrocytes from six donors. Next to this donor variation, multiple 
platelet- or growth factor concentration methods are available[111,112]. These different 
methods isolate diverse blood fractions with different platelet yields and with or without 
red and white blood cells[111,113]. All these dissimilarities complicate the comparison 
of results between different research groups. Therefore, caution has to be taken into 
account regarding safety and efficacy when considering the translation of PRP as an OA 
treatment into clinical studies.   
We obtained PRP with an approximately 6.8 fold platelet increase above baseline. The 
amount of growth factors found in PRPr was comparable to those reported by oth-
ers[114,115]. PRPr inhibited multiple IL-1 beta induced effects in OA chondrocytes. It 
beneficially affected genes involved in the formation and degradation of extracellular 
matrix, as well as genes related to inflammation. Additionally, PRPr diminished IL-1 beta 
induced NFkB activation, a mechanism known to be involved in many pathologic OA 
processes[96,116,117]. Revealing the relevant mechanisms and processes could im-
prove the application of PRP in a clinical setting. Although additional studies are needed 
before proceeding to clinical translation, we consider these encouraging results for the 
further study of PRP as a conservative, autologous and low-cost treatment for OA. 
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Probably the most striking example of musculoskeletal regeneration is the growing of 
an entire limb by a salamander, after it is traumatically amputated. This classic example 
unfortunately doesn’t apply to humans, but (local) stem cells are indispensable in pro-
viding a renewable cell source for physiological tissue homeostasis and regeneration 
after musculoskeletal tissue injury. Stem cells have been isolated from the following 
musculoskeletal tissues: bone marrow, adipose tissue, periosteum, perichondrium, ten-
dons, ligaments, muscle, cartilage, bone and synovial membrane or -fluid. We chose to 
refer to these cells as mesenchymal progenitor cells (MPCs). Cells from these different 
tissues are generally isolated by mincing the tissue followed by enzymatic digestion. 
Overall, the cells are positive for CD44, CD90, CD105, (CD146), CD166 and STRO-1 
and negative for CD31, CD34, CD45 and CD117. On the whole, cell yields from these 
tissues and proliferation capacities of these cells appear to be within the same order of 
magnitude. Cells derived from the various musculoskeletal tissues have all been shown 
to have a multi-lineage differentiation potential, although they do show differentiation 
preferences, in general for differentiating towards the tissue they were originally derived 
from. Regenerative capacities of local stem cells are based on two characteristics. In 
the first place, they have the ability to differentiate into mature tissue cells, thereby con-
tributing to new tissue formation. As a second quality, local stem cells secrete trophic 
factors that may be responsible for another mechanism of stem cell-mediated tissue 
repair. These trophic factors are capable of attracting (more) stem cells to the damaged 
area and they can play an immunomodulatory role. Musculoskeletal stem cells posses 
















Regeneration of tissues happens on a daily basis throughout our lives. For many years 
scientist have been trying to elucidate this process, which is delicately regulated by 
molecular and cellular events. The growing of an entire limb by a salamander after its 
traumatic amputation is one of the most remarkable examples of musculoskeletal re-
generation. This process is called epimorphosis, and is characterised by cellular dedif-
ferentiation and proliferation at the wound site [5]; Local mesenchymal cells lose their 
phenotype, start proliferating as blastemal cells followed by redifferentiation in order 
to form the tissues required for the newly formed limb [5]. This example, which is very 
appealing to one’s imagination, regrettably doesn’t relate to humans. Still, (local) stem 
cells are indispensable in providing a renewable cell source for physiological tissue ho-
meostasis and regeneration after tissue injury [40]. In the 1960s, the work of Alexander 
Friedenstein demonstrated that mesenchymal stem cells (MSCs) are locally present in 
the bone marrow of adults [41]. More recently, it became clear that most specialized 
tissues in the body contain a local pool of stem- or progenitor cells. Local stem- or 
progenitor cells can be derived from all musculoskeletal tissues and show quite some 
resemblances to bone marrow derived MSCs (BMSCs) [118,119,120]. A multitude of 
nomenclature to denote these cells is being used in literature. For this chapter we will 
refer to them as local Mesenchymal Progenitor Cells (MPCs) that are present in the tis-
sues of the musculoskeletal system. 
Different properties and functions can be appointed to MPCs. To review them we will 
subsequently describe the following aspects:
- Derivation: overview of MPCs derived from various musculoskeletal tissues.
- Characteristics and properties: markers, yield and proliferation, ageing and senes-
cence.
- Regenerative capacity: differentiation of MPCs and the secretion of trophic factors 
that can influence tissue regeneration.
- Potential applications: in vivo animal and clinical results regarding tissue regenera-







The musculoskeletal system consists of many different tissues. MPCs have been iso-
lated from the following mesenchymal tissues: bone marrow [42], adipose tissue [121], 
muscle [122], cartilage [123], synovial membrane or -fluid [46,124], periosteum/peri-
chondrium [125,126], tendons/ligaments [127,128] and bone [129] (Figure 17.1). Cells 
derived from these various tissues have different specific characteristics and capacities, 
but they also display many similarities. The main common feature of these various cell 
populations is that they all have the potential to differentiate into multiple mesodermal 
lineages. A brief description of the various tissue sources for MPCs is given below.
Bone marrow 
BMSCs are the most extensively studied musculoskeletal MPCs. BMSCs are non-hema-
topoietic cells that reside in the bone marrow. They were first described by Friedenstein 
et al., as clonal, plastic adherent cells, functioning as a source of the osteoblastic, ad-
ipogenic and chondrogenic cell 
lineages [130].BMSCs play an 
important role in the bone mar-
row’s microenvironment [131]. 
The main function of MSCs in the 
bone marrow is to create a tissue 
framework, serving as mechani-
cal support for the hematopoietic 
cell system. For further specifics 
on BMSCs we refer to the pre-
vious chapter where BMSCs are 
extensively discussed. 
Adipose tissue
Adipose tissue is derived from 
the mesenchyme and contains 
a supportive stroma. Zuk et al. 
were the first to report the iso-
lation of multi-potent stem cells 
from this stromal fraction of adi-
pose tissue [132]. We would like 
to mention specifically the pos-
sibility to harvest local fat from 
fatpads in the joint. These stuc-
tures have been demonstrated to 
contain MPCs [133,134]. A clear 
advantage of this cell population 
Figure 1:  Local mesenchymal progenitor cells (MPCs) can 
be derived from all these musculoskeltal tissues. Liga-
ments and perichondrium are not shown in this image, but 















is their ready accessibility and the excellent availability of large quantities of tissue that 
can be harvested. Also for further specifics of this cell population we refer to the previ-
ous chapter. 
Muscle 
Roughly two MPC groups can be found in adult muscle tissue: satellite cells (which are 
considered uni-potent stem cells) and multi-potent muscle-derived stem cells. Satellite 
cells were first described in 1963. Satellite cells comprise a heterogenous cell popula-
tion that resides under the basal lamina which surrounds muscle fibres [135]. Within this 
heterogenous cell population a Pax7 positive sub-population can be identified which is 
called the “typical” satellite cell [136] Adult muscle satellite cells can give rise to transient 
amplifying cells (progenitors) and myoblasts. These myoblasts fuse with myofibres and 
play a principal role in postnatal skeletal muscle growth and regeneration [137]. The 
multi-potent muscle-derived stem cells (also referred to as skeletal muscle side popula-
tion) have been discovered more recently. These cells comprise a more homogenous 
cell population that is less abundant in adult muscle [138]. These cells play a role during 
muscle homeostasis and regeneration. While they do posses multi-lineage differentia-
tion potential, these skeletal muscle side population cells display a distinct preference 
for myogenic differentiation. 
Cartilage
Articular cartilage is an avascular, aneural tissue of a stiff but compressible nature. The 
density of cells present in cartilage is very low, and cell mobility is limited through the 
surrounding matrix. The lack of vascularisation and innervation together with a low cell 
density and the relative immobility of the cells in cartilage, are the reasons why cartilage 
has a very low capacity for self-repair [123]. In general, cartilage defects caused by 
trauma or mechanical wear, tend to further degenerate instead of regenerate. Various 
studies have shown that the superficial zone of articular cartilage regulates cartilage de-
velopment and growth [139,140]. The first report describing isolation of a population of 
stem/progenitor cells from the superficial zone dates from 2004 [141]. Recently, Koelling 
et al. reported on the isolation of a population of progenitor cells from repair tissue of 
late stage human osteoarthritic cartilage which could not be isolated from healthy car-
tilage [142]. These cells possessed characteristics of clonogenicity, multipotency and 
migratory activity. Although most studies regarding cartilage derived progenitor cells 
comprise articular cartilage, other cartilage types such as meniscus [118] and interver-
tebral discs [143,144] contain progenitor cells as well.  
Synovium and synovial fluid
Cells present in the synovium produce synovial fluid that functions as a joint lubricant. 
The synovium is a thin (2 to 3 cell layers thick) membrane lining the non-articular joint 
surfaces, thereby providing a synovial fluid-filled cavity around the cartilage [124]. De Bari 






in 2001 [145]. Various names have been used for describing stem- or progenitor cells 
derived from the synovium, including synovium-derived stem cells, synovium-derived 
MSCs, and synovial progenitor cells. Interestingly, synovial MPCs can be generated 
from healthy synovium but also from rheumatoid- and osteoarthritis patients [146,147].
The number of MPC/stem cells in synovial fluid increases after trauma and these cells 
have been hypothesized to be important in repair of intra-articular structures after injury. 
For instance, the number of colony forming cells in synovial fluid was reported to be a 
100-fold higher in knees several weeks after injury of the anterior cruciate ligament than 
in knees from healthy volunteers [46]. These cells are likely to originate from the synovial 
membrane, since there is a positive correlation between intra-articular synovial frag-
ments and the number of MPCs in synovial fluid [148]. Moreover, MPCs locally present 
in the synovium were found to proliferate in response to damage in an animal OA model 
[45]. The injured tissues can attract MSC from this source to the synovial fluid by the 
secretion of cytokines and chemokines such as stromal cell-derived facor-1 (SDF-1), 
CXCR4 or VEGF [149]. 
Periosteum and perichondrium  
These cells are amongst the first musculoskeletal tissues that have been used to regen-
erate bone and cartilage. The first report describing the osteogenic function of perios-
teum dates from 1742 [150] and Fell et al. were the first to describe culturing and isola-
tion of periosteum cells in 1932 [151]. Periosteum as well as perichondrium contains a 
so-called cambium layer, which is attached to the bone and cartilage respectively. This 
cambium layer contains cells, capable of proliferating in order to form new tissue. The 
periosteum and perichondrium plays a role in cartilage or bone remodelling during the 
skeletal growth period and during repair after wounding. 
Tendon and ligament
In their biological function, tendons and ligaments mainly transmit tensile forces. Per 
definition, tendons form the link between a muscle belly and a bone, while ligaments 
attach bone to bone [152]. Ligaments are composed of the same basic components 
as tendons, although differences do exist to provide the specific mechanical properties 
needed for their tasks. For instance, the collagen fibrils in ligaments are not uniformly 
parallel oriented, in order to allow for multi-axial loading patterns [152]. The primary unit 
of a tendon or a ligament is the collagen fiber. This extracellular matrix is produced by 
the tissue cells that lie between the collagen fibers [153]. An intriguing feature of tendon 
is its possible plasticity. Conversion of tendon into cartilage has been observed as a 
consequence of (non)surgical trauma [154,155]. Various tendons and ligaments, includ-
ing cruciate ligaments, periodontal ligaments and patellar- and hamstring tendons, have 
















Bone and bone marrow are physically virtually co-localized. Local MPCs have been 
demonstrated to grow out of trabecular bone fragments, either with or without enzy-
matically digesting the fragments [158,159]. Since the close anatomical relationship 
between these cells and BMSCs, a definitive statement about whether these cells arise 
from a different source is difficult to make. Furthermore, MPCs derived from trabecular 
bone become virtually identical to bone marrow derived MSCs upon subcultivation for 
approximately two passages [129]. Therefore, these cells will not be discussed sepa-
rately here. 
Characteristics and Properties 
Cell markers
Today it is unavoidable to characterize the obtained cells by fluorescence activated cell 
sorting (FACS) analyses. This technique is introduced from the field of haematology 
where research on stem and progenitor cells is further advanced. In contrast to the 
haematology, unique markers for mesenchymal and progenitor cells are not yet avail-
able [160]. Therefore a large set of different markers is used. Virtually all described MPC 
populations used in research are heterogeneous groups of cells, attributing to different 
characterisations by different investigators. According to the International Society for 
Cellular Therapy (58), a multipotent stromal cell is defined by the following criteria (a) 
its property of adherence to plastic; (b) its phenotype: negative for: CD14 or CD11b, 
CD19 or CD79a, CD34, CD45, HLA-DR, and positive for CD73, CD90, CD105; and 
(c) its capacity to be differentiated into three lineages, chondrocyte, osteoblast, and 
adipocyte. Criteria (a) and (c) are met by MPCs derived from all tissues discussed in 
this chapter. These topics will be further dealt with later in this section. Regarding cell 
phenotype, our literature review showed that MPCs derived from the previously men-
tioned tissues are negative for CD31, CD34, CD45 and CD117. They are reported to be 
positive for CD44, CD90, CD105, CD146, CD166 and STRO-1 [119,122,124,128,13
7,148,156,157,161,162,163,164,165,166,167,168,169]. Although this combination of 
positive and negative markers is quite comparable for markers generally accepted for 
bone marrow- and adipose tissue derived MSCs, differences between the two latter cell 
populations and MPCs derived from other mesenchymal tissues have been reported 
[118,119,120,163,170]. Most frequently reported difference between these cells is dif-
ferentiation capacity, which will be discussed later in this chapter. Some groups have 
described a so-called “side population (SP)” of progenitor cells. These cells, originally 
described as hematopoietic stem cells, have a unique FACS profile after staining with 
Hoechst 33342 dye. They can not only be obtained from bone marrow but from other 
tissues as well, including synovium and muscle [171,172]. Transcriptional profiles for 






upregulated in SP cells are genes that implicate the quiescent status of the cells, mainte-
nance pluripotency and the capacity to undergo asymmetric division [173]. Some groups 
claim that these cells have superior properties in comparison to the remaining “main 
population” of cells, but this topic is too specific to include in this chapter. 
Cell yield: isolation and proliferation
The common protocol for isolation of MPCs, irrespective of tissue source, is mincing 
the tissue followed by enzymatic digestion. The enzyme collagenase is mostly used for 
this purpose, sometimes in combination with other enzymes like dispase. The duration 
of digestion and enzyme dose is variable, but in general lower collagen content of tis-
sues results in a shorter isolation protocol. After tissue digestion, MPCs are in general 
selected upon plastic adherence, which is in accordance to BMSC isolation [174]. This 
doesn’t hold true for muscle satellite cells or cartilage derived MPCs. These cells are 
selected using vitrogen gel or fibronectin adherence respectively [141,175]. However, 
it is to be expected that these generally applied MPC isolation protocols are merely 
empirically based and not necessarily optimized. Changing concentration, duration and 
composition of enzymes might further increase cell yields as well as their viability.
Occasionally, cells are isolated by cutting the tissue in small pieces for cells to grow out. This 
is often done if the amount of tissue is too limited to obtain sufficient cell number after en-
zymatic digestion. Results of these studies demonstrate that for bone, perichondrium and 
tendon it is indeed possible to obtain cells with multilineage capacity this way [157,158,176].
For isolation of MPC from bone marrow aspirates a different protocol is followed. These 
cells are not isolated enzymatically but solely selected by adherence to tissue culture 
plastic after plating the biopsy. Sometimes, this is preceded by lyses of the red blood 
cells and/or a density gradient centrifugation to select the mononuclear fraction. 
Cell yields from different tissues vary per isolation source and also depend on the origi-
nal cellularity of the tissue. Sakaguchi et al. found comparable colony forming units 
(CFU) per 103 nucleated cells for adipose, synovium-, periosteum- and muscle derived 
MPCs [119]. Bone marrow showed less CFU per 103 nucleated cells, but this was 
compensated by a higher number of nucleated cells per tissue volume. Others report 
roughly comparable results with a tendency towards higher colony forming units per 
nucleated cells obtained from synovium compared to periosteum, muscle and cruci-
ate ligaments [118,120]. No unambiguous differences regarding the proliferation of the 
isolated cell populations could be observed up to passage eight, although synovial 
derived cells showed a trend towards higher proliferation [119,120]. Overall, cell yields 
from these tissues and proliferation capacities of the isolated cells appear to be within 
the same order of magnitude. Therefore, the ease of harvesting sufficient amounts of 
tissue might become of more importance for selection of the most suitable cell source 
















To evaluate the possibilities to prevent or treat musculoskeletal disorders using autolo-
gous cell-based therapies, it is important to know how the number and function of MPC 
in musculoskeletal tissues are affected by age and/or disease. In the ageing organism, 
regenerative capacities of tissues tend to decrease [177,178]. Possible explanations 
for this declining regenerative capacity could be an age-related change in numbers or 
features of MPCs (cell intrinsic factors) or modifications in the surrounding environment 
(cell extrinsic factors) [122]. These alterations have not been fully elucidated yet, and 
literature about this subject is sometimes contradictory. 
In bone marrow for instance, a reduction of colony-forming efficiency was found with in-
creasing age using donors ranging from infants to the age of 60 years [179]. Scharstuhl 
et al. on the other hand, found no correlation between age and the number of mono-
nuclear cells in bone marrow, BMSC yield, cell size, proliferative capacity or cellular 
spectrum of the harvested cells from adult human donors [180]. Similarly, for perios-
teum derived MPCs opposing results have been published regarding the influence of 
age. Both donor age dependent [181] and independent [182] effects on osteochondro-
genic potential of periosteum MPCs have been reported. Periosteal cells are reported 
to maintain osteochondrogenic potential up to ten population doublings. This potential 
eventually diminishes upon further passaging [183]. 
Muscle tissue is the last tissue for which inconsistencies are described regarding age-
related findings. The number of progenitor cells in muscles has been reported to de-
crease, remain constant or increase with rising age [184]. Other cell intrinsic factors like 
telomere shortening and increased tendency to undergo apoptosis play a role in declin-
ing muscle regeneration upon ageing too [184]. Cell extrinsic factors that determine 
appropriate activation and efficient proliferation before terminal differentiation, are also 
proposed to play a key role in regenerating capacities of ageing muscle tissue. This is 
explained here with some examples. In aged muscle, progenitor cells prematurely shift 
from a proliferation phase to a differentiated state due to alterations of Wnt and Notch 
signaling [185,186]. This leads to less regeneration capability in aging organisms. Inter-
estingly, this trend appears to be reversible. When aged satellite cells are exposed to 
a young systemic environment, Notch activation is re-established again [187]. Another 
known feature of satellite cells is the tendency to convert to fibroblasts in vitro upon 
increasing age. Exposure of aged cells to serum derived from young animals reduces 
this tendency, further emphasizing the role of extrinsic factors in (aged) tissue regenera-
tion [187]. 
Cartilage derived chondroprogenitor cells are described to have a relative high telomer-
ase activity [188]. Telomerase, first described by Greider et al., prevents telomere short-
ening during cell division [189]. By doing so, this enzyme postpones cell senescence 






derived progenitors undergo a high number of initial population doublings before a pla-
teau is reached upon approximately 50 population doublings. After approximately 25 
population doublings telomerase activity appears to decrease, leading to morphological 
and functional cell senescence [188].
Synovium MPCs have also been described to have limited senescence and can be 
expanded in vitro to large numbers. Their proliferative capacity doesn’t appear to be af-
fected by donor age. However, despite their high proliferative capacity, synovium MPCs 
have undetectable telomerase activity [145]. Their multipotent capacity is not influenced 
by donor age, cell passages or cryopreservation [145].  
In summary, the fact that regenerative capacities of ageing tissues tend to decrease 
is not entirely understood. However, it is clear that both cell intrinsic and cell extrinsic 
properties play a role in this process. In order to evaluate the applicability of cell-based 
therapies in musculoskeletal disorders, animal and clinical studies are a prerequisite. 




MPCs derived from the various described musculoskeletal tissues have all been shown 
to have a multilineage differentiation potential [118,119,190]. This means they all have 
been shown to be able to differentiate into multiple mesodermal lineages including the 
osteogenic, adipogenic and chondrogenic lineage. The only exception is the “typical” 
satellite cell, which is generally considered a unipotent myogenic stem cell [122]. Al-
though the latter may be regarded as a myoprogenitor cell, it does have true stem cell 
properties including self-renewal by asymmetric division [191]. Although cells derived 
from these previously mentioned tissues have the capacity to differentiate into different 
lineages, they all show a preference, in general for differentiating towards the tissue 
they were originally derived from. So, cartilage derived MPCs show a tendency towards 
chondrogenic differentiation [192] and muscle derived MPCs towards the myogenic 
lineage [193]. Since no differentiation protocols are available for differentiating cells in 
vitro towards a tendon, synovial or periosteal lineage for instance, cells derived from 
these tissues commonly are differentiated into adipocytes, osteocytes and chondro-
cytes as well to prove multilineage differentiation potential. Periosteal MPCs have great 
osteogenic potential [125] whereas synovium derived MPCs have a preference for the 
chondrogenic lineage [194]. Nevertheless, it is very difficult to state that local progeni-
tors from one type of tissue are more suitable to form a certain tissue than other MPCs. 















groups of cells, it is hard to tell whether differentiation preferences arise from specific 
stem cell related features or are simply a consequence of differences in the presence 
of local (further differentiated) progenitors. Furthermore, differentiation studies in vitro 
are not directly translatable to an in vivo situation. MPCs are exposed to specific local 
(micro)environments during tissue development as well as during the mature stage. 
When in vivo applied, it seems logical that these cells can respond different to tissue 
specific growth factors or other stimuli. More information about the microenvironments 
of the various MPCs is necessary, together with knowledge about the heterogeneity 
of cell populations. An increasing number of clonal studies using single cells to show 
true multilineage differentiation and/or self-renewal of different MPCs are reported 
[127,137,195,196]. Direct comparison of clonal cells derived from different musculo-
skeletal tissues should be a focus of future research in order to form a founded opinion 
about optimal cell sources. 
Besides differentiating into mesodermal lineages, bone marrow stromal derived cells 
have been shown to be able to give rise to hepatic cells (endodermal lineage) and ma-
ture astrocytes and neurons (ectodermal lineage) as well [197,198]. This process, where 
a stem cell differentiates into cell types from a different germ layer than the one it origi-
nally resided in, is termed transdifferentiation. Although this has not been extensively 
investigated for the MPCs discussed in this chapter, muscle derived MPCs for example 
have been demonstrated to be able to transdifferentiate into endo- and ectodermal lin-
eages as well [199]. This might suggest that MPCs from other sources might also have 
transdifferentiation capacity, which has to be shown in future investigations.
Trophic factors
MPCs can contribute to tissue repair by differentiating into a mature tissue cell and 
forming extracellular matrix to repair damaged tissue. In addition these cells contribute 
to tissue repair: by the production of trophic factors. These trophic factors are capable 
of attracting (more) stem cells to the damaged area and they can have an immunomod-
ulatory effect [43]. For bone marrow and adipose derived cells there is a fast increasing 
amount of information on trophic factors [200,201]. MPCs derived from bone marrow 
and adipose tissue, but also MPCs from periodontal ligament, have been shown to 
have a suppressive effect upon peripheral blood mononuclear cell proliferation [166]. 
This suppressive effect was found both in mixed lymphocyte reactions (allowing cell-cell 
contact) and in transwell co-cultures (avoiding direct contact). The latter emphasizes the 






Potential Applications for Therapies
Huge potential resides in the MPCs discussed in this chapter regarding musculoskeletal 
tissue regeneration, either by differentiating into more mature tissue cells or by their 
modulatory properties. The potential of MPCs for tissue regeneration or immune modu-
lation is demonstrated by the huge amount of clinical trials that are already performed or 
are still ongoing, using bone marrow derived MSCs [131,202]. The application of these 
cells encompasses various fields, including cardiovascular diseases, osteogenesis im-
perfecta, graft versus host disease and neurological disorders like amyotrophic lateral 
sclerosis, etc. [160,202]. 
Clinical studies or applications with musculoskeletal stem cells generated from other 
tissues than bone marrow have been performed with muscle derived MPCs, periosteum 
and perichondrium. Muscle MPCs have been used in clinical trials for treating myocar-
dial ischemia [203]. Periosteum has proven it’s added value in treating bone defects 
[204,205] and has been used as a therapy for local cartilage defects for more than two 
decades [206,207]. Perichondrium has been applied as a graft to treat isolated chondral 
defects [208,209]. Although MPCs likely play a role in these studies, tissue transplants 
were used rather than isolated cells. Therefore, we cannot state that the positive results 
were solely based on the regenerative capacities of transplanted MPCs. Furthermore, 
although promising results were obtained using periosteum for treating bone defects, 
golden standard still is the use of autologous bone grafts. Regarding local cartilage 
defects, subchondral drilling and autologous chondrocyte implantation (see later) have 
become the main therapies. Animal experiments with MPCs of other musculoskeletal 
tissues show hopeful results. Muscle MPCs have been reported to contribute to up 
to 94% of myofibers after intramuscular injection into dystrophic mice [210]. Further-
more, satellite cells have been shown to be able to undergo approximately 14-17 cell 
doublings after single cell transplantation in vivo [137]. A possible drawback of muscle 
MPCs is their low migrating capacities requiring local delivery, although homing of these 
cells into damaged muscle after intravenous injection has been reported [193]. Synovial 
MPCs in their turn have proven in vivo to contribute to cartilage repair [211], menis-
cal regeneration [50], muscle repair [212] and to accelerate remodeling of tendon to 
bone healing in a bone tunnel model [213]. Lastly, tendon- and ligament derived MPCs 
can play a role in regenerating damaged tendon and ligament respectively [214,215]. 
Although cartilage has been shown to contain progenitor cells, applications using only 
these MPCs do not yet exist. In the field of cartilage repair, autologous chondrocyte 
implantation is a well established, cell-based and clinically applied cartilage repair tech-
nique [216]. This technique however uses predominantly differentiated chondrocytes 
to fill the cartilage defect, thereby not meeting the definition of stem cell therapy. The 
















In summary, the applicability of MPCs of a certain tissue for an application will depend on 
ease of harvesting and the ability to control function. At the moment, further evidence has to 
come from properly organized and controlled animal as well as clinical studies. 
The variability of the outcome of different studies where MPCs are used is of great 
concern. Part of the variation might be due to variation in MPC characteristics between 
donors. Better characterisation of the cells or selection of cells before use can improve 
outcome. The first study with cell selection (although this did not involve MPCs), for 
regenerative medicine of the musculoskeletal system has been performed in cartilage 
repair [217]. In addition to the variation in MPC characteristics, variability in outcome of 
clinical studies will also be caused by the differences in the host environment where the 
cells are introduced. Stage of disease, but also general patient characteristics like BMI, 
age and gender will determine MPC fate and function [179]. How these factors influence 
MPCs is largely unknown at the moment. It is important to take this into account when 
designing clinical studies.
Instead of actually applying or injecting MPCs for musculoskeletal disorders, some ther-
apies aim at stimulating or attracting stem cells to the damaged tissue. Some examples 
of this approach are shockwave therapy, pulsed electromagnetic fields (PEMF) or the 
use of cell attracting growth factors. These strategies are being investigated as pos-
sible therapies for osteoporosis, bone non-unions, osteochondral defects and cartilage 
regeneration [218,219,220,221]. 
Tumour formation
Although formation of tumours after the use of adult MPCs have never been reported, 
the capacities of MPC are not yet fully investigated and understood. The role of BMSCs 
in carcinogenesis is a relative new feature. BMSCs have a distinct homing potential to a 
wide range of organs after systemic administration [222,223,224]. The ability of BMSCs 
to home to primary tumour sites and metastases has been demonstrated by several 
studies [225,226,227]. Their role at these tumour sites and their potential effect on 
tumour development can be bivalent. Both pro- and antiproliferative effects of BMSCs 
have been reported regarding this aspect (reviewed in [228]). Possible explanations for 
these contradictory findings might be the immunomodulatory effects of BMSCs, which 
can be both in favour and to the detriment of tumour development. Another factor might 
be the excretion of VEGF by BMSCs, which plays a role in (neo)vascularisation. 
The effect or role of the MPCs in tumour formation or -growth has not been investigated 
so far. It is a known fact that cells can undergo karyotypic changes upon (long-term) 
culturing in vitro [229,230]. Cell based regenerative therapies have to be proceeded 
cautiously, and these aspects certainly have to be investigated before proceeding to 






Conclusions, Discussion and Future Development in Research
It is clear that local progenitor cells can be isolated from various tissues in the muscu-
loskeletal system and that these cells can play a role in tissue repair. Overall, cell yields 
from the different tissues, proliferation capacities and cell membrane markers of the iso-
lated cells appear to be similar. Cells derived from the various musculoskeletal tissues 
have all been shown to have a multilineage differentiation potential. Besides differentiat-
ing into a mature tissue cell, secretion of trophic factors is assigned a possible function 
of stem cell that might be important in tissue repair. Musculoskeletal progenitor cells 
posses a huge capacity for application in regenerative medicine. Table 1 summarizes 
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Yes Yes + / +
Muscle Differentiation Yes Yes + / +
Cartilage Differentiation Yes Performed with 
cartilage derived 









Differentiation No Performed with 







Yes No ± / -**
 * these are arbitrary measures. +, ± and - represents a good, medium and limited availability (i.e. 
amount of obtainable tissue)  and accessability (i.e. invasiveness of procedure needed to harvest the 
tissue) respectively. 
** in maxillofacial surgery, the periodontal ligament is readily available and accessible. However, in 
limbs this cell source is less abundant and accessible. 















It is not always straightforward to determine whether the isolated MPCs are really local 
cells, especially in damaged tissues. Tissue damage has been demonstrated to attract 
stem cells from the circulation. These cells are recruited from the bone marrow and 
home in the damaged tissue to support repair [231]. These recruited cells, once iso-
lated from damaged tissue, might therefore be mistaken for local MPCs. Furthermore, 
the tissues of the musculoskeletal system, with exception of cartilage and tendon, are 
well vascularised. These small vessels contain pericytes. A pericyte is a relatively undif-
ferentiated cell, which serves to support small vessels. They were first described in the 
19th century as cells located between the endothelial cells and the parenchymal cells in 
capillaries and post capillary venules. Apart from their role in blood vessel formation, 
pericytes were recognized to contribute to bone formation [232] and they might play 
an important role in tissue repair and regeneration in many musculoskeletal tissues. 
Pericytes have multilineage differentiation capacity too, and there could be a chance 
that these cells are very closely related to the local progenitors described in this chap-
ter. However, only recently they regained a lot of interest as adult progenitor cells with 
multilineage capacity and methods to isolate and purify these cells are being developed 
[233]. Especially in well vascularised tissues, such as bone marrow, adipose tissue and 
muscle, the perivascular cells might be regarded as local MPC. Further research will 
have to elucidate the role of local stem cells as well as pericytes and systemic stem 
cells present in the circulation, in intrinsic tissue repair capacity as well as their use in 
cell therapy. 
For cell therapeutic application optimal isolation and culture conditions for each cell 
type has to be found and tailored for every specific application. Choice for optimal cell 
type to regenerate a tissue might very likely depend on criteria related to ease of har-
vesting. In this respect, bone marrow and adipose tissue are attractive candidates for 
harvesting large amounts of cells in a relatively easy procedure.
The various musculoskeletal stem cells all have multilineage differentiation capacity. Al-
though this offers interesting opportunities, it also emphasizes the importance of learn-
ing to control and direct differentiation and tissue formation by these cells to prevent 
undesired tissue- or tumour formation. Better characterisation of musculoskeletal stem 
cells and more knowledge about lineage differentiation is required to fully understand 
the potential of each individual source of cells for each of the different applications. In 
this respect, not only differentiation into mature tissue cells, but also the secretion of 
trophic factors deserves more study. Furthermore the fate of the cells after application 
in-vivo has to be studied  with modern imaging techniques both in animal and in human 
patients [60] to be able to answer the questions: Where do they home?;How long do 
they stay viable?; What is their activity?  Finally there is a need for more understanding 
of how characteristics of host microenvironment influence fate and function of the cells 
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Background: Mesenchymal stem cells (MSCs) are promising candidates for OA thera-
pies, although their mechanism of action remains unclear. MSCs have recently been 
discovered to secrete anti-inflammatory cytokines and growth factors. We studied the 
paracrine effects of MSCs on OA cartilage and synovial explants in vitro. 
Methods: MSC-conditioned medium was prepared by stimulating primary human MSCs 
with TNFα and IFNγ (50 ng/ml each). Human synovium and cartilage explants were cul-
tured in MSC-conditioned medium or in control medium, containing the same amount 
of added TNFα and IFNγ but not incubated with MSCs. Explants were analyzed for 
gene-expression and the production of nitric oxide (NO). The presence of the inhibitor 
of nuclear factor kappa B alpha (IκBa) was assessed by Western blot analysis.
Results: Synovial explants exposed to MSC-conditioned medium showed decreased 
gene expression of interleukin-1 beta (IL-1β), matrix metalloproteinase (MMP)1 and 
MMP13, while suppressor of cytokine signalling (SOCS)1 was upregulated. In cartilage, 
expression of IL-1 receptor antagonist (IL-1RA) was upregulated, whereas a disintegrin 
and metalloproteinase with thrombospondin motifs (ADAMTS)5 and collagen type II al-
pha 1 (COL2A1) were downregulated. MSC-conditioned medium reduced NO produc-
tion in cartilage explants and the presence of IκBa was increased in synoviocytes and 
chondrocytes treated with MSC-conditioned medium. 
Conclusions: In an inflammatory environment, MSCs secrete factors which cause mul-
tiple anti-inflammatory effects and influence matrix turnover in synovium and cartilage 





















Osteoarthritis (OA) is characterized by a catabolic and inflammatory joint environment. 
To this date, no drugs are available to structurally modify OA processes or prevent 
progression of the disease [234]. The use of mesenchymal stem cells (MSCs) as a treat-
ment option in cartilage regenerative therapies is under extensive investigation [235]. 
MSCs have chondrogenic potential and are experimentally being implanted in focal 
cartilage defects, showing promising results [236]. In OA, more generalized cartilage 
lesions and joint inflammation are present, thereby limiting the usefulness of focal treat-
ments. In order to treat the joint as a whole, MSCs have been injected intra-articularly 
in pre-clinical and some initial clinical studies as a treatment for OA [54,55,237]. Animal 
studies have shown beneficial effects of MSCs on cartilage morphology and histology 
in various OA models [47,54,55]. Interestingly, studies using cell tracking in cartilage 
repair show only limited cartilage formation by chondrogenic differentiation of the in-
jected MSCs [54,55]. Instead, the applied cells are mostly retrieved from other articular 
structures, like the synovium. Apparently, the intra-articularly injected MSCs only oc-
casionally differentiate into chondrocytes to actively produce extracellular matrix. This 
implies a different OA modifying mechanism, like influencing the micro-environment by 
paracrine actions, stimulating locally present progenitor cells to repair OA damage or by 
attracting circulating endogenous progenitor cells to enable repair [238]. We studied the 
influence of MSCs on their local micro-environment by the secretion of bioactive factors. 
Some of these factors, including interleukin-6 (IL-6), IL-10, indoleamine 2,3-dioxygen-
ase (IDO), hepatocyte growth factor (HGF) and transforming growth factor beta (TGFβ), 
have immunomodulatory properties [44,239],whereas others are involved in extracellu-
lar matrix turnover such as matrix metalloproteinases (MMPs) and their inhibitors, tissue 
inhibitors of metalloproteinases (TIMPs) [240]. In addition, trophic effects of MSCs to 
stimulate chondrocyte proliferation and matrix deposition have been shown [241]. Aim 
of our study was to explore the protective effects of MSCs on OA related processes 
in a controlled and standardized environment, by investigating the paracrine effects of 
MSCs on OA synovium and cartilage explants in vitro. These paracrine effects were 
studied by means of MSC-conditioned medium; medium containing factors secreted 
by MSCs. Since MSCs increase their immunomodulatory properties in response to an 
inflammatory stimulus, and inflammation plays a substantial role in OA pathology, we 
challenged our cells with the inflammatory cytokines TNFα and IFNγ [242,243]. We 
measured the presence of factors in MSC-conditioned medium involved in inflamma-
tion, tissue regeneration and extracellular matrix turnover. Furthermore, we evaluated 
the effects of MSC-conditioned medium on osteoarthritic cartilage and synovium by 
analyses of the expression of genes related to inflammation and matrix turn-over, the 
production of nitric oxide (NO) and prostaglandin E2 (PGE2) and activity of P38 mitogen-
activated protein (MAP) kinase and nuclear factor kappa B (NFκB) pathways. These two 








Cells and tissue preparation
Human MSCs (hMSCs) were isolated and cultured from heparinized femoral-shaft mar-
row aspirate of nine patients undergoing total hip arthroplasty (after written informed 
consent; protocol # MEC-2004-142) using previously described procedures [157]. This 
procedure was previously confirmed to yield MSC on the basis of morphological criteria, 
expression of CD105 marker and absence of CD34 marker and an adipogenic, osteo-
genic and chondrogenic differentiation potential [157]. Cells were seeded at a density of 
2300 cells/cm2 and cultured in DMEM containing 1 g/L glucose, 10 % fetal calf serum 
(FCS), 50 µg/ml gentamicin, 1.5 µg/ml fungizone, 1ng/ml fibroblast growth factor-2 and 
0.1 mM l-ascorbic acid 2-phosphate (MSC culture medium). Human synovial explants 
(approximately 10 mm3) and cartilage explants (approximately 70 mm3) were obtained 
as surgical waste material from seven patients undergoing total knee replacement sur-
gery. All patients implicitly consented to the use of these tissues for scientific research 
(protocol # MEC-2004-322). Explants were pre-cultured for 48 hours in DMEM con-
taining 1 g/L glucose, 2 % FCS, 50 µg/ml gentamicin and 1.5 µg/ml fungizone. Syn-
oviocytes and chondrocytes were isolated from synovium and cartilage respectively as 
described previously [245] by treating explants from either tissue with 0.2 % protease 
(Sigma-Aldrich,Zwijndrecht, Netherlands) and subsequent overnight digestion in DMEM 
containing 4.5 g/L glucose, 10 % FCS, 50 µg/mL gentamicine and 1.5 µg/mL fungizone, 
supplemented with 0.15 % collagenase B (Roche Diagnostics, Mannheim, Germany). 
Conditioned medium preparation and explant culture
Subconfluent hMSC monolayer cultures (passage two) were used to obtain conditioned 
medium. MSC conditioned medium from four donors was prepared by incubating hM-
SCs for 24 hours in MSC culture medium. To stimulate the secretion of immunomodula-
tory factors by MSCs, TNFα and IFNγ (50 ng/ml each, PeproTech, London, UK) were 
added to the MSC culture medium for five other MSC donors. After 24 hours the me-
dium was collected and centrifuged for eight minutes at 700 G to remove cellular debris. 
MSCs and the supernatant of the medium (MSC-conditioned medium) were harvested 
separately and stored at -80 ◦C until further use. MSC processing for gene expression 
analysis is described later in this section. Control (unconditioned) medium was made 
of plain MSC culture medium for the first four MSC donors, and MSC culture medium 
supplemented with TNFα/IFNγ (50 ng/ml each) for the five cytokine-stimulated MSC 
donors. Both control media, with or without TNFα/IFNγ, were incubated without MSCs 
at 37 ◦C for 24 hours and stored at -80 ◦C until further use. TNFαIFNγ. Except for the 
absence of MSCs during incubation, the control medium was treated identical to MSC-
conditioned medium. In experiments using MSC-conditioned media from non-stimulat-
ed donors, control medium without TNFα/IFNγ was used. Stimulated MSC-conditioned 



















Synovium and cartilage explants were cultured in MSC-conditioned medium or in con-
trol medium for 48 hours. Explants from each synovium or cartilage donor were cultured 
in triplicate samples per condition in 24-well plates in a total volume of 1.0 ml, consisting 
of 500 µl MSC-conditioned medium and 500 µl freshly added DMEM containing 50 µg/
ml gentamicin and 1.5 µg/ml fungizone. Depending on the amount of explant material 
that could be obtained from a given donor, explants were cultured in conditioned me-
dium from one to four separate MSC donors. After culturing for 48 hours, explants for 
gene expression analyses and media were harvested and stored at -80 °C until further 
use. MSC conditioned medium without TNFα/IFNγ from four MSC donors was used on 
two synovium and cartilage donors. Conditioned medium from MSCs stimulated with 
TNFα/IFNγ from five MSC donors was used on five synovium and cartilage donors.
We additionally studied the effect of MSCs in a co-culture system of synovium and car-
tilage explants [27]. In short, synovium and cartilage explants from the same donor were 
cultured together, thereby preventing direct contact between cartilage and synovium by 
using Millicell filter inserts with a pore size of 0.4 µm (Millipore, Amsterdam, the Nether-
lands). These experiments were performed on synovium and cartilage from one donor in 
triplicates using pooled MSC-conditioned media from 5 different MSC donors. 
Gene expression analysis
The frozen explants were processed using a Mikro-Dismembrator S (B. Braun Biotech 
International GmbH, Melsungen, Germany). RNA from explants was extracted using 
RNA-Bee™ (TEL-TEST, Friendswood, USA) according to manufacturer's guidelines and 
subsequently precipitated with chloroform 20 % (v/v). RNA from MSCs was extracted 
using RLT (Quiagen, Venlo, the Netherlands) and beta-mercaptoethanol 1 % (v/v). All 
RNA was further purified using RNeasy Micro Kit (Qiagen, Hilden, Germany) with on-
column DNA digestion. Nucleic acid content was determined spectrophotometrically 
(NanoDrop ND1000; Isogen Life Science, IJsselstein, The Netherlands). Complemen-
tary DNA and polymerase chain reactions (PCRs) were performed as described before 
[89]. RT-PCR primer nucleotide sequences are listed in table 1. Data were normalized to 
a best keeper index (BKI) of three reference genes GAPDH, UBC, HPRT1 [246]. Relative 
expression levels were calculated using the 2-ΔΔCt method [91]. 
Nitric oxide and prostaglandin E2 measurements
Nitric oxide (NO) and prostaglandin E2 (PGE2) secretion by synovium and cartilage was 
analyzed in the cryopreserved media from the synovium and cartilage explants culture 
experiments. NO secretion was determined by quantifying its derived product, nitrite, in 
medium using a spectrophotometric method based upon the Griess reaction [94]. Brief-
ly, 100 µl of culture medium or sodium nitrite (NaNO2) standard dilutions were mixed 
with 100 µl of Griess reagent (0.5 % sulphanilamide, 0.05 % naphtyl ethylenediamine 
dihydrochloride, 2.5 % H3PO4). The absorption was measured at 540 nm. PGE2 secre-






MN, USA) according to manufacturer’s guidelines. NO measurements were performed 
on triplicate samples from five synovium and cartilage donors separately. For the PGE2 
assay the triplicate samples per condition were pooled before measurement to obtain 
values from four synovium and four cartilage donors.
Western blotting for p38 and NFκB signaling pathway analyses
The amount of native and phosphorylated P38 MAP kinase and the amount of inhibitor 
of kappa B alpha (IκBa) was determined by Western blot analysis of total protein ex-
tracts from fibroblast-like synoviocytes and chondrocytes exposed to MSC-conditioned 
medium. Synoviocytes and chondrocytes from two donors each were used. Subcon-
fluent monolayers of synoviocytes and chondrocytes (passage 2-4) were cultured in 
pooled MSC-conditioned medium (from five MSC donors) or control medium for either 
10 minutes (for IκBa determination) or for 3 hours (for p38 MAP kinase signaling). The 
chosen incubation times were based on an experiment using different durations of IFNγ/
TNFα treatment to predefine the optimal time-point to evaluate possible paracrine MSC 
effects (data not shown). Based on previous reports, IFNγ/TNFα dependent IκBa degra-
dation was determined in a period ranging from five minutes to one hour and p38 MAP 
kinase phosphorylation in a period of 3 - 24 hours [86,247]. 
Total protein fractions were isolated using M-PER Protein extraction reagent (#78501, 
Thermo Scientific) with 1 % protease inhibitor Complete (Roche, Manheim, Germany). 
Protein concentrations were determined by the BCA protein assay (Pierce Chemical, 
Rockford, IL). For each sample, 8µg of total protein fraction was separated by 10 % 
SDS-PAGE gels and transferred on PVDF membranes by Western blotting. Membranes 
were blocked for 2h in 0.1 % TBS-T containing 5 % dry milk powder, washed three 
times in 0,1 % TBS-T and incubated with primary antibodies against α-Tubulin, p38 
MAP kinase, phosphorylated p38 (all diluted 1:1000; respectively 2148, 9212 and 9211, 
Cell Signaling Technology, Leiden, the Netherlands) or IκBa (1:500; sc-371, Santa Cruz 
Biotechnology, Heidelberg, Germany) overnight at 4 °C following manufacturer’s proto-
col. An anti-rabbit HPR-linked secondary antibody (1:1000; 7074, Cell Signaling) was 
added and incubated for 1h at room temperature. The blots were visualized by means 
of SuperSignal Chemiluminescent system (34077, Thermo Scientific) using manufac-
turer’s instruction. Image analysis and quantification was performed using the National 
Institute of Health Image J freeware (release 1.44X; http://rsb.info.nih.gov/ij/).
Analyses of mesenchymal stem cells and conditioned media
Stimulated and non-stimulated MSCs from four donors were analysed for gene expres-
sion of IL-6, TIMP2, HGF, TGFβ-1 and IDO as described in the gene expression analysis 
section. TIMP2, HGF, IL-6 and TGFβ-1 protein levels were measured in stimulated and 
non-stimulated MSC-conditioned media from three donors by means of ELISAs (R&D 
systems, Abingdon, UK) according to the protocol supplied by the manufacturer. All 



















determine the amount of IDO enzymatic activity in MSC-conditioned media, the level of 
its metabolite, kynurenine, was measured spectrophotometrically as described before 
[248]. In brief, 100 µl of 30 % trichloroacetic acid (Sigma-Aldrich, St. Louis, USA) was 
added to 200 µl of culture supernatant, which was incubated at 50 °C for 30 min, and 
then centrifuged at 10,000 G for 5 minutes. 75 µl of supernatant was then added to 
an equal volume of Ehrlich’s reagent (100 mg P-dimethylbenzaldehyde and 5 ml glacial 
acetic acid; Sigma-Aldrich St. Louis, USA) and optical density was measured at 490 
nm.
Data analyses 
All data are presented as mean ± standard deviation. Statistical analyses were per-
formed using a mixed model ANOVA (SPSS 17.0.2; SPSS Inc., Chicago, USA), which 
takes the within donor correlation into account. Treatment using MSC-conditioned me-
dia vs control medium was considered a fixed factor and these effect were statisti-
cally considered as independent observations. The synovium or cartilage donors were 
considered a random factor and measurements of the separate samples per donor 
were regarded correlated observations. Donor was included into the model to adjust for 
absolute differences in expression levels between explant donors. A log-transformation 
was applied to all gene expression data before statistical analyses to approach normal 
data distribution. A p-value < 0.05 was considered statistically significant. 
Results
MSCs display immunomodulatory properties in response to inflammatory cyto-
kine exposure.
To determine which factors might be involved in the anti-inflammatory effects caused by 
the MSC-conditioned medium, we analyzed TNFα/IFNγ stimulated and non-stimulated 
MSCs for gene expression and protein secretion of various immunomodulatory factors 
and growth factors. Stimulation of MSC’s with the inflammatory cytokines upregulated 
gene expression of IDO and IL-6, while TIMP2 and TGFβ-1 were markedly downregu-
lated (Fig. 1a; P < 0.001 for all genes). HGF, IL-1β and TIMP1 gene expression was not 
significantly altered by the priming procedure (data not shown). 
The amount of secreted IL-6, HGF, TIMP2, TGFβ-1 and IDO enzymatic activity in condi-
tioned medium from TNFα/IFNγ stimulated and unstimulated MSCs was measured (Fig 
1b). IL-6 was significantly elevated in TNFα/IFNγ stimulated MSC-conditioned medium 
(approximately 15-fold, P < 0.001), as was IDO activity (approximately 60-fold, P < 
0.001) compared with non-stimulated conditioned medium. HGF, TIMP2 and TGFβ-1 














IDO assay-on-demand (Hs00158027.m1, Applied Biosystems, Capelle a/d 











MMP1 Fw: CTCAATTTCACTTCTGTTTTCTG 
Rv: CATCTCTGTCGGCAAATTCGT
MMP13 Fw: CTCAATTTCACTTCTGTTTTCTG 
Rv: CATCTCTGTCGGCAAATTCGT
TIMP1 Fw: TGCCGCATCGCCGAGAT 
Rv: ATGGTGGGTTCTCTGGTG
TIMP2 Fw: ATGGTGGGTTCTCTGGTG 
Rv: CGGTACCACGCACAGGA
ADAMTS4 Fw: CAAGGTCCCATGTGCAACGT 
Rv: CATCTGCCACCACCAGTGTCT
ADAMTS5 Fw: CAAGGTCCCATGTGCAACGT 
Rv: CATCTGCCACCACCAGTGTCT
COL2A1 Fw: GGCAATAGCAGGTTCACGTACA 
Rv: CGATAACAGTCTTGCCCCACTT
ACAN Fw: TCGAGGACAGCGAGGCC 
Rv: TCGAGGGTGTAGCGTGTAGAGA
Table 1. Primer nucleotide sequences of the tested genes
IL-6: interleukin-6, HGF: hepatocyte growth factor, TGFb1: transforming growth factor beta-1, IDO: 
indoleamine 2,3-dioxygenase, IL-1b: IL-1 beta, IL-1RA: IL-1 receptor antagonist, SOCS: suppressor 
of cytokine signalling, MMP: matrix metalloproteinase, TIMP:  tissue inhibitor of MMP, ADAMTS: a dis-




















Figure 1. Influence of TNFα/IFNγ stimulation on MSC gene expression (A) and MSC secretions (B). 
In order to stimulate the immunomodulatory capacity, MSCs were treated with TNFα and IFNγ for 24 
hours. Media from TNFα/IFNγ stimulated and unstimulated MSCs were analyzed for various factors 
and corrected for control medium containing 10 % FCS. Gene expression data are presented as box-
plots for 4 experiments performed in triplicate. Cell secretion data are presented as means ± standard 
deviations for 3 experiments performed in triplicate; IL-6 = interleukin 6, IDO = indoleamine 2,3-di-
oxygenase, TIMP2 = tissue inhibitor of matrix metalloproteinase 2, TGF beta-1 = transforming growth 






Figure S1. The paracrine effects of TNFα/IFNγ stimulated MSCs were determined in synovium and 
cartilage co-culture, a model resembling more closely the in vivo situation. The MSC secretome modi-
fied expression of genes related to inflammation and matrix turnover in synovium (A) and cartilage (B). 
This experiment was performed as confirmation of previously performed experiments using separate 
synovium and cartilage explants. Data are presented as means ± standard deviations for 1 experiment 




















Figure 2. Effects of factors secreted by non stimulated MSCs on expression of genes related to 
inflammation and matrix degradation in human osteoarthritic synovial explants. Data are presented as 
boxplots for 3 experiments, in which MSC-conditioned medium from 3 MSC donors was applied to 
triplicate explants from 3 OA donors; explants were treated for 48 hours. IL-1beta = interleukin-1 beta, 







Factors secreted by stimulated mesenchymal stem cells modify genes related 
to inflammation and matrix turnover in synovium and cartilage.
We evaluated whether factors secreted by MSCs affected inflammatory and catabolic 
processes in osteoarthritic synovium and cartilage. First we performed experiments in 
which we cultured synovium and cartilage explants in conditioned medium from MSC 
donors which were not stimulated with TNFα/IFNγ (unstimulated MSC-conditioned me-
dium). None of the genes analyzed (mentioned later in this section) in either synovium or 
cartilage were significantly affected or affected more than two-fold by this unstimulated 
MSC conditioned medium ( Fig. 2, 3). Therefore, we did not include this condition in 
our further experiments. All further presented experiments were performed using con-
ditioned medium from TNFα/IFNγ-stimulated MSCs (designated as MSC-conditioned 
medium).
In synovial explants, MSC-conditioned medium downregulated IL-1β (P = 0.014), 
MMP1 (P = 0.034) and MMP13 (P = 0.016) gene expression, while SOCS1 expression 
Figure 3. Effects of factors secreted by non stimulated MSCs on expression of genes related to 
inflammation and matrix degradation in human osteoarthritic cartilage explants. Data are presented as 
boxplots for 3 experiments, in which MSC-conditioned medium from 3 MSC donors was applied to 
triplicate explants from 3 OA donors; explants were treated for 48 hours. ADAMTS = a disintegrin and 



















was upregulated (P = 0.002) compared to control medium (Fig. 4). MSC-conditioned 
medium did not evidently affect IL-1RA or SOCS3 gene expression of synovial explants. 
In cartilage explants, MSC-conditioned medium upregulated IL-1RA gene expression, 
while ADAMTS5 and COL2A1 expression were downregulated (Fig. 5; P < 0.001 for all 
genes). ADAMTS4 and SOCS3 were non significantly downregulated by 2.5-fold and 
1.6 fold respectively. SOCS1, MMP1, MMP13 and ACAN expression of cartilage ex-
plants were not clearly influenced by factors secreted by MSCs.
The interaction between cartilage and synovium is an important aspect in the pathogen-
esis of osteoarthritis. To evaluate the validity of our results in a more complex environ-
ment resembling more closely the in vivo situation, we exposed co-cultures of cartilage 
and synovium explants to MSC-conditioned medium (pooled from five MSC donors). 
Control experiments using pooled MSC-conditioned medium on separate cartilage and 
synovium explants revealed effects on gene expression level matching the effects ob-
served using MSC-conditioned medium from individual donors (data not shown). MSC-
conditioned medium affected gene expression levels in our co-culture model similar to 
our single explant culture model (Supp. Fig 1a,b). Synovium showed downregulation of 
IL-1β (2.7-fold) and upregulation of SOCS1 (4.6-fold). MMP1 and MMP13 appeared un-
influenced by MSC-conditioned medium. In cartilage, gene expression of IL-1RA (3.3-
fold) and SOCS1 (1.8-fold) was upregulated, whereas ADAMTS5 (2.0-fold) and COL2A1 
(1.9-fold) were downregulated by MSC-conditioned medium compared to control medi-
um. These results confirm the previously described results obtained in separate cultures 
using synovial or cartilage tissue, indicating that MSCs can have an effect in a more 
complex system that better mimics in-vivo conditions.
Figure S2. To evaluate whether the TNFα/IFNγ model reflected pathological OA processes, we tested 
the effects of TNFα/IFNγ on synovial explants from 3 donors. Data are presented as boxplots for 3 






Figure 4. Effects of factors secreted by TNFα/IFNγ stimulated MSCs on expression of genes related 
to inflammation and matrix degradation in human osteoarthritic synovial explants. Data are presented 
as boxplots for 5 experiments, in which MSC-conditioned medium from 5 MSC donors was applied to 




















Effects of mesenchymal stem cells on nitric oxide and prostaglandin E2 secre-
tion 
Cartilage explants secreted more NO than synovial explants, whereas the latter pro-
duced the most PGE2 (Fig 7a-b). In cartilage explants, MSC-conditioned medium ex-
erted a small but significant (P = 0.005) decrease in the NO secretion from 112 ± 20 
µM to 93 ± 18 µM, together with a 50% decrease in PGE2 secretion (not statistically 
significant) from 0.98 ± 0.78 ng/ml to 0.49 ± 0.18 ng/ml. No effects were seen in syno-
vial explants. 
Effects of Mesenchymal stem cells on intracellular signalling pathways
To evaluate possible signalling pathways that are influenced by MSCs, we cultured 
isolated human synoviocytes and chondrocytes in MSC-conditioned medium and ana-
lyzed phosphorylated p38 MAP kinase and IκBa amounts by Western blot. MSC-con-
ditioned medium did not influence p38 MAP kinase phosphorylation in either cell-type 
(Fig. 8a). Non-phosphorylated p38 MAP kinase was constitutively expressed for all con-
ditions (data not shown), as was α-Tubulin. Treatment with MSC-conditioned medium 
increased the presence of IκBa (Fig 8b) in both cell-types, thereby indicating that MSCs 
secrete factors which inhibit NFκB activation. 
Figure S3. Effects of TNFα/IFNγ on OA 
cartilage explants. Data are presented 
as boxplots for 3 experiments performed 
in triplicate; explants were treated for 








OA is a disabling disease where many catabolic and inflammatory processes play a role 
[8]. MSCs have chondrogenic potential, but can also play a role in immunomodulation 
and tissue regeneration by secretion of soluble factors [249]. In this study we showed 
for the first time such an effect of MSCs on OA tissues. Exposure of synovial and car-
tilage explants to MSC-secreted factors resulted in gene expression profiles and pro-
duction of factors consistent with anti-inflammatory and anti-catabolic activity in these 
tissues. This included beneficial effects on the expression of genes related to inflamma-
tion (IL-1β, IL-1RA, SOCS1) and matrix degradation (MMP1, MMP13 and ADAMTS5) in 
synovium or cartilage. These results were confirmed in a co-culture model of synovium 
and cartilage, a system resembling more closely the in-vivo situation. Next to the effects 
on gene expression, MSC-conditioned medium reduced production of the inflamma-
tory mediator NO in cartilage explants and increased presence of IκBa in synoviocytes 
and chondrocytes. The phosphorylation and degradation of IκBa, which normally binds 
NFκB, is an essential and first step in activation of the NFκB pathway. NFκB has been 
Figure 5. Effects of factors secreted by TNFα/IFNγ stimulated MSCs on expression of genes related 
to inflammation and matrix turnover in human osteoarthritic cartilage explants. Data are presented as 
boxplots for 5 experiments, in which MSC-conditioned medium from 5 MSC donors was applied to 



















reported to induce gene expression of, amongst others, IL-1β, TNFα, MMP1, MMP3 
and MMP13, indicating it’s role as a main pathway involved in inflammation and matrix 
degradation [96]. 
We needed to stimulate MSCs to achieve secretion of sufficient amounts of immuno-
modulatory factors to influence OA cartilage and synovial explants. We challenged our 
cells with TNFα and IFNγ as described before [242,243]. TNFα is an extensively stud-
ied cytokine in OA research [8,250] and the presence of IFNγ producing T-cells in OA 
synovium has been indicated [251]. To study whether this model reflected pathological 
OA processes, we tested the effects of TNFα/IFNγ on explants from three of the five 
patients (Supp. Fig. 2, 3). Several inflammatory and catabolic effects were observed in 
both tissues at gene expression level, together with a significantly increased NO and 
PGE2 production as well as p38 phosphorylation and IκBa degradation. Taken together, 
this indicates that TNFα/IFNγ induced various processes which are relevant in OA [8,96]. 
Figure 6. Influence of factors secreted by TNFα/IFNγ stimulated MSCs on NO (A, B) and PGE2 secre-
tion (C,D) by synovium (left panels) and cartilage (right panels) explants. Data are presented as box-
plots for 5 experiments (NO) or 4 experiments (PGE2), in which MSC-conditioned medium from 5 MSC 
donors was applied to triplicate explants from 5, respectively 4, OA donors. Regarding NO measure-
ments, all triplicate samples were measured individually; regarding PGE2 measurements, triplicates 
were pooled and measured in duplicate. Explants were treated for 48 hours; NO = nitric oxide, PGE2 = 






The stimulated MSCs in our experiments produced IL-6, HGF, TIMP2 and TGFβ-1 and 
displayed a high enzymatic IDO activity. The selection of this panel of factors was based 
on the fact that they are known to be secreted by MSCs at high levels and their known 
involvement in general inflammation processes or joint metabolism [250,252]. IDO is 
an important factor for the inhibition of T-cell proliferation and has been reported to 
decrease joint inflammation [253]. The role of IL-6 in osteoarthritis, however, is contro-
versial (reviewed in [8]). Although it is in general considered an inflammatory mediator, 
IL-6 deficient mice were shown to have a lower proteoglycan synthesis with a higher 
incidence of subchondral bone sclerosis [254], and increased cartilage damage which 
was reduced by IL-6 injection [255]. These results indicate possible advantageous roles 
of IL-6 in immune modulation. The other factors we determined in MSC-conditioned 
medium, HGF, TIMP2 and TGFβ-1, all play a role in tissue regeneration and cartilage 
matrix turnover [256,257,258]. 
MSC-conditioned medium upregulated SOCS1 gene expression in synovium and 
caused a trend towards SOCS3 downregulation in cartilage. SOCS1 is a negative regu-
lator of macrophage and dendritic cell activation, while SOCS3 is a positive regulator of 
these immune cells (reviewed in [259]). Furthermore, the presence of SOCS1 has been 
reported to limit joint destruction in inflammatory arthritis, whereas SOCS3 upregulation 
in chondrocytes has been shown to contribute to cartilage damage [260,261]. 
OA synovium and cartilage are known to have a very heterogeneous gene expression 
Figure 7. Influence of factors secreted by TNFα/IFNγ stimulated MSCs on P38 MAP kinase phos-
phorylation (A) and IκBa presence (B) in both synoviocytes and chondrocytes was measured by 
Western blot. Presence of IκBa was increased in both cell types by MSC-conditioned medium, thereby 
indicating an inhibitory effect on NFκB activation. Data are presented as means ± standard deviations 
for single values obtained in 2 experiments; cells were treated for 3 hours for p38 MAP kinase evalua-
tion or 10 minutes for IκBa analysis. P38 MAP kinase = p38 mitogen-activated protein kinase, IκBa = 



















pattern between patients or between different areas within the same patient [262,263]. 
Due to this high variation it is challenging to obtain consistent results. Nevertheless, 
we found significant effects of factors secreted by MSCs on inflammatory and matrix 
degrading processes. Although no clear effects of stimulated MSC-conditioned medium 
were observed on various other genes and factors we analyzed, many trends were seen 
pointing towards an overall decreased inflammatory and catabolic environment. Syno-
vial explants exhibited a lower average gene expression of SOCS3 and a higher expres-
sion of IL-1RA after treatment with factors secreted by MSCs. In cartilage, SOCS1 was 
higher expressed and ADAMTS4, MMP1 and MMP13 genes were lower expressed on 
average in MSC-conditioned medium treated samples. Next to this, in cartilage a trend 
towards a diminished PGE2 production was found. Even though these effects were 
small and not significant, partially due to a low sample size, they supported our confi-
dence in the potential of MSCs as environmental modulators and their beneficial role in 
modifying OA tissues. 
Wu et al. found a beneficial trophic effect of MSCs on GAG production by bovine chon-
drocyte pellets in a non-inflammatory environment [241]. We did not observe an effect 
on ACAN gene expression and found a downregulation of COL2A1 by MSC-condi-
tioned medium. It could be hypothesized that in an inflammatory environment, MSCs 
are mainly triggered to counteract inflammation instead of stimulating matrix formation. 
This is further supported by the observed increase of the immunomodulatory factors 
IDO and IL-6 in conditioned media from TNFα/IFNγ stimulated MSCs, although the 
amount of growth factors between stimulated and non-stimulated MSCs remained simi-
lar. Possible anabolic effects of secreted growth factors may become more obvious in 
conditions without inflammation. 
We have not assessed whether our observed paracrine effects were specific for MSCs. 
It was recently shown that skin fibroblasts suppress inflammation in an arthritis model 
[264], while others found no immunosuppressive properties of skin fibroblasts in a sep-
sis model [265]. We did not study fibroblasts since we consider this cell-type unsuitable 
for intra-articular application. MSCs have the advantage of being immune privileged, 
and they have the capacity of chondrogenic differentiation, a mechanism of action 
which is likely to be at least part of their regenerative capacity for cartilage repair [266]. 
Next to this, MSCs are locally present in multiple joint tissues [267] and are able to react 
to the joint environment, as shown by the increased presence of MSCs in synovium and 
synovial fluid after joint injury [45,46]. This suggests that the increased intra-articular 
presence of MSCs is part of a natural healing process. The administration of MSCs in 
an osteoarthritic joint could be a therapy for OA mimicking and enhancing this healing 
process and thereby provide a natural and autologous treatment for OA. 
To our knowledge, this is the first study indicating that factors secreted by MSCs cause 






synovium. We performed culture experiments for 48 hours, a common time-point to 
evaluate processes at a gene-expression level in our group [268]. Generally, this time-
point is too soon to evaluate effects at a protein level on matrix components like proteo-
glycans or aggrecan. Therefore we evaluated proteins which are known to respond very 
fast and induce other processes such as NO, PGE2, IκBa or p38 MAP kinase. Further 
studies are warranted to investigate the effects on structural properties of the cartilage 
using longer-term cultures and in vivo experiments. 
MSC-conditioned medium undoubtedly contained many more factors than the ones we 
have measured, including for instance TNFα stimulated gene-6 [269]. The whole panel 
of bio-active factors probably works in concert to achieve the anti-osteoarthritic effects 
observed in our study. Since intra-articularly injected MSCs have been shown to survive 
in an intra-articular environment up to at least four to six weeks [47,55], they could pro-
vide the ultimate long term delivery of a cocktail of OA modifying factors. 
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Background: Mesenchymal stem cells (MSCs) are promising candidates for osteoar-
thritis (OA) therapies. We studied the effects of intra-articularly injected bone marrow 
derived MSCs (both rat and human), as well as freshly isolated rat bone marrow mono-
nuclear cells (BMMNCs), on pain, structural damage and inflammation in a rat OA model 
in-vivo.
Methods: OA was induced unilaterally by injection of mono-iodoacetate (MIA). After 
three weeks, the 32 animals were randomly divided into four groups: 1. control, 2. rat 
MSCs, 3. rat BMMNCs, 4. human MSCs. Four weeks after treatment, pain was as-
sessed with an incapitance tester, subchondral bone alterations were measured with 
µCT and cartilage quality and joint inflammation were analyzed with histology. 
Results: All therapies were well tolerated by the animals. Animals treated with rat MSCs 
distributed significantly more weight to the affected limb after treatment than before 
treatment, although no statistically significant difference was observed compared to 
saline treated animals. MIA injected knees displayed significant cartilage damage, sub-
chondral bone alterations and synovial inflammation compared to contralateral knees. 
No statistically significant differences between treatment groups regarding any of these 
outcome measures were observed. 
Conclusions: This is the first study evaluating the effect of cell therapy on pain, as well 
as structural changes and synovial inflammation in a small animal OA model. No statisti-
cally significant effects of the cellular therapies compared to saline injection were found. 








































Osteoarthritis (OA) is a degenerative joint disease characterized by inflammation and 
catabolic processes, leading to progressive cartilage degeneration. Cartilage has lim-
ited intrinsic repair capacity and so far no drugs are available to structurally modify OA 
processes [234]. Mesenchymal stem cells (MSCs) are promising candidates for cartilage 
regeneration and OA therapies since they have chondrogenic potential and the ability 
to form extracellular matrix [42]. Additionally, MSCs have immunomodulatory capacities 
by secreting anti-inflammatory factors and growth factors [44], which could possibly en-
counter inflammatory and catabolic aspects of OA. Therefore, MSCs have been injected 
intra-articularly in pre-clinical and some initial clinical studies as a treatment for cartilage 
damage and OA, showing promising results [47,50,51,53,54,55,56,237,270]. Animal 
studies using cell tracking after cell injection showed only limited cartilage formation 
by chondrogenic differentiation of these MSCs [47,50,51,54,55,56]. Instead, injected 
cells were mostly found in other parts of the joint, like the synovium. Furthermore, a 
decreased amount of inflammatory cytokines in synovial fluid was found in MSC treated 
OA joints [49]. These findings underline the potential dual role of MSCs as an OA modi-
fying drug, not only able to regenerate damaged cartilage but also positively affecting 
the entire joint homeostasis.
The effects of MSC therapy on pain or other clinical outcome measures are difficult to 
assess in animal studies, and therefore they are not extensively documented. Never-
theless, pain is the main reason to proceed to joint replacement in OA patients [271]. 
As there appears to be limited relation to structural joint damage and pain in patients 
[22,271], separate evaluation of this outcome measure is essential to assess the effi-
cacy of cell therapies. The mono-iodoacetate (MIA) model has been extensively studied 
as a pain model for OA in animals [272,273,274]. 
MSCs as an OA therapy appear promising, but several practical issues hinder broad 
clinical translation. Extensive culture procedures are necessary to obtain MSCs, a costly 
and time consuming procedure requiring special facilities. Bone marrow mononuclear 
cells (BMMNCs) on the other hand, can be harvested in a one-step procedure. These 
cells contain various progenitors [275] which could also attenuate degenerative OA 
processes. Another variable impeding clinical translation is the fact that many preclinical 
studies regarding this subject use MSCs from young and healthy animals. Conflicting 
results have been described regarding the influence of patient age and disease stage 
on the presence of MSCs and their regenerative potential [180,276,277]. OA modifying 
effects of MSCs from human OA patients in a pre-clinical model would facilitate clinical 
translation based on more realistic expectations. 
In order to evaluate multiple aspects of OA pathology and to explore potential options 






tured MSCs (both rat and human), as well as rat BMMNCs, on pain structural damage 
and inflammation in a MIA rat OA model in vivo. 
Methods
Ethical approval
All human material was obtained after written informed consent, as approved by the lo-
cal medical ethical committee (protocol # MEC-2004-142). All animal experiments were 
performed after approval of the animal ethical committee (protocol # EMC116-10-07). 
Preparation and colony forming capacity of bone marrow derived cells
Human MSCs were isolated and cultured from heparinized femoral-shaft marrow aspi-
rate of two patients undergoing total hip arthroplasty using previously described pro-
cedures [157]. Cells were cultured in DMEM containing 10% fetal calf serum (FCS), 50 
µg/ml gentamicin, 1.5 µg/ml fungizone, 1ng/ml fibroblast growth factor-2 and 0.1 mM 
l-ascorbic acid 2-phosphate (MSC culture medium). All media were renewed twice a 
week.
Rat MSCs were isolated by flushing morselized femurs and tibiae from four week old 
rats. The harvested cells were cultured in MSC culture medium similar to human MSCs. 
For both cell-types, passage 2-3 cells were used for intra-articular injection. Rat bone 
marrow mononuclear cells (BMMNCs) were obtained by cell separation of the harvest-
ed bone marrow using a Ficoll gradient (Ficoll-Paque™ PLUS, d = 1,077, GE Health-
care, Vienna, Austria) at 1,000 G. BMMNCs were removed from the gradient interface, 
washed in physiological saline and subsequently injected. To assess the presence of 
MSCs in BMMNCs, aliquots of these cells were seeded at a density of 12 x 104 cells/
cm2 and cultured in MSC culture medium. After 10 days, colonies consisting of more 
than 50 cells were counted to determine the percentage of colony forming cells. It was 
demonstrated that these isolated BMMNCs had an average of one colony forming cell 
per 84,000 ± 20,000 mononuclear cells, confirming previous studies describing one cell 
in 10,000 – 250,000 BMMNCs to have MSC characteristics [276,278].  
Animal experimental design
Osteoarthritis was induced unilaterally in 32 male Wistar rats (Harlan Netherlands BV, 
Horst, the Netherlands) of 16 weeks old. OA induction was performed by an intra-artic-
ular injection of 300 µg mono-iodoacetate (MIA). Contralateral control knees were not 
injected with any substance. Rats were randomly divided into four treatment groups: 
1. Control; 2. Rat MSCs; 3. Rat BMMNCs and 4. Human MSCs. Saline was used as a 
control and as vehicle for all other injections; all injections were applied under isoflurane 







































UK). Treatments were given three weeks after OA induction in order to allow the initial 
inflammatory phase after MIA injection to cease and structural damage to occur. Rat 
MSCs and human MSCs were given at a dose of 1 x 106 cells per joint, rat BMMNCs 
were given at a dose of 10 x 106 cells per joint. Viability of all cells was assessed before 
injection and after injection, on the remainder of the cells in the syringe, by means of try-
pan blue exclusion tests. Overall cell viability was 96.3 ± 3.5% before injection and 95.5 
± 1.7% (mean ± SD) for the remainder of the cells after injection. Rats where euthanized 
four weeks after treatment, knee joints were harvested for further analyses.
Hind limb weight distribution measurements 
Hind limb weight distribution was measured using an incapacitance tester (Linton Instru-
mentation, Norfolk, UK) as an index of joint discomfort as described previously [273]. 
Animals were habituated to the apparatus starting two weeks prior to experiments. Rats 
were positioned on the incapitance tester with each hind limb resting on a separate force 
plate. The force exerted by each hind limb was measured in grams and averaged over a 3 
second period. Each rat was measured for 5 subsequent times per day on 2 consecutive 
days by an observer blinded to the given treatment. The average of 10 obtained readings 
was used to calculate the weight on the affected limb as a percentage of total weight dis-
tributed by both hind limbs. Rats were measured before inducing OA, three weeks after 
inducing OA (before treatment) and four weeks after treatment. 
µCT procedure and analysis 
To evaluate cartilage damage before cell treatment a µCT arthrography (µCTa) was per-
formed as described previously [279]. Briefly, rat knees were injected with 50 µl non-
diluted ioxaglate 320 (Hexabrix, Hazelwood, MO), mixed with epinephrine 10 µg/ml 
(Centrafarm, Etten-Leur, the Netherlands) to induce vasoconstriction and to prevent 
loss of intra-articular ioxaglate. A µCTa was made using the Skyscan 1076 µCT scanner 
(Skyscan, Kontich, Belgium). Scan time was fifteen minutes at an isotropic voxelsize of 
35 µm, voltage of 55 kV, current of 181 mA, field of view 35 mm and a 0.5 mm alumi-
num filter, over 198° with a 1° rotation step. All scans were reconstructed identically. 
Patellar cartilage volume was measured in 3D using data analysis software (CT Analyzer, 
Skyscan, Belgium) [280]. 
For subchondral bone analysis, fixated knee joints were scanned four weeks after treat-
ment ex-vivo. Scan time was 30 minutes at an isotropic voxel size of 18 µm, voltage 
of 60 kV, current of 167 mA, field of view 35 mm and a 0.5mm filter over 198° with a 
0.4° rotation step. Ex-vivo CT scans were segmented into binary datasets using an 
automated thresholding algorithm [281]. The subchondral bone part of the distal femur 
epiphysis was separated from other bone structures using in-house software. Subchon-
dral plate thickness, plate volume and total pore volume was measured in the cortical 
bone of the femoral trochlea [20]. Subchondral plate porosity was expressed as a per-






All MIA injected knees and two contralateral control knees per treatment group were 
used for analyses, leading to a total of 8 knees per group.
Tissue harvest and histologic evaluations 
After euthanasia, all rat knees were excised and fixed in formalin 4% (v/v) for one week. 
After µCT scanning, joints were decalcified with formic acid 10% (v/v) for 3 weeks and 
embedded in paraffin. Coronal sections were stained with Safranin O to evaluate struc-
tural cartilage damage and Thionin to visualize the amount and distribution of GAG. 
Thionin was used to evaluate GAG distribution due to a low sensitivity of Safranin O in 
the case of severe GAG loss [282]. Cartilage quality was evaluated with a score ranging 
from 0-6 for structure using previously described stages by Pritzker et al. [283], and a 
score ranging from 0-4 for GAG staining intensity. GAG staining intensity and structure 
grading were multiplied with a previously described staging score: 1. 0–25%; 2. 25–
50%; 3. 50–75%; 4. 75–100% of cartilage surface affected [280]. This way, a maximum 
score of 16 for GAG staining intensity and 24 for structural damage could be obtained 
for each cartilage structure, where a high score represents a high amount of GAG loss 
or structural damage. Scoring was performed on the patella, trochlea, tibial plateau and 
femoral condyles at three different positions. An average score for GAG and structure 
was calculated for each joint compartment. 
Synovial inflammation was assessed using a hematoxylin eosine staining. Synovial thick-
ness was measured from the bone margin to the capsule in the parapatellar recesses at 
the location where the synovium folds from the capsule over the femoral bone, based 
on a previously described method [284]. Synovial thickness was determined at the 
medial and the lateral side at three positions and averaged to obtain a single value per 
knee. Measurements were performed using the NanoZoomer Digital Pathology program 
(Hamamatsu Photonics, Ammersee, Germany). The amount of synovial inflammation 
was assessed by ranking the knees in an order from minimum to maximum (score 1 - 
40) based on synovial fibrillation and cellular infiltration in the subsynovial tissue. 
All MIA injected knees and two contralateral control knees per treatment group were 
used for analysis by an observer blinded to the given treatment, leading to a total of 8 
knees per group.
Statistical analysis 
The effect of treatment on the difference between weight distribution on the hind limbs 
before and after MIA and between the cellular treatments were analyzed using a re-
peated measures ANOVA test for all groups, followed by a paired t-test for all groups 
separately. Quantitative µCT and histology data was analyzed by means of unpaired 
t-tests to evaluate MIA induced effects and one-way ANOVA tests for treatment effects. 
Semi-quantitative histology scores were compared using non-parametric Mann-Whit-







































(SPSS 17.0.2; SPSS Inc., Chicago, USA). For all tests, P values < 0.05 were considered 
statistically significant.
Results 
All cell injections were well tolerated by the animals without any macroscopical sign of 
inflammation or rejection. 
Hind limb weight distribution
As a measure of pain we determined weight distribution over the hind limbs. Rats 
loaded both hind limbs equally at the start of the experiments. At baseline, the limbs 
that received MIA bore 50.6 ± 1.6 % of the weight and the contralateral limbs 49.4 
± 1.6 % (mean ± SD). Three weeks after MIA injection, weight distributed to the af-
fected leg was significantly reduced compared to baseline (45.8 ± 5.4 % vs 50.6 ± 
1.6 %, P<0.001, Fig 1A, mean ± SD), indicating pain sensation. No differences were 
observed between the treatment groups at this time point (P = 0.937), pointing to-
wards a random distribution of MIA induced pain. Four weeks after cellular treat-
ment, the group treated with rat MSCs was the only group that had significantly 
more weight distributed to the affected limb after treatment than pre-treatment ( 51.2 
± 5.0 % vs 46.5 ± 4.1 %, P = 0.003, Fig 1B-E, mean ± SD). When comparing the 
treatment groups after 4 weeks, no significant differences were observed (P = 0.651, 
Fig. 1F).
Structural integrity: cartilage quality and subchondral bone alterations
uCT arthrography was used to assess loss of cartilage volume elicited by the MIA in-
jection as a measure of cartilage quality before cellular treatments. MIA injected knees 
displayed a smaller cartilage volume than control knees (0.48 ± 0.15 mm3 vs 0.82 ± 
0.17 mm3, P < 0.001, data not shown, mean ± SD). Cartilage volume did not differ be-
tween the MIA injected knees of the different treatment groups (P = 0.929), indicating a 
random distribution of cartilage loss before application of the treatment.
Cartilage quality at the end of the experiments was measured on histology with a semi-
quantitive score for GAG loss and structural damage. Cartilage damage was most pro-
nounced in the patellofemoral region and all presented data reflect this compartment. 
For this compartment the scores of the patella and the trochlea were accumulated, 
leading to a score range for GAG loss from 0 to a maximum loss of 32 and a score range 
for structural damage from 0 to a maximum damage of 48. MIA injected knees showed 
more GAG loss than non-MIA injected knees (24.0 (0.0 – 32.0) vs 1.5 (0.0 – 2.0), P < 
0.001, Fig. 2A-C, range (95 % CI)). No significant between the treatment groups were 






Structural cartilage damage was significantly present in MIA injected knees versus con-
trol knees (4.4 (0.0 - 8.5) vs 1.3 (0.0 - 2.2), P < 0.001, Fig. 2D, range (95 % CI)). Be-
tween the different treatment groups, no statistically significant differences were found 
(P = 0.959). 
Figure 1. Assessment of hind limb weigh distribution Hind limb weight distribution was deter-
mined as an index of joint discomfort. MIA caused a reduction of weight distributed to the affected 
limb (A). Rat MSC injection was the only treatment that caused a significant increase in weight distrib-








































Ex vivo uCT was used to evaluate trochlear subchondral bone porosity and thickness 
after treatment. Overall, MIA injected knees had a significantly more porous (6.3 ± 6.2 % 
vs 2.0 ± 0.8 %, P < 0.001, mean ± SD) and thinner (221.1 ± 29.4 µm vs 253.8 ± 19.1 
µm, P = 0.005, mean ± SD) subchondral plate than control knees (Fig. 3A-D), which 
is in concordance with previously reported early OA related changes [20,285,286]. No 
statistically significant differences between treatment groups were observed regarding 
porosity (P = 0.208) or subchondral plate thickness (P = 0.607).
Synovial inflammation
Synovial inflammation was evaluated by measuring synovial thickness at the parapatel-
lar recesses and ranking the samples based on synovial fibrillation and cellular infiltration 
(Fig. 4A,B). MIA injected knees had a thicker synovium (730.4 ± 94.8 µm vs 601.6 ± 
32.6 µm, P < 0.001, mean ± SD) and inflammation was ranked higher (24.5 (5.0 – 40.0) 
vs 5.0 (1.0 – 12.0), P < 0.001, range (95 % CI)) than control knees without MIA injec-
Figure 2. Cartilage quality Thionin staining demonstrated evident GAG loss and mild structural 
cartilage damage in MIA injected knees compared to contralateral control knees (A-D). No significant 






tion (Fig. 4C,D). No significant differences were observed between treatment groups for 
synovial thickness (P = 0.115) or inflammation ranking (P = 0.111). 
Since the data on synovium suggested possible differences between the treatment 
group we performed explorative statistical analyses by comparing individual treatement 
groups with the saline injected control group. This revealed that synovium in the group 
injected with rat MSCs showed a trend to be thicker than in the saline injected group 
(P = 0.071) but not more inflamed (P = 0.382). Interestingly, the synovium in the group 
injected with human MSCs was significantly thicker (P = 0.028) and had a trend to be 
more inflamed (P = 0.083) than the saline injected group (P = 0.028). Injection with the 
mononuclear fraction of rat bone marrow did not affect synovium thickness (P = 0.733) 
nor inflammation (P = 0.574).
Figure 3. Subchondral bone plate evaluation µCT analyses displayed increased porosity and thin-
ning of trochlear subchondral bone plates in MIA injected animals compared to contralateral control 









































OA is a disabling disease where many catabolic and inflammatory processes play a role 
[8]. MSCs are promising candidates for OA treatment. MSCs have chondrogenic poten-
tial, but also play a role in immunomodulation and tissue regeneration by the secretion 
of soluble factors [249]. We studied the effects of intra-articularly injected cultured MSCs 
(both rat and human), as well as rat BMMNCs, on pain in addition to inflammation and 
structural damage in a rat OA model in-vivo. We used multiple techniques to evaluate 
these outcome measures by blinded observers, including hind limb weight distribution to 
assess pain, uCT analyses to assess subchondral bone changes and histological evalua-
tion of cartilage quality and synovial inflammation.
Figure 4. Synovial thickness and inflammation Hematoxylin eosine staining illustrating increased 
synovial thickness, fibrillation and subsynovial cellular infiltration in MIA injected knees compared to 
contralateral control knees. No significant differences between treatment groups were found. Magnifi-






We did not find statistically significant differences between the different treatment 
groups on any of the structural outcome measures. The rat MSC treated group was 
the only group which significantly increased loading of the affected limb after treatment, 
although no significant difference at the endpoint of the study was found compared to 
the saline injected animals.
Since knee pain in OA patients is a major reason for knee replacements and pain is known 
to be badly correlated to structural damage [22,271], we consider it important to include 
this outcome measure to evaluate the efficacy of OA modifying therapies. To date, two 
other studies are known describing the influence of MSCs on pain and range of motion 
in large animal OA models, with conflicting results. Black et al. reported an improvement 
in lameness, pain on manipulation and range of motion in dogs treated with MSCs for 
naturally developed OA [48]. Frisbie et al. on the other hand, found no improvement in 
pain and range of motion following MSC treatment in a horse OA model [49]. Pain can be 
measured using several methods and is a complicated phenomenon consisting of inflam-
matory and neuropathic aspects [287,288]. Further evaluation of multiple pain aspects is 
needed to assess the capacity of MSCs to alleviate osteoarthritic pain.
One of the goals of our study was to compare the efficacy of allogeneic rat MSCs, allo-
geneic rat BMMNCs and xenogeneic human MSCs in their OA modifying capacity. Due 
to limited overall treatment effects, the value of this comparison is fairly limited. How-
ever, it should be noted that no severe adverse effects were observed in our study after 
intra-articular application of allogeneic rat MSCs, allogeneic rat BMMNCs or xenogeneic 
human MSCs.  Albeit MSCs have been previously described to be immune privileged 
[249,289], more recent reports show that MSCs maintain a degree of immunogenicity 
that may limit their longevity and attenuate their advantageous effects [290,291,292]. 
We found no macroscopic signs of inflammatory responses in the (sub)acute phase 
after cell injections, indicating that they did not induce a substantial immune response. 
Nevertheless, we can not rule out that the MSCs used in this study elicited a mild im-
munological reaction given their non-autologous origin. This could account for the his-
tological response of the synovial membrane in the group injected with rat and, more 
particularly, human MSCs as indicated by our explorative statistical analyses and might 
also counteract possible favorable effects of these cells, resulting in mild overall treat-
ment effects.
We used a mild OA model since we hypothesized that a fully degenerated joint would 
be beyond the repair capacity of cellular therapies. A disadvantage of this approach is 
that at the moment of cell injections certain animals had not developed evident OA-like 
characteristics on µCTa. After excluding animals without MIA-induced cartilage damage 
at the moment of treatment (four animals in total), the possible beneficial effects of rat 
MSC compared to saline became more pronounced for all outcome measures, but still 







































Previous studies have shown positive effects of intra-articularly injected MSCs on carti-
lage quality in various animal models [47,55,57]. These studies used surgical OA models 
with a joint instability component. Two of these reports used cell tracking and showed 
homing of the cells mainly to the damaged structure and the synovium [47,55]. This 
indicates an indirect protective effect of the MSCs and does not point towards actual 
regeneration of cartilage. The fact that there was no joint instability component in our 
model which could have been attenuated by MSCs, could explain the modest effects of 
our cellular treatments. This is in accordance with Frisbie et al., who found no effect of 
MSCs on cartilage quality in a horse osteochondral defect OA model [49]. In addition, 
Matsumoto et al. found just a trend towards improved cartilage quality after injection of 
muscle-derived stem cells (MDSCs) in a rat MIA OA model [54]. The effects of MDSCs 
became only clear after they were transduced with bone morphogenetic protein 4 and 
sFlt-1, a vascular endothelial growth factor antagonist. We used an OA model affecting 
the entire joint without mechanical instability, in that way resembling the majority of clini-
cal OA patients. The fact that in such models repeatedly very modest effects of stem cell 
therapies are reported and that the effects are increased after genetic cell manipulation 
indicates that further optimization is required before large scale clinical application. 
Another factor influencing the effect of MSCs could be the time of injection. We in-
jected our cell preparations after the inflammatory phase of the MIA model had ceased. 
Although MSCs are known to have immunosuppressive capacities [249], MSCs need 
stimulation in order to exert their immunosuppressive role [293,294]. Possibly, the 
amount of inflammation in our model did not elicit an immunomodulatory MSC function, 
thereby minimizing potential beneficial effects.  
The capacity of intra-articularly injected MSCs to regenerate cartilage in defects or to 
limit cartilage damage in surgical OA models with a joint instability component has 
been demonstrated by others [47,50,51,52,53,55,56,57,295], indicating the potential 
of this strategy for joint diseases. The effects of MSCs applied in OA models without 
an instability component as found by others [49,54] and presented in the current study 
are slightly beneficial, but overall remain modest. The fact that we did not observe clear 
effects in our study could have many causes including the use of a mild OA model, 
the absence of apparent inflammation upon time of injection or the fact that we used 
non-autologous cells. Further optimization could make use of cell tracking methods al-
lowing further insight in the function and survival of the cells [50], genetic manipulation 
of administered cells [54] or by selection or pre-treatment of MSCs [296] to generate 
subpopulations which are most suitable for modifying OA processes. Since OA is a 
multifactorial disease consisting of many simultaneous processes, assessment of the 
effect of cellular therapies on structural joint aspects, joint inflammation as well as pain 
in various OA models and after application in early and later stages of the disease is 
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Background: The use of superparamagnetic iron oxide (SPIO) for labeling cells holds 
great promise for clinically applicable cell tracking using magnetic resonance imaging 
(MRI). For clinical application, an effectively and specifically labeled cell preparation is 
highly desired (i.e. a high amount of intracellular iron and a negligible amount of extra-
cellular iron). In this article we compare ferumoxides and ferucarbotran, two previously 
described SPIOs for labeling human Bone Marrow Stromal Cells (hBMSCs) and chon-
drocytes.   
Methods: hBMSCs and chondrocytes were labeled using ferumoxides-protamine sul-
fate complexes or ferucarbotran. Labeling protocols for either approach were based on 
previously reported protocols. Outcome parameters were labeling efficiency, total iron 
load (TIL), and intra- and extracellular iron load. TIL of labeled cells was measured using 
inductively coupled plasma - optical emission spectrometry. Other outcome parameters 
were based on light microscopy evaluation of labeled cells, which were stained using 
Perl’s iron stain. 
Results: Cell labeling using ferumoxides-protamine resulted in higher labeling efficien-
cies for both cell types compared to ferucarbotran (96.1 vs 89.2% for hBMSCs and 
99.8 vs 97.2% for chondrocytes). Furthermore, ferumoxides-protamine showed a high-
er TIL compared to ferucarbotran (89.6 vs 51.3 pg/cell for hBMSCs and 75.9 vs 28.1 
pg/cell for chondrocytes). For both cell-types, ferumoxides-protamine labeling resulted 
in a higher intracellular iron load and a lower amount of extracellular iron aggregates 
compared to ferucarbotran.
Conclusions: Cell labeling using ferumoxides-protamine complexes and ferucarbotran 
resulted in histologically clearly visible labeling of both hBMSCs and chondrocytes. 
Ferumoxides-protamine complexes resulted in a superior labeling efficiency and TIL 
relative to labeling with ferucarbotran. Furthermore, ferumoxides-protamine complexes 
resulted in a higher intracellular iron load and a lower amount of extracellular iron. We 
consider ferumoxides-protamine to be a more effective and specific labeling method 






















Cell tracking is a necessary tool for determining the efficacy and safety of cell based re-
generative therapies. Cell labeling using superparamagnetic iron oxide (SPIO) particles 
allows subsequent in vivo cell tracking using magnetic resonance imaging (MRI) and 
has already entered the clinical arena [62,63,64]. Ferumoxides and ferucarbotran are 
two SPIOs frequently described for the purpose of cell labeling and -tracking using MRI. 
Both SPIOs have comparable particle sizes (60-150 nm), but whereas ferumoxides par-
ticles have a dextran coating, ferucarbotran particles are carboxydextran coated [297]. 
These additional carboxyl groups associated with ferucarbotran lead to a higher affinity 
to the cell membrane [298]. This difference in coating appears to be the main reason 
why efficient labeling of non-phagocytic cells with ferumoxides requires additional use of 
a transfection agent, while adequate labeling of non-phagocytic cells with ferucarbotran 
can be accomplished without the need of an additional agent [297,298]. Several trans-
fection agents are being used to facilitate cellular incorporation of ferumoxides [298,299]. 
Amongst them, protamine sulfate is the most interesting from a clinical point of view 
since it is already used for, and has FDA approval as, a heparin antidote [300]. When ap-
plying SPIO labeled cells in vivo or clinically, an effectively and specifically labeled prepa-
ration of cells is highly desired (i.e. a high intracellular iron load and a negligible amount 
of extracellular iron). Effective labeling is essential since MRI sensitivity is reported to be 
influenced by total iron load (TIL) per cell [301]. Moreover, the endocytosed SPIO parti-
cles are known to dilute upon 5-8 cell divisions [302]. A high intracellular amount of iron 
is likely to positively influence the duration of MRI traceability. Extracellular iron on the 
other hand, could potentially be endocytosed by host cells, or generate MRI signal voids 
on its own. Effective cell labeling of different cell types, including human bone marrow 
stromal cells (hBMSCs), using ferumoxides-protamine or ferucarbotran has been de-
scribed in numerous publications [297,298,300,303,304,305,306]. Although for both 
approaches comparable labeling efficiencies up to approximately 100% have been re-
ported regarding hBMSC labeling, both methods are hampered by the occurrence of 
extracellular iron nanoparticle aggregates [298,300,304,305,306,307].  No publications 
are known comparing ferumoxides-protamine sulfate to ferucarbotran labeling directly 
on the same cell-types. This study aims to compare both approaches based on accept-
ed protocols found in current literature. Outcome measures were labeling efficiency, TIL, 
intra- and extracellular iron load. We performed our experiments on the two cell types 








hBMSCs and human chondrocytes were isolated and cultured using previously de-
scribed procedures [157,313] (after informed consent; MEC-2004-142)(after approval 
by the local ethical committee; MEC-2004-322).. . 
Fresh medium was applied to all cells every 3 to 4 days. All media consisted of DMEM 
containing 10% FCS, 50 µg/ml gentamicin and 1.5 µg/ml fungizone. Cells were trypsin-
ized at subconfluency and subsequently passaged. Cells from the third to the sixth pas-
sage, both freshly collected and cryopreserved, were used for the labeling experiments. 
Cell labeling 
Cells were labeled using ferumoxides (Endorem®, Guerbet S.A., Paris, France) -prot-
amine sulphate (LEO Pharma N.V., Wilrijk, The Netherlands) complexes or ferucar-
botran (Resovist®, Bayer Schering Pharma AG, Berlin, Germany). Labeling proto-
cols used for both SPIOs closesely resembled labeling protocols found in literature 
[297,298,300,303,304,305,306]. 
Ferumoxides- protamine sulfate
Both hBMSCs and chondrocytes were grown till 80-90% confluency in six-well plates. At 
that time, existing medium was removed and 1 ml of fresh DMEM containing 10% FCS 
was added per well. Protamine sulfate was prepared as a fresh stock solution of 1 mg/ml 
in distilled water. Ferumoxides was diluted in serum-free DMEM to a final concentration of 
100 µg/ml. Protamine sulfate was added to the ferumoxides solution to a final concentra-
tion of 5 µg/ml. After 3 to 5 minutes of intermittent shaking by hand at room temperature, 
the ferumoxides-protamine solution was added to the freshly applied medium on the cells 
in a 1:1 v/v ratio (final dose 100 µg of iron per well of a six-well plate). 
Ferucarbotran
Both hBMSCs and chondrocytes were seeded in six-well plates at a density of 50,000 
cells per cm2 on day one. After 24 hours, existing medium was discarded. Subse-
quently, 1 ml of fresh medium was applied and ferucarbotran was added to the media 
at a final concentration of 100 µg/ml (final dose 100 µg iron per well of a six-well plate). 
Labeling efficiency
Medium was removed after 24 hours of incubation with either ferumoxides-protamine 
complexes or ferucarbotran. Cells were washed twice using PBS, trypsinized and re-
plated in six-well plates (seeding density 10,000 cells/cm2). Replated cells were fixed 
within one day and stained using Perl’s iron stain (Klinipath BVBA, Duiven, The Nether-
lands) according to the manufacturers protocol. All samples were evaluated using light 





















were considered positive if blue granules were present within cell boundaries. A mini-
mum of 100 randomly selected cells was counted per sample at 400X magnification. 
Total iron load per cell
TIL was measured in samples containing trypsinized cells using inductively coupled 
plasma - optical emission spectrometry (ICP-OES). Cell pellets of unlabeled and la-
beled cells were dried for 72 h at 60°C. Then they were digested in 40µl of a 3:1 v/v 
mixture of ultra-pure perchloric acid (EM Science, Gibbstown, NJ, USA) and ultra-pure 
nitric acid (JT Baker, Deventer, The Netherlands) at 60 ºC for 24 hours. To the digested 
substance 4 ml MiliQ was added and emission was measured at 259nm with a Perkin 
Elmer Optical Emission Optima 4300 DV Spectrometer. The amount of iron per sample 
was determined by calibration to a standard curve, which was generated using a com-
mercially available ICP-OES standard iron solution (Merck, Schiphol, The Netherlands) 
in a range of 0 to 50 µg/ml. 
Evaluation of intra- and extra-cellular iron 
To further discriminate between intra- and extracellular iron load, a grading score was 
developed. In this score, quantity of both intra- and extracellular iron was graded on 
a four-point scale (table 1). All samples were stained using Perl’s iron stain and evalu-
ated using light microscopy. Amount of intracellular iron was based on number of in-
tracellular blue granules. A minimum of 100 randomly selected cells per sample was 
manually evaluated for intracellular iron according to this score at 400X magnification. 
Extracellular iron was quantified based on number and size of extracellular SPIO aggre-
gates. Analysis of extracellular iron was based on 40 randomly selected fields of view 
at 100X magnification in order to get a representative evaluation of the total well. Iron 
particles were considered extracellular if they were not localized within cell boundaries. 
Iron within the boundaries of dead cells was not considered extracellular. All samples 
were evaluated independently by two blinded observers. 
Data analysis
All experiments have been performed with triplicate samples for each of the three dif-
ferent hBMSC and chondrocyte donors except for TIL measurements, which were per-
formed with triplicate samples for one hBMSC and one chondrocyte donor. Indepen-
dent scores of both observers were compared and proved to be similar. For further 
calculations all data from both observers regarding intra- and extracellular iron was 
accumulated per sample. Data is shown in terms of percentage distribution of different 
grades of intra- and extracellular iron of all evaluated samples. Labeling efficiencies and 
percentages of different grades were compared using a mixed model ANOVA, in which 
treatment was considered a fixed factor and the three different donors a random factor. 







Labeling efficiency and total iron load per cell
SPIO labeling using ferumoxides-protamine or ferucarbotran resulted in histologically 
clearly visible label uptake in both cell types (Figure 1). Blue stained SPIO particles 
were seen in the cytoplasm of cells, mostly around the nuclei. No apparent effects of 
either labeling procedures were seen in terms of changes in cell morphology or viability. 
Ferumoxides-protamine showed a higher labeling efficiency compared to ferucarbotran 
for hBMSCs (96.1 ± 4.5% vs 89.2 ± 8.0%;  P = 0.008) and chondrocytes (99.8 ± 0.3% 
vs 97.2 ± 1.8%; P < 0.000). ICP-OES measurements of ferumoxides-protamine labeled 
cells showed a higher TIL for hBMSCs (of 89.6 ± 14.9 vs 51.3 ± 4.35 pg/cell) and chon-
drocytes (75.9 ± 9.53  vs 28.1 ± 3.04 pg/cell) compared to ferucarbotran. 
Evaluation of intra- and extracellular iron 
For further evaluation of the distribution of TIL between the intra- and extracellular com-
partment we scored all samples using a four-point grading system (table 1). Figure 2A 
shows representative examples of all different grades of intracellular iron. Ferumoxides-
protamine complexes resulted in a markedly higher intracellular iron load compared to 
Figure 1: Perl’s iron stain of SPIO labeled hBMSCs (left) and chondrocytes (right). Blue stained SPIO 





















ferucarbotran for both cell types (Figure 2B). In ferumoxides-protamine labeled hBMSCs 
64.2 ± 26.1% of cells had an intermediate to high intracellular iron load compared to 
21.9 ± 22.0% of ferucarbotran labeled hBMSCs (P < 0.000). In ferumoxides-protamine 
labeled chondrocytes 96.6 ± 2.2% of cells showed an intermediate to high amount of 
intracellular iron versus 45.6 ± 8.4% in the ferucarbotran labeled cells (P < 0.000). 
The amount of extracellular iron was evaluated using a comparable four-point grading 
system (table 1). Extracellular iron presented as aggregates varying in size from barely 
visible to large aggregates up to the equivalent of fifty cell diameters. Aggregates in all 
samples were seen both sticking to cell membranes and as loose aggregates. Figure 
2C shows representative examples of all different grades of extracellular iron. Ferumox-
ides-protamine labeling of cells resulted in less extracellular iron compared to ferucar-
botran in both cell-types (Figure 2D). In ferumoxides-protamine labeled hBMSCs 19.3 
± 13.7% of fields of view showed an intermediate to high amount of extracellular iron, 
compared to 47.6 ± 19.1% in the ferucarbotran labeled conditions (P = 0.001). When 
labeling chondrocytes a comparable difference was observed. In 20.2 ± 11.1% of fields 
of view an intermediate to high amount of extracellular iron was observed in the feru-
moxides-protamine labeled condition, compared to 57.2 ± 10.2% in the ferucarbotran 
labeled cells (P < 0.000). 
Table 1: Description of four-point grading score used for evaluation of intra- and extracellular iron
Intracellular iron load Appearance intracellular compartment
Absent No blue granules 
Low 1-20 blue granules 
Intermediate 21-100 blue granules
High >100 blue granules or granules no longer separately 
distinguishable 
Extracellular iron load Appearance extracellular compartment
Absent No aggregates
Low 1-5 aggregates < 1 cell size
Intermediate >5 aggregates < 1 cell size or 1-5 aggregates 1-10 cell sizes







In this study we performed a direct comparison on two primary cell types (hBMSCs and 
chondrocytes) of two SPIO labeling approaches using ferumoxides-protamine complex-
es and ferucarabotran. Both strategies resulted in effective labeling of both cell types. 
However, we did find significant differences in the quality of cell labeling. For both cell 
types ferumoxides-protamine resulted in a higher percentage of labeled cells (96.1-
99.8% vs 89.2-97.2%) and a higher TIL (75.9-89.6 pg/cell vs 28.1-51.3 pg/cell) com-
pared to ferucarbotran. In addition, ferumoxides-protamine complexes also resulted in 
a higher amount of intracellular iron together with a lower amount of extracellular iron 
aggregates in both cell-types. 
Both ferumoxides and ferucarbotran contain particles ranging from 60-150 nm [297]. 
When complexing ferumoxides to protamine sulfate however, much larger particles are 
formed up to approximately 2,000-2,500 nm [308]. Several articles reported the fact 
Figure 2: Perl’s iron stain of representative examples of all four different intra- and extracellular iron 
grades (A, C) and intra- and extracellular iron grade distribution (B, D) of hBMSCs and chondrocytes 
labeled using ferumoxides-protamine (Fe-Pro) and ferucarbotran. Ferumoxides-protamine resulted in 
a higher percentage of cells showing a high to intermediate amount of intracellular iron particles (B) 
and a lower percentage of fields of view showing a high to intermediate amount of extracellular iron 





















that cellular uptake in transfection experiments is positively influenced by increasing par-
ticle size of transfection complexes [309,310]. These articles describe the fact that larger 
particles can sediment faster onto cells and that larger particles have a bigger payload. The 
latter results in the delivery of more transfection material at a similar cell-surface occupation. 
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[297] Hsiao et 
al. (2007)
Ferucarbotran  100 
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et al. (2008)
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Comparable labeling efficiencies and cellular iron loads have been reported for hBMSCs labeling us-
ing ferumoxides-protamine sulfate and ferucarbotran. Majority of articles mention the occurrence of 
extracellular iron aggregates. Mailander et al. indirectly quantified this amount of extracellular iron. TA: 
transfection agent. NM: not mentioned. 







Several studies describe the use of ferumoxides-protamine complexes or ferucarbotran 
for labeling of hBMSCs [297,298,300,303,304,305,306]. In general, these reports show 
comparable labeling efficiencies and cellular iron loads for both techniques (table 2). La-
beling efficiencies of 71-100% have been described, dependent on the protocol used. 
Iron load per cell ranged from 10.9 - 44.7 pg/cell. Unfortunately none of the published 
articles directly compared both labeling methods. In our study the observed labeling 
efficiencies and TIL per cell for hBMSCs labeling using both ferumoxides-protamine 
and ferucarbotran were similar to those previously reported, making it possible to relate 
our results to the articles listed in table 2. In various studies modifications of labeling 
protocols have been mentioned in order to increase cellular uptake or decrease the oc-
currence of extracellular iron deposits. Several publications describe the use of heparin 
washes (10 U/ml) to dissolve extracellular ferumoxides-protamine sulfate complexes 
[300,304,306]. Moreover, Pawelczyk et al. report in their publications the approach 
of allowing cells to take up additional iron complexes for two days after the labeling 
procedure [300,306]. We did not include heparin washes or additional time for feru-
moxides-protamine complex endocytosis in our main experiments, in order to better 
compare both techniques. In additional experiments, where we included heparin wash-
es (10 U/ml) and additional time to endocytose ferumoxides-protamine complexes, the 
amount of extracellular iron appeared to decrease during microscopic evaluation (data 
not shown). This observation was made for both cell types, making ferumoxides-prota-
mine even more favourable over ferucarbotran.  
Ferucarbotran labeled hBMSCs showed rather poor intracellular labeling with approxi-
mately 80% of cells showing no or low amounts of intracellular iron. Although not the 
primary scope of this report, we adjusted the labeling protocol regarding ferucarbotran 
in order to increase the quantity of intracellular iron. We were able to greatly improve cel-
lular SPIO uptake of hBMSCs labeled with ferucarbotran, by labeling 5 hours after cells 
were seeded instead of 24 hours and by labeling in a serumfree environment (data not 
shown). Unfortunately this simultaneously led to an increase in amount of extracellular 
iron observed, making this an unfavourable option.
In our study we did not perform differentiation, viability or cytotoxicity assays.  Cell  la-
beling using both  SPIOs has been shown not to influence  several cell behaviour char-
acteristics [297,298,300,303,304,305]. [311]. We did not observe increased cell death 
or changes in morphology between labeled cells versus unlabeled controls for both 
cell-types. Labeling chondrocytes using ferumoxides-protamine did result in a distinct 
higher amount of intracellular iron compared to hBMSC labeling. Differences between 
labeling different cell-types using SPIOs have been reported previously [302,312]. The 
high amount of intracellular iron might have an effect on chondrocyte metabolism. This 
needs to be further investigated before proceeding to any in vivo or clinical experiments. 
Conclusions
We have shown ferumoxides-protamine sulfate to be a more effective and specific 
way of SPIO labeling compared to ferucarbotran for both primary hBMSCs and human 
chondrocytes. 
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Background: Articular cartilage has very limited intrinsic regenerative capacity, mak-
ing cell-based therapy a tempting approach for cartilage repair. Cell tracking can be a 
major step towards unraveling and improving the repair process of these therapies. We 
studied superparamagnetic iron oxides (SPIO) for labeling human bone marrow-derived 
mesenchymal stem cells (hBMSCs) regarding effectivity, cell viability, long term metabol-
ic cell activity, chondrogenic differentiation and hBMSC secretion profile. We additionally 
examined the capacity of synovial cells to endocytose SPIO from dead, labeled cells, 
together with the use of magnetic resonance imaging (MRI) for intra-articular visualiza-
tion and quantification of SPIO labeled cells.
Methods: Efficacy and various safety aspects of SPIO cell labeling, were determined us-
ing appropriate assays. Synovial SPIO re-uptake was investigated in vitro by co-labeling 
cells with SPIO and green fluorescent protein (GFP). MRI experiments were performed 
on a clinical 3.0T MRI scanner. Two cell-based cartilage repair techniques were mim-
icked for evaluating MRI traceability of labeled cells: intra-articular cell injection and cell 
implantation in cartilage defects. Cells were applied ex vivo or in vitro in an intra-articular 
environment and immediately scanned. 
Results: SPIO labeling was effective and did not impair any of the studied safety as-
pects, including hBMSC secretion profile. SPIO from dead, labeled cells could be taken 
up by synovial cells. Both injected and implanted SPIO-labeled cells could accurately 
be visualized by MRI in a clinically relevant sized joint model using clinically applied cell 
doses. Finally, we quantified the amount of labeled cells seeded in cartilage defects 
using MR-based relaxometry. 
Conclusions: SPIO labeling appears to be safe without influencing cell behavior. SPIO 
labeled cells can be visualized in an intra-articular environment and quantified when 






















Articular cartilage provides low friction and allows for efficient load bearing and distribu-
tion in synovial joints. Cartilage is avascular, aneural and lacks lymphatic drainage. Con-
sequently, natural repair mechanisms are underprovided, giving cartilage a very limited 
intrinsic regenerative capacity [13]. Current cell-based cartilage repair techniques aim 
at restoration of the functional properties of damaged cartilage. Human bone marrow-
derived mesenchymal stem cells (hBMSCs) and chondrocytes are two cell-types cur-
rently used for these approaches 
[216,237,314,315]. hBMSCs can be either implanted in focal defects, or injected intra-artic-
ularly to repair more generalized cartilage lesions like osteoarthritis [237,315]. Chondrocytes 
are mainly being used for implantation in focal cartilage defects, a procedure known as 
autologous chondrocyte implantation (ACI) [216,314]. Despite the improvements made in 
cell-based cartilage regeneration in the past decades, repaired cartilage does not entirely 
resemble native cartilage and can not guarantee a permanent solution at this moment [217]. 
To elucidate the relevant repair mechanisms and for optimization of cell-based thera-
pies, it is necessary to determine the fate of implanted cells. Superparamagnetic iron 
oxides (SPIOs), such as ferumoxides, have already been used clinically for cell label-
ing and in vivo cell tracking in dermal oncology, neural regeneration and pancreatic islet 
transplantation [316]. No negative effects of the labeling procedure have been report-
ed in these initial clinical studies. Before implementing this approach to an orthopedic 
application, any possible negative influence of SPIO labeling on cell behavior must be 
ruled out. Besides repopulation of damaged tissue through proliferation and differentia-
tion of hBMSCs, secretion of certain trophic factors by transplanted hBMSCs has more 
recently been suggested as a possible mechanism by which hBMSCs promote tissue 
regeneration [4]. These bioactive molecules could provide a regenerative microenviron-
ment to initiate a self-regulated regenerative response. To our knowledge, the effects 
of SPIO labeling on factors secreted by hBMSCs have not been investigated before. 
Another point of interest is the feasibility of tracking SPIO-labeled cells within the joint 
in relation to other anatomical structures, using a clinical magnetic resonance imag-
ing (MRI) protocol, in a model of clinically relevant size. For these purposes, it must be 
checked how long cells retain the SPIO label and it should be validated if generated 
MRI signals arise from originally labeled cells. Next to cell visualization, quantification of 
labeled cells implanted in cartilage defects by MRI could provide an exquisite opportu-
nity to longitudinally map the role and contribution of implanted cells to cartilage repair. 
The aim of this study was to label hBMSCs using SPIOs and evaluate the effects of iron 
incorporation on cell viability, long term metabolic cell activity, differentiation and secretion 
profile. Furthermore we examined the SPIO retention of labeled cells and the capacity of 
synovial cells to endocytose SPIO from dead, labeled cells. Finally, we studied the use 








All human samples were obtained after approval by the Erasmus MC medical ethical 
committee. hBMSCs were isolated from heparinized femoral-shaft marrow aspirate of 
patients undergoing total hip arthroplasty (after written informed consent; protocol # 
MEC-2004-142). Articular cartilage and synovial explants were obtained as redundant 
material from patients undergoing total knee replacement surgery. All patients implicitly 
consented to the use of these tissues for scientific research (protocol # MEC-2004-
322).
Cell isolations and cultures 
hBMSCs and human chondrocytes were isolated and cultured using previously de-
scribed procedures [157,245]. All isolated cells or explants were cultured in DMEM con-
taining 10% FCS, 50 µg/ml gentamicin and 1.5 µg/ml fungizone (defined as standard 
medium) unless stated otherwise. hBMSCs were cultured using additional 1ng/ml FGF2 
and 1x10-4 M vitamin C. All hBMSCs and chondrocytes were used at passage 2-5 in 
labeling experiments.
SPIO labeling 
SPIO labeling was performed using ferumoxides (Endorem®, Guerbet S.A., Paris, France) 
complexed to protamine sulfate (LEO Pharma N.V., Wilrijk, Belgium) as described earlier 
[331]. For removal of extracellular iron, cells were washed with PBS containing heparin 
10 U/ml (LEO Pharma B.V., Breda, the Netherlands). SPIO labeling mix was made at 
a constant concentration of 100 µg/ml ferumoxides with 5 µg/ml protamine to ensure 
identical particle formation [308]. Cells were labeled with doses ranging from 2.5–25 µg/
cm2 of ferumoxides. 
Labeling efficiency, chondrogenic differentiation and functional assays 
Histological iron detection was performed using a Perl’s iron stain (Klinipath BVBA, 
Duiven, the Netherlands) according to the manufacturer’s protocol. Labeling efficiency 
was determined in triplicate samples for three donors by manually counting labeled cells 
stained with Perl’s iron [331]. Total iron load was measured in triplicate samples from 
three donors by inductively coupled plasma - optical emission spectroscopy [331]. Cell 
viability was evaluated by trypan blue exclusion. After labeling, cells were seeded in 
96-well plates at a density of 10,000 cells per well. AlamarBlue® (Invitrogen, Breda, the 
Netherlands) was used according to manufacturer’s protocol for longitudinal measure-
ment of metabolic cell activity at day 0, 3 and 7. 
Chondrogenic differentiation was performed in triplicate samples on hBMSCs pellets 
from two donors according to previously reported protocols [334]. Chondrogenically 





















Developmental Studies Hybridoma Bank, Iowa City, IA) and thionine stain [334,335]. 
hBMSCs used for gene expression analysis and glycosaminoglycan (GAG) measure-
ments were chondrogenically differentiated in alginate beads [87] using an otherwise 
identical differentiation protocol. RNA extraction, cDNA synthesis, real-time RT-PCR 
and collagen II primers for gene expression analysis were described earlier [90]. GAG 
measurements were performed using a dimethylmethylene blue (DMB) assay [336]. 
To investigate the influence of SPIO labeling on cytokines secreted by hBMSCs, labeled 
and unlabeled cells from five donors were cultured for 24 hours in serumfree standard 
medium supplemented with ITS+1 (serum replacement; BD Bioscience, Bedford, MA) 
in a 1:100 v/v ratio. Secretion of tumor necrosis factor-alpha (TNF-α), interferon-gamma 
(IFN-γ), interleukin (IL)-6, IL-10, vascular endothelial growth factor (VEGF) and fibroblast 
growth factor 2 (FGF2) were analyzed in duplicate samples using a human Cytokine Bead 
Array flexsets (BD Bioscience, Breda, the Netherlands) according to the manufacturer’s 
protocol. Flow cytometric measurements were performed on a FACSCanto II (BD, San 
Jose, CA, USA) and analyzed using FACSDiva software version 6.1.2 (BD Biosciences).
Intra-articular cell injections and cell implantations
Due to the ex vivo nature of our MRI experiments, all cells were fixed in 4% formalin prior 
to injection or implantation. SPIO-labeled hBMSCs were injected ex vivo into porcine 
knees (Yorkshire x Landrace, 35 kilograms, age 4-5 months) in a dose range of 0.1x106 
to 5x106 labeled cells (injected in 100 µl physiological saline). For cell implantation, os-
teochondral plugs with a diameter of 8 mm were harvested from porcine femoral con-
dyles ex vivo. Circular full-cartilage defects of 6 mm diameter (approximate volume of 
75 µl) were created in those plugs. Cells from two donors were suspended in 1% Agar 
(Fluka BioChemika, Sigma-Aldrich, Buchs, Switzerland) in saline before implantation. A 
total of 1x106 cells were seeded per defect in vitro (cell concentration of 13x106 cells/
ml), containing 0.3 – 100% labelled cells (i.e. 0.04x106–13x106 labeled cells/ml). Cell 
implantation was also performed ex vivo in an intact porcine knee according to previ-
ously described autologous chondrocyte implantation (ACI) procedures [216]. The knee 
joint was opened and a circular cartilage defect was created (diameter 6 mm; volume 75 
µl). A periosteal flap was sutured on top of the defect using PDS 6-0 sutures (Johnson 
& Johnson, New Brunswick, New Jersey) and fibrin glue (Tissucol® Duo 500, Baxter, 
Uden, the Netherlands) was applied at 90% of the edges of the flap as a sealant. 1x106 
SPIO-labeled cells suspended in 1% Agar, were seeded into the defect and fibrin glue 
was used to seal the final 10% of the periostal flap margin. The joint was closed in layers 
afterwards. All surgical procedures - except the cell seeding and fibrin glue application 
- were performed under water in order to prevent air artifacts on MRI. 
Validation SPIO-generated signal
To validate if SPIO-generated signal was related to originally labeled cells, or that SPIO 






fected chondrocytes were co-labeled with SPIO. Cells were lentivirally transduced and 
constitutively expressed GFP under the control of a CMV promoter (SHC003 vector, 
Sigma-Aldrich Mission®, shRNA library). To investigate the fate of SPIO after cell death, 
we considered the cell type used for labeling less relevant and chose chondrocytes over 
hBMSCs due to their substantially higher transduction efficiency. 25 x 104 GFP+-SPIO+ 
cells were seeded in duplicates on synovial explants from two human donors. Cells 
were alive or killed (by repeated free-thaw cycles) before seeding. Cells and synovial 
explants were co-cultured for five days. Fluorescent images were made from frozen 
sections using an Axiovert s100 microscope (Carl Zeiss B.V., Sliedrecht, the Nether-
lands). Subsequently, samples were stained using Perl’s iron stain and corresponding 
fields of view were evaluated by light microscopy. GFP and SPIO containing cells were 
determined by manually counting a minimum of 100 cells per sample. 
Magnetic Resonance Imaging
Scanning was performed on a clinical 3.0T MRI scanner (General Electric Healthcare, 
Milwaukee, Wisconsin). A 3D SPGR sequence was used to scan labeled hBMSCs in 
vitro (TR 87.7 ms, TE 15.1 ms, FOV 17 mm, matrix 512x512, scanning time 11 min. 35 
sec.) in combination with a custom made receive-only surface coil with a diameter of 1 
cm. Scanning of injected or implanted hBMSCs in intact porcine knees was performed 
using a FIESTA-3D sequence (TR 7.9 ms, TE 2.2 ms, FOV 140 mm, matrix 512x256, 
scanning time 28 min. 46 sec.) and a clinical phased-array head coil. Images of hBM-
SCs implanted in defects in vitro were obtained by a Spin Echo sequence (TR 1500 ms, 
TE 40 ms, FOV 40 mm, matrix 512x512, scanning time 14 min. 42 sec.) and a custom 
made receive-only surface coil with a diameter of 3 cm. R2*-mapping was performed in 
duplicate samples for two hBMSC donors by a SPGR sequence (TR 45ms, TE 4 – 120 
ms, FOV 40 mm, matrix 256x256, scanning time 21 min. 21 sec.). R2* values were 
calculated and validated by mono-exponential curve fitting (MATLAB 7.0.1, MathWorks, 
MA). Voxels with an r2 <0.95 were excluded from the measurements. 
Statistical analysis
Statistical differences between different treatment groups were analysed by the paired 
Student t-test (normality test p>0.05). P-values of ≤0.05 were considered statistically 






















Labeling effectivity and cell behavior. 
hBMSCs were efficiently labeled with ferumoxides-protamine sulfate complexes (Figure 
1A). We observed a labeling efficiency ranging from 41.2 ± 33.5 % at an SPIO dose of 
2.5 µg/cm2 to 94.5 ± 7.8 % at an SPIO dose of 25 µg/cm2 (Figure 1B) with resulting 
average total iron loads (TILs) of cells ranging from 4.0 ± 2.9 pg/cell to 19.5 ± 6.1 pg/
cell (Figure 1C). Both labeling efficiency and TIL increased in relation to SPIO labeling 
dose up to a dose of 10 µg/cm2. The higher SPIO dose of 25 µg/cm2 did not significantly 
increase labeling efficiency (P = 0.42) or average TIL (P = 0.50). hBMSC viability was 
not influenced by SPIO labeling for dosages up to 25 µg/cm2 (Figure 1D). Additionally, 
SPIO labeling did not inhibit cell metabolic activity compared to unlabeled controls for at 
least seven days (Figure 1E). Based on these results an SPIO dose of 10 µg/cm2, cor-
responding to a final labeling concentration of 50 µg/ml SPIO, was considered optimal 
and used in all further experiments. 
Chondrogenic differentiation was studied in cell pellets consisting of labeled and unla-
beled cells at different ratios (0, 10, 50 and 100% of labeled cells). Differentiation was 
unaffected in all pellets containing labeled hBMSCs (10 - 100%) compared to control 
pellets consisting of unlabeled cells only. All pellets displayed a cartilaginous extracel-
lular matrix rich in GAG and collagen type II (Figure 2A-H). Moreover, quantitative mea-
surements revealed SPIO-labeled hBMSCs to produce comparable amounts of GAG 
Figure 1. Labeling human Bone Marrow stroma-derived mesenchymal Stem Cells (hBMSCs) 
using Superparamagnetic Iron Oxides (SPIO). Perl’s iron stain showing effective endocytosis of 
SPIO (A), leading to labeling efficiencies of approximately 95% (B) and a total iron load of approximate-
ly 20 pg/cell (C). SPIO labeling did not impair cell viability (D) or subsequent metabolic cell activity (E) 






(Figure 2I). In addition, gene expression of collagen type II was unaltered in SPIO-la-
beled hBMSCs after chondrogenic differentiation (Figure 2J). 
To evaluate the influence of iron incorporation on cell secretions, we tested six cytokines 
containing anti- and pro-inflammatory cytokines as well as growth factors. No effect of 
SPIO-labeling on the secretion profiles was found (Table 1). SPIO-labeled hBMSCs pro-
duced comparable quantities of the anti- and pro-inflammatory cytokine IL-6 (P = 0.39) 
and the growth factor VEGF (P = 0.31) compared to unlabeled control cells. Further-
more, SPIO labeling did not induce the production of the pro-inflammatory cytokines 
TNFα and IFNγ, the anti-inflammatory cytokine IL-10 or the growth factor FGF2. These 
four factors were not detectably secreted by control or SPIO-labeled hBMSCs. 
Figure 2. Chondrogenic differentiation of hBMSCs is not affected by SPIO labeling. Collagen 
II immunohistochemistry and Perl’s iron stain demonstrated SPIO labeling to have no effect on pellet 
size or collagen II production, while iron remained present in differentiated pellets (A-D). Glycosamino-
glycan deposition was also unaffected, as can be seen by thionin stain (E-H) and DMB assay (I). Gene 
expression of collagen II was unaltered by SPIO labeling (J). All analyses were performed after 35 days 
of differentiation. Insets display low magnification overviews of the entire pellets. Results shown for 





















Cell visualization by MRI. 
All cell doses injected intra-articularly could be visualized by MRI. The number of in-
jected cells was related to the number and extent of areas with signal loss detected by 
MRI (Figure 3A-D, arrows). Injected hBMSCs were found scattered throughout the joint, 
clearly distinguishable from anatomical structures in all conditions. In addition, presence 
of labeled cells did not interfere with regular evaluation of knee anatomy.
For cell implantation experiments we created cartilage defects of 75 µl in porcine os-
teochondral plugs in vitro (Fig. S1A). Labeled hBMSCs implanted in cartilage defects 
were homogenously distributed and could be clearly distinguished from surrounding 
bone and cartilage by MRI. The extent of signal loss in the seeded plugs was dependent 
on the labeled cell dose used (Figure 3E-I). The minimal labeled cell concentration we 
could visualize was 0.4 x 106/ml. To show the potential applicability of this technique in 
a clinical ACI-like procedure, we subsequently implanted labeled hBMSCs in a cartilage 
defect in an intact porcine knee. In this setting the SPIO-labeled cells were also clearly 
distinguishable from the surrounding tissues (Figure 3J). Post MRI, Perl’s iron stain con-
firmed SPIO positive cells to be present inside the defect (Fig. S1B).
Cytokine (all values in pg/ml) Control cells SPIO labeled cells
TNFα ≤ d.l. ≤ d.l.
IFNγ ≤ d.l. ≤ d.l.
IL-6 489 ± 613 330 ± 242
IL-10 ≤ d.l. ≤ d.l.
VEGF 193 ± 103 265 ± 102
FGF2 ≤ d.l. ≤ d.l.
hBMSC secretion profile of four cytokines and two growth factors was not influenced by SPIO labeling. 
Cytokines were measured in serum free 24 hour supernatant of labeled and unlabeled cells. SPIO did 
not induce the secretion of pro-inflammatory cytokines (TNFα, IFNγ), nor did it alter the secretion of 
the anti- and pro-inflammatory cytokine IL-6 or the growth factor VEGF. The anti-inflammatory factor 
IL-10 and growth factor FGF2 were not secreted at a detectable level by control or SPIO-labeled cells. 
TNF-α: tumor necrosis factor-alpha, IFN-γ: interferon-gamma, IL: interleukin, VEGF: vascular endothe-
lial growth factor, FGF: fibroblast growth factor, ≤ d.l.: below detection level (10pg/ml). Results shown 
for duplicate samples from five hBMSC donors.






A point of interest is whether observed areas with signal loss are generated by originally 
labeled cells, since SPIO remains in the joint after labeled cells die. The joint cavity is 
lined by an inner layer of synovial tissue that contains macrophages. We investigated 
the capacity of synovial cells to endocytose SPIO from labeled cells, by seeding dead 
Figure 3. MRI visualization of SPIO-labeled hBMSCs in an intra-articular environment. Injected 
cells were visualized in a dose dependent manner (A-D, in-plane resolution 273 x 273 µm; slice thick-
ness 600 µm). Cells were found scattered throughout the joint (arrows) and could be discerned from 
intra-articular structures. Labeled cells implanted in cartilage defects in vitro were homogeneously dis-
tributed and imaged in a comparable way; dose dependent and clearly distinguishable from structures 
like cartilage and bone (E-I; in-plane resolution 78 x 78 µm; slice thickness 1500 µm). After implanting 
cells in a cartilage defect in an intact porcine knee, MRI showed the cells inside the defect (J; in-plane 
resolution 273 x 273 µm; slice thickness 400 µm). In (A); b: bone; c: cartilage; c.l.: cruciate ligament. 
Intra-articular cells in porcine knees were imaged as a single sample for one donor. hBMSCs implanted 





















or living GFP-SPIO co-labeled chondrocytes on synovial tissue explants. In the synovi-
um samples seeded with living GFP-SPIO co-labeled cells, GFP+ cells were observed 
immediately after seeding (Fig. S2A). Moreover, GFP+-SPIO+ cells were found after the 
co-culture period of five days, suggesting these cells to be originally labeled chondro-
cytes (Figure 4A and 4B). When seeded with dead GFP-SPIO co-labeled cells, fluores-
cence microscopy confirmed the vast majority of cells to have died directly following 
Figure S1. In vitro and ex vivo cell implantation procedures. Osteochondral plugs with a diam-
eter of 8mm were created from the femoral part of porcine knees (A). Ex vivo, post-MRI Perl’s iron 
stain shows macroscopically the presence of blue, iron containing cells in the defect (B). Dotted line in 
(A) represents created defect. Intra-articular cell implantation in a porcine knee was performed for one 
donor.
Figure S2. Cell seeding on synovial explants. Fluorescent images directly after seeding GFP+-
SPIO+ cells on synovial explants showing abundant GFP signal in samples seeded with living cells (A), 
while GFP signal is absent in samples seeded with dead cells (B). This confirmed that the vast majority 
of killed cells had not survived the multiple freeze-thaw procedures. Representative images are shown 






the freeze-thaw procedure (Fig S2B). After five days of co-culture, 88.4 ± 11.4 % of the 
SPIO+ cells were GFP¯ in these samples, indicative of iron re-uptake by synovial cells 
(Figure 4C-E). Next to this, extracellular SPIO aggregates were found attaching to the 
synovial membrane (Figure 4D inset). In samples seeded with living chondrocytes, 25.5 
± 10.5 % of SPIO positive cells showed no GFP signal either. Whether this was due 
to extinguishing GFP signal from originally labeled chondrocytes, synovial re-uptake of 
SPIO from living cells, or caused by iron re-uptake from seeded cells that died during 
the co-culture period, could not be determined.
Figure 4. SPIO re-uptake by 
human synovial explants. Fluo-
rescent images and Perl’s iron stain 
of GFP-SPIO co-labeled chondro-
cytes seeded on synovial explants. 
GFP+-SPIO+ cells, indicating orig-
inally seeded chondrocytes, were 
seen in samples seeded with living 
cells (A,B). In samples seeded with 
dead cells, GFP¯-SPIO+ cells were 
found, indicating SPIO re-uptake by 
synovial cells (C,D). Furthermore, 
extracellular SPIO aggregates were 
observed attached to the synovial 
explants (D, inset). Approximately 
90% of SPIO+ cells in samples 
seeded with dead chondrocytes 
were not originally labeled cells, 
compared with 25% of SPIO+ cells 
in samples seeded with living cells 
(E). Arrows indicate SPIO con-
taining cells. Results shown for 





















Cell quantification by MR-based relaxometry. 
In addition to visualization of seeded cells by MRI, we were able to quantify the concen-
tration of hBMSCs seeded in defects in vitro by applying a R2* mapping technique, in 
which R2* = 1/T2* (Figure 5A-E). A linear relationship between R2* values and labeled 
cell concentrations of 0.4 x 106 – 2.6 x 106 cells/ml was found (Figure 5F). R2* values 
ranged from 45 ± 22 - 460 ± 120 ms-1 for these labeled cell concentrations. Below 
Figure 5. Quantification of SPIO-labeled cells implanted in cartilage defects in vitro. Trans-
verse R2* maps from identical osteochondral plugs as shown in figure 3, visualize the differences in 
labeled cell concentrations (A-E; in-plane resolution 156 x 156 µm, slice thickness 700 µm). A linear 
relationship between labeled cell concentration and R2* value was found in a range of 0.4 x 106 – 
2.6 x 106 cells/ml (F). Grey voxels inside the defects represent positions where R2* values could not 
be obtained due to a too low (mainly in A,B) or too high (mainly in E) local concentration of SPIO. 
Results shown for duplicate samples from two hBMSC donor for samples containing 0; 1.3 x 105; 4.0 
x 105 and 1.3 x 106 cells/ml. Samples containing 4.0 x 104; 8.0 x 105 and 2.6 x 106 cells per ml were 






0.4x106 cells/ml, SPIO-generated R2* signal was insufficient for reliable differentiation 
from defects seeded with unlabeled hBMSCs. At the very high labeled cell concentra-
tion of 13x106 labeled cells/ml R2* values could no longer be determined, since the 
values exceeded those measurable with our clinical acquisition parameter range. At 
this high SPIO concentration a signal-to-noise ratio of approximately 1.6 was obtained, 
which signifies that the signal loss was not reliably discernable from background noise. 
Discussion
Cell-based cartilage repair techniques are developing rapidly, and the use of hBMSCs 
as a treatment for focal cartilage defects and osteoarthritis shows promising results 
[315,317]. Clinically translatable cell tracking represents a vital tool to aid in the elu-
cidation of the repair mechanisms of these therapies, and in further improving them. 
In this study we have shown that SPIO labeling of hBMSCs is effective and does not 
impair cell viability, long term metabolic cell activity, chondrogenic differentiation, or the 
secretion of a panel of six cytokines involved in inflammation and tissue regeneration. 
We were able to accurately visualize intra-articular SPIO-labeled hBMSCs and quantify 
cells seeded in localized cartilage defects by means of an R2* mapping MRI technique. 
Regarding the influence of SPIO labeling on chondrogenic capacity of BMSCs, some 
discrepancies can be found in recent reports. Some groups mention no influence of 
SPIO labeling on chondrogenic differentiation of BMSCs [300,318], whereas others do 
report a negative effect [319,320]. These conflicting data could be due to the wide va-
riety in protocols for SPIO labeling and chondrogenic differentiation used. Furthermore, 
the influence of cellular iron load on chondrogenic differentiation has been described 
[320,321]. As reported in this paper we found no SPIO-related negative effects in our 
Figure S3. Chondrogenic differentiation of cryopreserved SPIO-labeled hBMSCs. Perl’s iron 
stain (A-D) and collagen II immunohistochemistry (A-C) of chondrogenically differentiated cryopre-
served hBMSCs. SPIO labeling of 10% of the cells did not influence pellet size or collagen II deposition 
compared to control cells (A and B). Using 50% of SPIO-labeled cells did negatively influence these 
outcome measures (C). Pellets consisting of 100% of labeled cells disintegrated within 7 days, show-






















chondrogenic assays with freshly isolated cells. However, we have observed inhibitory 
effects if we used cryopreserved cells in pellets containing ≥50% labeled cells, although 
pellets with 10% labeled cells appeared unaltered (Fig. S3A-D). Therefore we recom-
mend further investigation regarding this subject when using cryopreserved hBMSCs. 
Besides cell proliferation and differentiation, other hBMSC capacities are relevant in re-
generative medicine as well. Recently, secretion of trophic factors was postulated as a 
possible role for hBMSCs in cartilage regeneration [4]. We demonstrated that the hBMSC 
secretion profile of six important factors involved in inflammation and cell growth was not 
affected by SPIO. Previous research has shown that SPIO labeling does not impair hBM-
SC immunomodulatory capacities in a mixed lymphocyte reaction [322]. Furthermore, it 
has been described that gene expression of neural stem cells, with the exception of iron 
homeostasis related genes, remains largely unaltered after SPIO labeling [323]. We report, 
to our knowledge, for the first time the influence of SPIO labeling on cell secretions at a 
protein level. These findings could be relevant for other regenerative medicine fields us-
ing hBMSCs, like cardiology, neurology and organ transplantation [324]. In summary we 
found no deleterious effects of our labeling procedure on cell functionality. When labeling 
only part of the applied cells, which in our experiments sufficed for accurate intra-articular 
MRI traceability, the risk of possible negative effects will even be further diminished.
In order to translate our labeling method to a cell tracking approach in an intra-articular en-
vironment, we investigated the MRI traceability of clinically used amounts of SPIO-labeled 
cells in a joint model of a clinically relevant size. Jing et al. previously visualized cells labeled 
with SPIO in rabbit knee joints by MRI [51]. Through the use of a clinical phased-array 
head coil and specific MRI parameters we were able to increase MRI resolution (in plane 
resolution 273 x 273 µm), which is higher than in other studies performing intra-articular cell 
tracking or general clinical anatomical intra-articular imaging by MRI [325,326]. This enabled 
dose-dependent visualization of labeled cells and discrimination from intra-articular struc-
tures like cruciate ligaments, cartilage and subchondral bone. Following our in vitro cell im-
plantation experiments, we visualized SPIO-labeled cells implanted in an ACI-like procedure 
in an intact porcine knee. Air artifacts show up as hypointensities on MRI, which interferes 
with the signal loss generated by labeled cells. To avoid these artifacts, we were obliged to 
perform this operation under water. This is impracticable in a clinical setting indicating that 
immediately post-operative this technique can be used to visualize cells that remained in the 
defect, but that the technique is unsuitable to discern labeled cells that might have leaked 
in the intra-articular space. These leaked-out cells could be identified after intra-articular air 
has resolved, which in our personal clinical experience occurs within a day.
SPIO for cell-labeling has great clinical potential, but unfortunately the label will dilute 
upon cell division. This could limit the duration that cells can be accurately detected by 
MRI. Previous results from our group and others show an approximate 75% decrease in 






5-8 cell divisions in rapidly dividing HeLa cells [328]. On the other hand, duration of trace-
ability increases with slower proliferating cells, and SPIO could be detected after 44 days 
in non-dividing human MSCs [328]. Accordingly, our group previously reported traceability 
in vivo of SPIO labeled human MSCs in a subcutaneous mouse model for at least seven 
weeks post labeling [318]. In additional experiments we found a marked decrease in 
SPIO-generated signal voids from proliferating labeled hBMSCs over a period of 14 days 
in vitro, representing 5-6 cell divisions (data not shown). How long SPIO labeled cells can 
be detected in an intra-articular environment remains to be studied in an in vivo model. 
Another point regarding accurate detection of labeled cells is the fact that cell death 
will not result in the disappearance of the label. SPIOs released from these cells could 
lead to misinterpretation of MR images. Pawelczyk et al. have previously shown ap-
proximately 10 - 20 % of local macrophages to become SPIO positive after injection of 
SPIO-labeled BMSCs in a subcutaneous inflammation mouse model [322]. Synovium 
contains the majority of macrophages present in synovial joints. We observed the vast 
majority of SPIO+ cells to be non-originally labeled after applying dead, labeled cells on 
synovial explants. In the case of cell implantation in a cartilage defect, SPIO re-uptake 
by host cells might be of less consequence because there is no direct contact between 
the cells seeded in the defect and the synovial membrane. Nonetheless, before clinical 
application we recommend in vivo animal studies using intra-articular cell tracking by 
MRI in combination with histological confirmation of the localization of originally labeled 
cells. This would enable the correct interpretation of obtained MR images. 
Besides visualizing cells, we were able to quantify beforehand known cell concentra-
tions implanted in cartilage defects in a clinically relevant cell-concentration range. To our 
knowledge, this has not been reported before in a model comprising biological tissue. Rad 
et al. were unsuccessful in translating their SPIO-labeled cell quantification experiments 
to an ex vivo setting [329], and Politi et al. did not validate their ex vivo quantification re-
sults afterwards [330]. Since the original concentration of applied cells is known in an ACI 
procedure, and seeded in a confined volume, it is possible to quantify the total amount of 
labeled cells and follow them in the same patient in subsequent MRI sessions. Since both 
hBMSCs and chondrocytes can be labeled using SPIO [331,332], these findings indicate 
the potential of SPIO labeling for tracking cells in numerous orthopedic treatments and 
many other regenerative medicine fields [333]. Cell visualization and especially quantifica-
tion using MRI can be a major step towards improvement in all these applications. 
In summary, we consider SPIO labeling to hold great potential for clinically translatable cell 
tracking using MRI in cell-based cartilage repair. In an experimental setting this would show 
the distribution and diffusion of the applied cells, thereby elucidating the regenerative mech-
anisms and providing opportunities to improve current repair strategies. The use of MRI has 
the advantage of simultaneous cell tracking and evaluation of cartilage regeneration in one 
MRI session.
Acknowledgements 
The authors are grateful to N. Kops, J.L.M. Koevoet, S.T. van Tiel and J. van der Slegt 
for their technical assistance; to M. Hoogduijn for his assistance in obtaining and an-
alyzing the CBA data; to A. Uijtterdijk for kindly providing porcine materials; to J.H. 
Waarsing for his support with statistical analyses; and to U. Woroniecka and B. Wolter-
beek for their assistance with the ICP-OES measurements. The monoclonal antibody 
developed by T. Linsenmayer was obtained from the Developmental Studies Hybridoma 
Bank developed under the auspices of the NICHD and maintained by The University of 
Iowa, Department of Biology, Iowa City, IA. Furthermore, the authors gratefully acknowl-
edge the support of the Smart Mix Program of the Netherlands Ministry of Economic 
Affairs and the Netherlands Ministry of Education, Culture and Science; and the ENCITE 







Human bone marrow 
mesenchymal stem cells 
embedded in alginate 
beads retain long-term 
immunomodulatory 
properties 
Esther Villafuertes, Gerben M. van Buul, Wendy L.M. Koevoet, Benjamin Fernandez-Gutierrez, 








Background: Bone marrow mesenchymal stem cells (BMSCs) are multipotent cells 
with activation dependent immunomodulatory properties. To investigate their immu-
nomodulatory properties, most studies use short term cultures of cells in monolayer. 
The environment of BMSCs could influence their immune regulatory capacity and it is 
unclear how the behaviour of BMSC in monolayers relates to their in vivo effects. For 
application in chronic inflammatory conditions BMSCs have to retain long-term immu-
nomodulatory properties. 
Methods: We studied the gene expression and secretion of immunomodulatory and 
growth factors by BMSCs in a control and in an inflammatory situation (IFNγ/TNFγ 
supplementation of 50 ng/ml each). Cells were grown in monolayer for short-term  
(3 days) experiments or encapsulated in alginate beads in a short-term and long-term 
culture (3 and 30 days). DNA content of the beads was determined as a measure of 
cell survival. Gene expression was measured by RT-PCR and cell secretions were 
measured using enzyme-linked immunosorbent assays.
Results: Embedded in alginate, BMSCs maintained their immunomodulatory properties 
during 30 days of culture, expressing IL-6, IDO, TGFγ1, VEGF, TIMP1 and TIMP2. We 
measured IL-6 and TIMP2 levels and IDO activity in the medium. Approximately 50% 
of cells survived the 30 day culture period. The response of cells in alginate during a 
short-term or long-term culture to IFNγ/TNFγ was similar to the response in short-term 
monolayer culture. 
Conclusions: Our data indicate that BMSCs embedded in alginate beads may act as 
a continuous immunomodulatory and trophic factor release system for several weeks, 








































Mesenchymal stem cells (MSCs) are  multipotent cells that have been found in several 
tissues such as bone marrow, adipose tissue, synovium, deciduous teeth, umbilical 
cord blood and blood vessels[337], [338], [339], [340]. MSCs have been used as therapeutic 
agents in experimental models of tissue injuries[341], [342], [343], [344], [345]. These studies show 
MSCs-dependent improvement of damaged tissues without a significant contribution of 
engrafted and differentiated cells[346],  [347], [348], [349], [350], [351]. This finding suggests that next 
to their capacity to differentiate into cells of mesodermal lineage, including osteoblasts, 
chondrocytes, myocytes and adipocytes, MSCs have the ability to stimulate endog-
enous tissues repair. This repair is orchestrated through the secretion of soluble factors 
that altered the tissue microenvironment[352].
Additionally, MSCs were shown to be able to modulate the immune response. This 
property is very useful in cases where inflammation plays an important role in tissue 
destruction like immune disorders or graft versus host disease (GvHD)[353]. Immune sup-
pression by MSCs requires activation by proinflammatory cytokines such as interferon 
(IFN)γ, tumor necrosis factor (TNF)α, interleukin (IL)1α or IL1β[294], [354], [355]. In vitro, MSCs 
can inhibit antibody production by B cells[356], the generation and function of antigen 
presenting cells[357] and T lymphocyte proliferation and pro-inflammatory cytokine pro-
duction[358], [359]. In vivo, MSC were shown to be able to reduce immune activity in au-
toimmune enteropathy[360], prolong heart and skin allograft survival[361], [362]  and improve 
experimental colitis[363]. The responsible mechanisms of this immune modulation are 
based on multiple factors including prostaglandin E2 (PGE2) and indoleamine 2, 3-di-
oxygenase (IDO), nitric oxide (NO) or cytokines such as [364] IL-6 [357], [365], [239]. Also, growth 
factors such as transforming growth factor β1 (TGFβ1) and  vascular endotelial growth 
factor (VEGF)[366] secreted by MSCs, have demonstrated to influence tissue repair as 
well as immunological processes [367].
Most studies consider the immunomodulatory properties of MSCs in monolayer culture. 
However, cells in monolayer, can differ considerably in their morphology, cell adhesion, 
cell cycle, and differentiation from those in three-dimensional (3D) environments in vitro 
or in vivo[368], [369], [370], [371], [372].  Indeed, the systemic administration of MSCs is character-
ized by early death of grafted cells or only small numbers of cells reach the target [347], 
[348], [349], [350], [351].
Additionally, analyses of the immunomodulatory properties of MSCs are mostly per-
formed in short-term experiments. In a clinical application when MSC would be used to 
modulate more chronic inflammatory reactions they have to be introduced in the area 
and the immunomodulatory properties have to be guaranteed for several weeks at least, 






Alginate is a natural and useful polymer for cell encapsulation because of its biocom-
patibility and an in vivo stability[373], [374], [375]. Inclusion in alginate beads is an easy way 
to prevent mechanical stress, but also, to diminish the negative influence of the injured 
environment on grafted cells, manipulate and deliver the cells near the injury and to set 
a better tracking of the phenotype of the grafted cells[376].
Therefore, the purpose of this study was to investigate the expression and secretion of 
immunomodulatory and growth factors by bone marrow MSCs (BMSCs) encapsulated 
in alginate beads under control and under inflammatory conditions (50 ng/mL TNFα and 
50 ng/mL IFNγ) in a long-term culture model. Furthermore, we investigated the behav-
iour of the cells after several weeks of encapsulation and test the ability of the embed-
ded cells to maintain their multilineage differentiation characteristics.
Material and methods
BMSCs isolation and expansion
Human BMSCs were isolated from heparinized femoral-shaft marrow aspirate from 4 
patients undergoing a total hip arthroplasty (after written informed consent with ap-
proval of the Medical Ethical Committee of Erasmus MC  protocol # MEC-2004-142). 
BMSCs were isolated according to procedures described before[157]. Briefly, bone mar-
row aspirate was plated out in basal medium (DMEM low glucose medium (Invitrogen, 
Carlsbad, CA) with 15% fetal calf serum (FCS; selected batch Lonza, Verviers, Belgium), 
50 µg/mL gentamycine (Invitrogen, Carlsbad, CA), 1.5 µg/mL fungizone (Invitrogen, 
Carlsbad, CA ), 1 ng/mL FGF2 (Instruchemie B.V. Delfzijl, the Netherlands) and 1x10-4M 
vitamin C (Sigma) and after 24 hours, non-adherent cells were removed with 2% FCS in 
PBS. Adherent cells were cultured and upon passaging seeded at a density of 2300 nc/
cm2 in basal medium and trypsinized (Invitrogen, Carlsbad, CA) at subconfluence. Cells 
from passage 3 were used for experiments.
BMSCs encapsulation
4 million/mL BMSCs were encapsulated in 1.2% low viscosity alginate (Keltone LV; 
Kelco, Surrey, UK) and beads were created by dripping through a 23˝ gauge needle 
into a CaCl2 solution. After 10 minutes the beads were washed twice with physiological 
saline and once with control medium ((DMEM low glucose medium with 10% FCS, 50 
µg/mL gentamycine, 1.5 µg/mL fungizone).
Stimulation of immunomodulatory properties
BMSCs encapsulated in alginate were incubated in control medium for a period of 48 
hours to homogenize the culture. To activate the immunomodulatory properties, BM-







































medium supplemented with IFNγ and TNFα (50 ng/mL each, PeproTech, London, UK). 
As controls, subconfluent BMSCs in monolayer were preconditioned 48 hours in control 
medium and then incubated with control or cytokine medium for 24 hours.
To evaluate whether BMSCs could still be activated after long-term culture in alginate, 
the encapsulated BMSCs were precultured for 30 days in preconditioning medium and 
then cultured in control or cytokine medium for 24 hours.  Beads were harvested 24 
hours after treatment for gene expression analyses and medium was harvested and 
stored at -80ºC for analyses of secreted factors. Agarose coated plates were used to 
avoid cell growing out of alginate beads.
DNA Content
To determinate cell survival after embedding in alginate beads in a course time t = 0, 
7, 14, 21, 30 days we measured the amount of DNA. Three samples of three beads 
from different culture wells were digested overnight at 56°C in papain digestion buffer 
(200 µg/mL papain (Sigma, St. Louis, MO, USA) in 50 mM ethylene diamine tetraac-
etate (EDTA) (Sigma) and 5 mM l-cystein hydrochloride (Sigma). The amount of DNA in 
each papain-digested sample were analyzed on the Wallac 1420 victor2 (Perkin-Elmer, 
Wellesley, MA) using an extinction filter of 340 nm and an emission filter of 590 nm by 
means of an ethidium bromide assay (Sigma) with calf thymus DNA as a standard[377]. 
Differentiation assays.
To evaluate if the BMSCs maintained their multilineage differentiation capacity after they 
have been embedded in alginate for 30 days, we released the cells from alginate using 
sodium citrate/EDTA (Sigma) and performed osteogenic and adipogenic differentiation 
during 21 days. For osteogenesis cells were seeded at 3,000 cells/cm2 and cultured 
in medium containing DMEM high glucose (Invitrogen), 10% FCS, β-glycerophosphate 
10 mM (Sigma), dexamethasone 0.1 µM (Sigma) and L-ascorbic acid 2 phosphate 0.5 
mM (Sigma). For adipogenic differentiation cells were seeded at 20,000 cells/cm2 and 
cultured in medium containing DMEM high glucose, 10% FCS, dexamethasone 1 µM, 
indo-methacin 0.2 mM, insulin 0.01 mg/mL, and 3-isobutyl-l-methyl-xanthine 0.5 mM 
(all from Sigma). All media contained 50 µg/mL gentamycine and 1.5 µg/mL fungizone. 
Histology evaluation was performed with Von Kossa staining (Sigma) for osteogenic dif-
ferentiation and oil-red O (Sigma) for adipose differentiation.
Gene expression analyses
To isolate RNA, 10 alginate beads were pooled and dissolved in 150 µL/bead 55 
mM sodium citric acid and spun down for 8 min at 1,400 rpm at 4°C. Cell pellets were 
resuspended in 1 mL RNABee (Tel-test, firendswood, TX, USA). For monolayer BMSCs 
cultures, 2 well plates from a 6 well plate were suspended in 1 mL RNABee. After addi-
tion of 0.2 mL/mL chloroform, samples were spun down for 15 min at 12000 rpm. Total 






the manufacturer's instructions (Qiagen, Hilden, Germany) and nucleic acid content was 
determined spectrophotometrically (NanoDrop ND1000; Isogen Life Science, IJssel-
stein, The Netherlands). cDNA was obtained according to manufacturer’s instructions 
using using RevertAid™ First Strand cDNA Synthesis Kit (MBI Fermentas, St. Leon-
Rot, Germany). Gene expression analysis was performed using ABI7000 for cycling. 
Ct values were corrected by the best housekeeper (BKI), which was calculated by the 
average of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ubiquitin C (UBC) 
and hypoxanthine phosphoribosyltransferase (HPRT). IL-6, tissue inhibitor of metallo-
proteinases (TIMP2), IDO, TGFβ1, TIMP1 and VEGF were analyzed in BMSCs. 
RT-PCR primer nucleotide sequences were as follows: GAPDH Fw: ATGGGGAAGGT-
GAAGGTCG; Rv: TAAAAGCAGCCCTGGTGACC. UBC Fw: ATTTGGGTCGCG-
GTTCTTG; Rv: TGCCTTGACATTCTCGATGGT. HPRT Fw: TATGGACAGGACTGAAC-
GTCTTG; Rv: CACACAGAGGGCTACAATGTG . IL6 Fw: TCGAGCCCACCGGGAAC-
GAA; Rv: GCAGGGAAGGCAGCAGGCAA. TIMP2 Fw: ATGGTGGGTTCTCTGGTG; Rv: 
CGGTACCACGCACAGGA. IDO assay-on-demand (Hs00158027.m1, Applied Biosys-
tems, Capelle a/d IJssel, the Netherlands). TGFβ1 Fw: GTGACAGCAGGGATAACA-
CACTG; Rv: CATGAATGGTGGCCAGGTC. TIMP1 Fw: TGCCGCATCGCCGAGAT; Rv: 
ATGGTGGGTTCTCTGGTG. VEGF Fw: GAGTGCCCACTGAGG; Rv: GCCTCGGCTTGT-
CAC. Relative expression levels were calculated using the 2-ΔΔCt method[91].
Enzyme-Linked ImmunoSorbent Assay
TIMP2 and IL6 protein levels were measured in stimulated and non-stimulated MSC-
conditioned media from three donors by means of ELISAs (R&D systems, Abingdon, 
UK) according to the protocol supplied by the manufacturer. All factors were corrected 
for the amounts present in standard MSC culture media. To determine the amount of 
IDO enzymatic activity in BMSCs media, the level of its metabolite, kynurenine, was 
measured spectrophotometrically as described before[248]. In brief, 100 µl of 30% trichlo-
roacetic acid (Sigma-Aldrich, St. Louis, USA) was added to 200 µl of culture superna-
tant, which was incubated at 50°C for 30 min, and then centrifuged at 10,000 × g for 5 
minutes. 75 µl of supernatant was then added to an equal volume of Ehrlich’s reagent 
(100 mg P-dimethylbenzaldehyde and 5 mL glacial acetic acid; Sigma St. Louis, USA) 
and optical density was measured at 490 nm.
Statistics
Analyses were performed by two way ANOVA with repeated measure using GraphPad 








































1. BMSCs retain their immunological properties in alginate 
First, to check the immunomodulatory properties of BMSCs in alginate, we compared 
the BMSCs’ response to TNFα and IFNγ exposition between monolayer and alginate 
beads. BMSCs embedded in alginate beads showed very similar alterations in the gene 
expression profile in response to TNFα/IFNγ as BMSCs in monolayer cultures (Fig. 1). 
We found an upregulation of IL-6 and IDO mRNA (p<0.05) in response to TNFα/IFNγ 
in monolayer and alginate culture. TIMP1 expression was not changed by cytokines in 
both conditions. TGFβ1 was downregulated in both conditions but only reached signif-
icance in alginate cultures (p<0.05), whereas TIMP2 and VEGF were only significantly 
downregulated in monolayer cultures (p<0.05).
To check whether BMSCs in alginate maintained their capacity to exert an immunologi-
cal response for a longer period, we performed 24 hours stimulation with control and 
cytokine medium in BMSCs embedded in alginate beads that were 30 days precultured. 
BMSCs were able to respond in the inflammatory medium likewise monolayer or only 48 
hours preconditioning alginate beads. After 30 days in alginate, TNFα/IFNγ upregulated 
IL-6 and IDO (p<0.05), downregulated TGFβ1, TIMP1 and TIMP2 (p<0.05), while VEGF 
was not significantly altered. (Fig. 1). Also, there seems to be higher TGFβ1 expression 
in the control BMSCs in 30d alginate beads compared to 48h.
2. Immunomodulatory and growth factors secretion by BMSCs cultured in algi-
nate beads.
Then we analyzed BMSCs´ secretion of IL-6 and TIMP2, together with their IDO activ-
ity after a short and long-term culture in alginate beads using monolayer as a control 
group. BMSCs secreted all the measured factors after 30 days culture in alginate beads 
(Table I). IDO activity and IL-6 secretion were increased by TNFα/IFNγ, in accordance 
with gene expression analysis, albeit IL-6 didn´t reach significance in the alginate cul-
tures due to the variances between donors. TIMP2 secretion was not affected by the 
cytokines in any of the three conditions. 
Because we observed a decrease in levels of secreted factors after 30 days in alginate 
we evaluated the effect of the alginate inclusion on BMSCs survival by measurements 
of the DNA content of the alginate beads at 0, 7, 14, 21 and 30 days of culture. DNA 
content appeared to decline after BMSCs inclusion in alginate beads (p<0.001) leaving 
approximately the 40% of the BMSCs at 30 days (Fig. 2). Apparently the remaining cells 
could still respond to inflammatory cytokines by secretion of factors.
3. Differentiation capacity of BMSCs after encapsulation in alginate.
To characterize the effect of alginate on BMSCs, we released the cells of one donor 






Fig. 1. Gene expression of immunomodulatory genes by human BMSCs with or without stimulation by 
cytokines (TNFa/IFNy) in monolayer or embedded in alginate beads after 3 days or 30 days in alginate. 
Data expressed as mean±SEM of 4 donors with duplicate or triplicate samples per donor. All individual 
data points were presented as dots, outliers (one in TGFβ1 and one in TIMP2 graph) were left out of the 
graphical representation but included in mean, SEM and statistical analyses. BKI: best house keeper index, 
an average of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ubiquitin C (UBC) and hypoxanthine 
phosphoribosyltransferase (HPRT); IL-6: Interleukin 6; IDO: indoleamine 2, 3-dioxygenase; TGFβ1: trans-
forming growth factor β1; VEGF: vascular endotelial growth factor; TIMP-1: tissue inhibitor of metallopro-


















































































































































































































































































































































































































































and compared it to 
BMSCs that were not 
embedded in alginate. 
BMSCs released from 
alginate were able to 
differentiate in osteo-
genic and adipogenic, 
although after inclu-
sion in alginate, both, 
at 3 and at 30 days, 
these capacities were 
diminished (Fig. 3).
.  
Fig. 2. DNA content of BMSC-alginate beads in a course time 
experiment. Data expressed as mean±SEM of three donors with tripli-
cate samples per time point per donor. *** p<0.001 compared to t=0.
 
released after  
30 days in 
alginate beads 
 
released after 3 
days in alginate 
bead 
Monolayer  
Adipogenesis     Osteogenesis 
Fig. 3. Osteogenic and adipogenic differentiation of BMSCs after release from alginate. 
Representative pictures are shown. Von Kossa staining is used for osteogenic differentiation with black 
indicating calcium-phosphate crystals. Oil-red O staining is used for adipogenic differentiation with red 








































the immunomodulatory effects of BMSCs and the enhancement of this function af-
ter pro-inflammatory stimuli in monolayer cultures is well established. However, little is 
known about their behavior in a 3D matrix such as alginate. In this study, we show the 
maintenance of the immunomodulatory capacities of BMSCs during a long term, 3D 
culture in alginate beads. Here, we have analyzed the gene expression analysis of BM-
SCs embedded in alginate, at short and long culture period and found that alginate is 
able to retain BMSCs alive and capable of responding to an inflammatory stimulus with 
secretion of immunomodulatory factors even after a long period of culture. 
BMSCs are known to be able to influence immune and wound healing processes by 
secretion of several factors [378], [44], [379]. Therefore BMSCs have received much attention 
and have been clinically applied, for example in graft versus host disease (GvHD), os-
teogenesis imperfecta or glycogen storage disease[380].  Studies that used cell tracking 
methods could not demonstrate the long-term presence of these cells after applications 
[381,382], [383]. This would limit effectiveness of the application of these cells for chronic dis-
eases. Here we demonstrate that BMSCs encapsulated in alginate beads upregulated 
gene expression of IDO and IL-6 after IFNγ and TNFα treatment  similar to BMSCs in 
monolayer and confirming a large body of previous data in monolayer culture[239] [384] [385]. 
These data open the possibility of a long-term release system of immunomodulatory 
factors by application of BMSCs encapsulated in alginate. 
For this study we have selected IL6, TIMPs, TGFβ, VEGF and IDO as factors secreted 
by MSCs that are known to play a role in modulation of inflammation. IDO in BMSCs 
promotes immunosuppression and improves experimental autoimmune encephalomy-
elitis (EAE)[386], [387], [388]. IL-6, on the other hand, could be anti-inflammatory, controlling 
the extent of local and systemic acute inflammatory response[389], [390], whereas in chronic 
inflammatory diseases such as collagen-induced arthritis, murine colitis or EAE it could 
be proinflammatory[391], [392].  Also, the observed maintenance of TIMP1 and TIMP2 gene 
expression may act locally and control the MMP-induced breakdown of the extracellular 
matrix[393].  In contrast with other studies, a downregulation of VEGF gene expression 
after pro-inflammatory treatment was found and this finding is in concordance with the 
downregulation of TGFβ1. In the immunomodulation field, TGFβ1 has been  largely 
associated with immunosurveillance suppression mechanism[394], [395] and its long-term 
overexpression leads to severe hyperplasia in normal epidermis or oral mucosa[396], 
[397,398]. VEGF levels in BMSCs correlate with angiogenesis required for tissue repair but 
it could also drive inflammation[399]. Summarizing, our data support the idea that BMSCs 
retain the capacity to secrete modulating factors after being encapsulated in alginate 






For this first study we have encapsulated our BMSCs in 1.2% low viscosity alginate, 
solidified by dripping beads in CaCl2 solution using a 23G needle to study the effect of 
secretion of immunomodulatory factors. This is the system we use in our laboratory to 
culture BMSCs or chondrocytes to form cartilage matrix[108], [400].  However, we appeared 
to lose more than half of the cells over time and the remaining cells had a slightly re-
duced capacity to differentiate osteogenically or adipogenically. This is in contrast to 
other studies that have shown a higher viability of BMSCs throughout 21 days of culture 
in alginate[401] and the increase of the expression of the osteogenesis markers osteocal-
cin and osteomodulin, and the adipogenesis marker PPARγ[402], [403], [404], [405], [406] . These 
differences may be due to the different concentration of BMSCs used. Most studies 
have used a final concentration of 1x106 – 2x106 BMSCs/mL, whereas we have used 
4x106 BMSCs/mL. This amount of cells may be excessive to amount of growth factors 
distributed in a gradient trough the alginate bead in a long term culture. Also, we did 
not add any other factors to the culture system. Additional experiments demonstrated 
that addition of ascorbic acid, to avoid oxidative stress on BMSCs in culture, did reduce 
cell loss (data not shown). Furthermore, size of the beads, concentration and type of 
alginate and BMSCs concentration need to be optimized depending on the final goal, 
since these aspects have been found to be important in the proliferative capacities and 
release profile of the BMSCs[407], [401]. Moreover, reduction of the size of the beads will 
be beneficial for clinical application by injection later on. It has been suggested that 
alginate beads could be used safe and effectively, to deliver stem cells percutaneously 
with minimal loss of viability[401], [408]. The application of BMSCs in alginate beads may be 
useful for several chronic inflammatory diseases, where the activity of BMSCs should be 
present for weeks or months.
Conclusion
In conclusion, our results indicate that after a long-term culture, BMSCs embedded in 
alginate beads preserve their ability to modulate their microenvironment by secreting 
several factors such as IDO, IL-6, TIMP-1, TIMP-2, TGFβ1 and VEGF. BMSCs embed-
ded in alginate beads may act as a continuous immunomodulatory and trophic factor 
release system for several weeks, making this an interesting system to investigate for 
application in chronic diseases such as rheumatoid arthritis, osteoarthritis, tendinitis, 
EAE, diabetes mellitus or myocardial infarction. 
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Osteoarthritis (OA) is a disabling joint disease with a high prevalence and incidence 
[1]. The numbers of patients which are prone to develop osteoarthritis is expected to 
increase due to an ageing population in combination with an obesity epidemic [1]. Next 
to this, older people have an enhanced wish for (joint) mobility compared to earlier days. 
To this day, OA treatment includes pain medication and lifestyle changes like weight loss 
and regular exercise. These treatments are symptomatic treatments which are not able 
to durably cure the disease [409]. If these conservative measures fail, the final treatment 
option is joint replacement. Unfortunately, joint prostheses have a limited lifespan and as 
a result they do not provide a final solution for OA. For this thesis we studied the working 
mechanisms and efficacy of two biological treatments as a long term disease modifying 
osteoarthritis drug (DMOAD). As a first treatment we used platelet-rich plasma releasate 
(PRPr) a preparation of bioactive factors indirectly derived from cells. The second treat-
ment was cell therapy using bone marrow-derived cells. We hypothesized that by using 
and stimulating one’s own biological repair mechanisms, it would be possible to break 
or slow down the vicious circle of cartilage degeneration that is characteristic for OA. 
In chapter 2 we evaluated the potential of PRPr that was isolated by means of centrifu-
gation from patients own blood. [111]. Platelets are small cell fragments derived from 
megakaryocytes, containing many bioactive factors. These can potentially reduce the 
effects of inflammatory mediators on osteoarthritic chondrocytes. PRPr inhibited mul-
tiple interleukin-1 beta (IL-1 beta) induced effects in OA chondrocytes. Addition of PRPr 
to chondrocytes beneficially affected genes involved in the formation and degradation of 
extracellular matrix, as well as genes related to inflammation. PRPr diminished IL-1 beta 
induced inhibition of collagen type II (COL2A1) and aggrecan (ACAN) gene expression. 
These are two important genes involved in cartilage matrix formation [410]. PRPr also 
reduced IL-1 beta induced increase of a disintegrin and metalloproteinase with throm-
bospondin motifs (ADAMTS)4 and prostaglandin-endoperoxide synthase (PTGS)2 gene 
expression. The products of these genes are involved in cartilage matrix degradation 
and inflammation respectively. In order to find a possible pathway through which PRPr 
exerts these effects, we studied the effects of PRPr on nuclear factor kappa B (NFkB) 
activation. NFkB is a protein family that controls apoptosis, inflammation and other im-
mune responses, and is thus involved in many pathologic OA processes [96,116,117]. 
PRPr fully counteracted IL-1 beta induced nuclear factor kappa B (NFkB) activation 
back to control levels with no IL-1 beta. 
This study demonstrated the capacity of a combination of bioactive factors to alter 
pathologic processes in OA chondrocytes. This could potentially improve the applica-
tion of PRP in a clinical setting, for instance the timing or frequency of administration. 
A limitation of this study was the use of a single pro-inflammatory factor to induce in-
flammation on a single cell-type in a short term in vitro model. OA pathophysiology on 
the other hand, is a complex interplay of many factors and tissues with a dynamic and 

















beneficial PRP effects on diseased cartilage or joints as a whole. Next to the limitations 
of our model, another drawback of the use of PRP as an OA treatment is the fact that 
injected biological compounds are known to reside in the joint for a limited time-span 
only [411]. We searched for a way to provide a durable presence of disease modifying 
factors in the joint. Since mesenchymal stem cells (MSCs) are able to secrete a broad 
panel of immunomodulatory factors and growth factors, we further focussed on this 
source of biological treatment as a durable DMOAD.
Friedenstein et al. were the first to describe colony-forming cells with osteogenic ca-
pacities derived from bone marrow [41]. Since then, a vast amount of research has 
been conducted concerning these multi-potent bone marrow-derived cells which were 
later denominated mesenchymal stem cells (MSCs) by Caplan et al. [412]. More re-
cently, progenitor cells with a high resemblance to bone marrow-derived MSCs have 
been isolated from many other musculoskeletal tissues and adipose tissue. In Chapter 
3 we reviewed the natural presence and characteristics of progenitor cells in various 
other tissues found in the joint, including adipose tissue, periosteum, perichondrium, 
tendons, ligaments, muscle, cartilage, bone and synovial membrane or -fluid. Cells from 
these various tissues are generally isolated by mincing the tissue followed by enzymatic 
digestion. In general, these cells have small dissimilarities from one another, but gener-
ally are very comparable to bone marrow-derived MSCs. Cell yields from these tissues 
and proliferation capacities of these cells appear to be within the same order of magni-
tude. Furthermore, cells derived from the various musculoskeletal tissues have all been 
shown to have a multi-lineage differentiation potential, although they in general do show 
some preference for differentiating towards the tissue they were originally derived from.
Regenerative capacities of local stem cells are based on at least two features. Firstly 
they have the ability to differentiate into mature tissue cells, thereby contributing to 
new tissue formation [42]. A second, more recently discovered feature of stem cells is 
the secretion of trophic factors that may be responsible for other mechanisms of stem 
cell-mediated tissue repair [43]. These trophic factors can alter the diseased micro-
environment towards an anti-inflammatory and regenerative state. Moreover, these fac-
tors are capable of stimulating locally present progenitor cells to repair OA damage or 
by attracting circulating endogenous progenitor cells, thereby further contributing to 
tissue repair [238]. Overall, we concluded that musculoskeletal stem cells derived from 
various sources posses a huge capacity for application in regenerative medicine. Better 
characterization of musculoskeletal stem cells and more knowledge about lineage dif-
ferentiation is required to fully understand the potential of each individual source of cells 
for each of the different applications. In this respect, not only differentiation into mature 
tissue cells, but also the secretion of trophic factors and the influence of host microen-
vironment on cell fate and function deserve more study. By far, the most knowledge has 
been gathered concerning bone marrow-derived MSCs. These cells have already been 






fects. Since one of the main aims of this thesis was to direct our studies towards clinical 
translation, this is the cell-type we chose for our further research.
Various pre-clinical and some initial clinical studies have already been performed apply-
ing intra-articularly injected MSCs to OA joints [54,55,237]. Animal studies have shown 
beneficial effects of MSCs on cartilage morphology and histology in various OA models 
[47,54,55]. Interestingly, studies using cell tracking in cartilage repair show only limited 
cartilage formation by chondrogenic differentiation of the injected MSCs [54,55]. In-
stead, the applied cells are mostly retrieved from other articular structures, such as the 
synovium. Apparently, the intra-articularly injected MSCs only occasionally differentiate 
into chondrocytes to actively produce extracellular matrix. This implies a different OA 
modifying mechanism, such as the previously mentioned paracrine effects of MSCs 
by secreting bioactive factors. Paracrine effects of MSCs have already been demon-
strated in other applications including cardiovascular regenerative medicine and organ 
transplantation. In these fields, factors secreted by MSCs have been shown to increase 
ventricular function after ischemic myocardial injury and to reduce the occurence and 
severeness of graft versus host disease, respectively [414,415]. Whether factors se-
creted by MSCs are also capable of influencing osteoarthritic environments was not 
known. Therefore, in chapter 4, we studied the influence of MSC-derived factors on 
OA cartilage and synovial explants in vitro. We prepared MSC-conditioned medium 
by stimulating primary human MSCs, to secrete bioactive factors, with tumor necrosis 
factor alpha (TNFγ) and interferon gamma (IFNγ). The stimulated MSCs produced IL-
6, hepatocyte growth factor (HGF), tissue inhibitor of MMP (TIMP)2 and transforming 
growth factor beta (TGFγ)-1 and displayed a high enzymatic indoleamine 2,3-dioxy-
genase (IDO) activity. IDO is an immunomodulatory enzyme with an anti-inflammatory 
function. Selection of this panel of factors as study targets was based on the fact that 
they are known to be secreted by MSCs at high levels and their known involvement in 
general inflammation processes or joint metabolism [250,252]. Synovial explants ex-
posed to MSC-conditioned medium showed decreased expression of the inflammation- 
or matrix degradation-related genes interleukin-1 beta (IL-1γ), matrix metalloproteinase 
(MMP)1 and MMP13. On the other hand, the anti-inflammation-related gene suppressor 
of cytokine signalling (SOCS)1 was upregulated. In cartilage, expression of the anti-
inflammation-related gene IL-1 receptor antagonist (IL-1RA) was upregulated. IL-1RA is 
a competitive non-functional binder to the IL-1 receptor and is already clinically used as 
a drug (Anakinra) to treat rheumatoid arthritis [416]. In addition, genes related to matrix 
degradation (ADAMTS5) as well as matrix formation (COL2A1) were downregulated. 
Additionally, MSC-conditioned medium reduced nitric oxide (NO) production in cartilage 
explants and the presence of the inhibitor of nuclear factor kappa B alpha (IκBa) was 
increased in synoviocytes and chondrocytes treated with MSC-conditioned medium. 
IκBa is the protein inhibiting the activation of NFkB, a protein family controlling apopto-
sis, inflammation and other immune responses. Based on these results, we concluded 

















inflammatory effects and influence genes involved in matrix turnover in OA synovium 
and cartilage explants. 
A limitation of our study, as in our PRP studies, was the use of a short term in vitro 
culture model to evaluate the paracrine effects of MSCs. We did use a more complex in 
vitro model than the one used in chapter 2 by performing experiments on cartilage and 
synovium as well as a pilot experiment where we combined both tissues in the same 
model. In this way, we resembled more closely the in vivo situation. Nevertheless, further 
in vivo studies are needed to demonstrate the efficacy of MSC injection as a treatment 
for OA. Next to the use of an in vitro model, another limitation of our study was the need 
to stimulate MSCs with supra-physiological concentrations of inflammatory factors in 
order to initiate an immunomodulatory function. Whether the level of inflammatory and 
catabolic factors in OA joints in-vivo is sufficient to elicit a regenerative response in 
MSCs remains to be elucidated, although we recently investigated in-vitro effects of 
bioactive factors in synovial fluid of OA patients on MSC immunomodulation. In this 
study, we found that synovial fluid upregulated the expression of genes in MSCs with 
an anti-inflammatory function and that synovial fluid stimulated MSCs to condition me-
dium in a way that suppressed lymphocyte proliferation in vitro [417]. MSC-conditioned 
medium undoubtedly contained many more factors than the ones we have measured in 
chapter 4. The whole panel of bio-active factors probably worked in concert to achieve 
the anti-osteoarthritic effects observed in this study. Several anti-inflammatory effects 
could be caused by the direct secretion of anti-inflammatory factors by MSCs, or by 
their influence on macrophages and the subsequent effect on their secretion of immu-
nomodulatory factors [418]. Next to these MSC-secreted bioactive factors, it has more 
recently been shown that the regenerative potential of MSCs might be related to cellular 
transfer of mitochondria and other cytosolic elements [419,420]. The anti-osteoarthritic 
effect of this aspect has to be further studied using different in-vitro models. Since we 
observed clear paracrine effects of MSCs and given that intra-articularly injected MSCs 
have been shown to survive in an intra-articular environment for up to at least four to 
six weeks [54,55], we believe that they could provide the ultimate long term delivery of 
a cocktail of OA modifying elements.
As a next step, we studied the effects of intra-articularly injected bone marrow-derived 
cells in a rat OA model in chapter 5. Since OA is a complex disease consisting of many 
features, we evaluated effects of cellular therapies on pain, cartilage structure and bone 
alterations as well as inflammation. We used intra-articular injection of monoiodoac-
etate (MIA) as an OA model. With the aim to maximize the options for clinical trans-
lation, we evaluated the efficacy of different cell-types. Firstly, rat MSCs were used 
as a species specific treatment to maximize crosstalk via soluble factors or cell-cell 
contact and to prevent immunogenic reactions as much as possible. Secondly, human 
MSCs derived from OA patient were injected in OA induced rat knees to evaluate the 






MSCs would be immune-privileged and therefore would not cause an inflammatory 
reaction and retain their immunomodulatory capacities [291]. Finally, freshly isolated rat 
bone marrow mononuclear cells were used as a one-step treatment for OA. This is a 
cell fraction which contains approximately 0.001% MSCs and other progenitor cells as 
well [276,421]. This cell fraction could have a high regenerative potential, and makes 
extensive culture procedures, which are necessary to obtain MSCs, unnecessary. All 
therapies were well tolerated by the animals without any external signs of inflammation, 
such as swelling or erythema. Animals treated with rat MSCs distributed significantly 
more weight to the affected limb after treatment than before treatment, indicating a 
decreased pain sensation. None of the other treatments significantly affected weight 
distribution to the affected limb. Regarding structural changes in the joint, MIA injected 
knees had significant cartilage damage and subchondral bone alterations compared to 
contralateral control knees. Rats treated with rat MSCs displayed the least MIA induced 
changes, albeit no statistically significant differences between treatment groups were 
observed. Rat MSCs and human MSCs induced a trend towards increased synovial 
inflammation. The treatments applied in this study resulted in some slight therapeutic 
effects. Although rat MSCs were able to reduce pain sensation compared to pre-treat-
ment animals, no statistically significant difference was observed compared to saline 
treated animals. This absence of significance could have been, at least partly, due to 
a lack of power or the OA model we used. Other groups, on the other hand, do report 
positive effects of intra-articularly injected MSCs on cartilage quality and other outcome 
parameters using different OA models, like meniscus resection or cruciate ligament 
transection [47,55,57]. The results of these studies indicated an indirect protective ef-
fect of the MSCs and did not point towards actual regeneration of cartilage. The fact 
that we used an OA model consisting of direct chemical cartilage damage, without me-
chanical joint instability, could explain the modest effects of our cellular treatments. This 
is in accordance with Frisbie et al., who found no effect of MSCs on cartilage quality in 
a horse osteochondral defect OA model [49]. In addition, Matsumoto et al. found just 
a trend towards improved cartilage quality after injection of muscle-derived stem cells 
(MDSCs) in a rat MIA OA model [54]. The effects of MDSCs became only clear after 
they were transduced with bone morphogenetic protein 4, which is involved in bone and 
cartilage development, and sFlt-1, a vascular endothelial growth factor antagonist. OA 
models like intra-articular MIA injection affect the entire joint without applying mechani-
cal instability, in that way resembling the majority of clinical OA patients. The fact that 
in such models repeatedly very modest effects of stem cell therapies are reported, and 
that the effects are increased after genetic cell manipulation, indicates that further op-
timization is required before the introduction of large scale clinical application. The lack 
of clear effects in our study could have had other reasons as well, including, the mild 
degree of inflammation upon MSC injection or the fact that we used non-autologous 
cells. We concluded that additional studies are warranted, with a focus on cell tracking, 

















Since a better understanding of the fate of the cells after intra-articular injection provides 
better insight in their regenerative role, and thereby options to increase their efficacy, 
we continued our studies by adapting a cell tracking method based on MRI for intra-
articular use. To permit possible future clinical studies using this technique, we aimed at 
setting-up a clinically applicable cell tracking method. Cell labeling with superparamag-
netic iron oxides (SPIOs) allows cell tracking using magnetic resonance imaging (MRI) 
[422]. SPIO particles influence a magnetic field, thereby generating signal voids on MR 
images. Once SPIOs are endocytosed by cells, these cells can be detected by MRI. 
The use of SPIOs enables cell labeling using only clinically applied substances and this 
technique has already entered the clinical arena in experimental settings in other fields 
[62,63,64,316]. In chapter 6 we compared two SPIOs, ferumoxides and ferucarbotran, 
for cell labeling. To label non-phagocytic cells with ferumoxides, the particles need to 
be complexed with a transfection agent like protamine sulfate, which is clinically applied 
as heparin antidote [303]. Ferucarbotran does not need to be complexed prior to cell 
labeling [298]. For clinical application, an effectively and specifically labeled cell prepa-
ration is highly desired. This means that labeled cells should contain a high amount of 
intracellular SPIO and a negligible amount of extracellular SPIO. We tested both SPIOs 
not only on MSCs but also on chondrocytes, since both cell-types are being used in 
cartilage regenerative medicine [216,423]. Cell labeling using ferumoxides-protamine 
sulfate resulted in higher labeling efficiencies and a higher iron load per cell for both 
cell types, as compared to ferucarbotran. Furthermore, ferumoxides-protamine sulfate 
labeling caused a lower amount of extracellular iron attached to the cell membranes. 
Therefore, we considered labeling with ferumoxides-protamine sulfate the superior ap-
proach to develop into a clinically applicable cell-tracking method.
We further evaluated this method by determining several aspects regarding safety and 
MRI traceability in chapter 7 in order to fine-tune this technique for in-vivo use in an 
intra-articular environment. We studied SPIO for labeling MSCs regarding effectivity, cell 
viability, long term metabolic cell activity, chondrogenic differentiation and MSC secre-
tion profile. We additionally examined the capacity of synovial cells to endocytose SPIO 
from dead, labeled cells, together with the use of magnetic resonance imaging (MRI) 
for intra-articular visualization and quantification of SPIO labeled cells. SPIO labeling 
was effective and did not impair any of the studied safety aspects, including MSC se-
cretion profile. SPIO from dead, labeled cells could be taken up by synovial cells. This 
implicates, since SPIO from originally labeled cells can be taken up by other cells, that 
labeled cells as visualized by MRI do not necessarily indicate originally labeled cells. 
Therefore, prior to clinical application we recommended in vivo animal studies using in-
tra-articular cell tracking by MRI in combination with another tracer to localize originally 
labeled cells. This would enable the correct interpretation of obtained MR images. Intra-
articular SPIO-labeled cells could accurately be visualized by MRI in a clinically relevant 
sized joint model using clinically applied cell doses. This was determined for injected 






regenerative medicine [58,423]. In the latter approach, chondrocytes or MSCs are di-
rectly placed in a cartilage defect in order to locally generate extracellular, cartilage-like 
matrix. Finally, for the local implantation approach we were able to quantify different 
amounts of labeled cells implanted in cartilage defects using MR-based relaxometry. 
Based on these results we concluded that SPIO labeling appears to be safe without 
influencing cell behavior. SPIO labeled cells can be visualized in an intra-articular envi-
ronment and quantified when seeded in cartilage defects. In an experimental setting this 
would show the distribution and diffusion of the applied cells, thereby elucidating the 
regenerative mechanisms and providing opportunities to improve current repair strate-
gies. Several techniques using MRI have been developed to evaluate cartilage structure 
and quality [424,425]. The use of MRI has the advantage of simultaneous cell tracking 
and evaluation of cartilage regeneration in one MRI session.
Since limited cell survival might be one of the aspects compromising long term effects 
of cell therapies, we studied a method to increase their longevity after application. In 
chapter 8 we encapsulated MSCs in alginate beads, enabling a long-lasting interplay 
between MSCs and their environment in the diseased joint. This interplay is necessary 
to initiate the regenerative function of MSCs, since MSCs need to be stimulated in order 
to exert their immunomodulatory role [242,243]. Once stimulated, MSCs are able to 
modulate chronic disease processes and structurally modify the pathophysiologic vi-
cious circle in OA. The alginate beads are permeable to small soluble factors as secret-
ed by MSCs and diseased tissues, yet they can protect MSCs from hostile interactions 
with the immune system by providing a physical barrier for invasion of host immune cells 
[426]. Next to this, the alginate will prevent escape of the MSCs from the intra-articular 
space as well as cell mortality due to non-adherence after application in the joint. We 
found that MSCs encapsulated in beads maintained their immunomodulatory properties 
and responded to inflammatory stimuli during 30 days of culture in vitro. However, we 
appeared to lose slightly more than half of the cells over time and the remaining cells 
had a reduced capacity to differentiate into the osteogenic and adipogenic lineages. 
We consider the diminished differentiation capacities of relatively low importance, since 
we regard their immunomodulatory capacity of more importance for their regenerative 
role and this is not dependent on their differentiation potential. This could even be an 
advantage, reducing the risk of osteochondral differentiation and thereby the formation 
of small cartilage fragments, known as loose bodies, in the joint. Nevertheless, size of 
the beads, concentration and type of alginate and BMSCs concentration need to be 
further optimized. These aspects are important in the survival, proliferative capacities 
and release profile of the BMSCs in terms of cellular interaction and diffusion proper-
ties of cellular nutrients as well as secretions [401,407]. Our data indicated that MSCs 
embedded in alginate beads may act as a continuous immunomodulatory or trophic 
factor release system for several weeks, making this a promising approach towards a 

















Concluding, in this thesis we demonstrated that biological treatments, by means of 
bioactive factors or cell therapies, may provide a promising future alternative for the 
symptomatic treatments currently available for OA. We found that bioactive factors 
concentrated from blood (PRP), as well as factors secreted by MSCs, have beneficial 
effects on various osteoarthritic processes in vitro. The use of MSCs has the potential 
advantage of providing a more durable treatment than the use of PRP, since MSCs are 
able to secrete bioactive factors for a longer period of time. Next to this, MSCs are 
locally present in multiple joint tissues [267] and are able to react to the joint environ-
ment, as shown by the increased presence of MSCs in synovium and synovial fluid after 
joint injury [45,46]. This suggests that the increased intra-articular presence of MSCs is 
part of a natural healing process. The administration of MSCs in an osteoarthritic joint 
could be a therapy for OA mimicking and enhancing this natural healing process and 
thereby provide a natural and autologous treatment for OA. At this moment, merely 
injecting MSCs into osteoarthritic joints shows promising, yet modest effects on pain 
and structural outcome measures. Further studies are warranted to further optimize 
these treatments. Cell-tracking is a crucial tool to elucidate the regenerative mecha-
nisms and provide insight into cell distribution and survival. Cell tracking of SPIO labeled 
cells using MRI allows accurate cell visualization with a high spatial resolution and in 
some circumstances even quantification of applied cells. These tracking tools enable 
additional improvement and optimization of current cell therapies. Encapsulating the 
cells in alginate beads could improve their intra-articular longevity after application, al-
lowing modification of osteoarthritic processes for a longer period of time. This would 











Future studies based on this thesis can be roughly divided into three (interconnected) 
aspects: 1) optimizing cell tracking techniques and thereby generating better insight in 
the relevant anti-osteoarthritic working mechanisms; 2) improving monitoring of various 
osteoarthritic processes to evaluate therapeutic efficacy, and 3) using this knowledge of 
cell function and osteoarthritic processes to further optimize the efficacy of the therapy 
and to develop new therapies. These components will be addressed hereafter.
Cell tracking
MRI is a great modality for high-resolution intra-articular cell tracking. Unfortunately, 
SPIO label is not necessarily associated with living cells, since it remains present after 
cells have died [322]. Cell tracking using a dual imaging technique, for instance optical 
imaging together with MRI, allows high resolution visualization of cells in combination 
with quantification of viable cells. For this purpose MSCs can be transduced with a 
luciferase gene construct [427]. Luciferase acts as a reporter in living cells and can 
be detected with bioluminescence imaging techniques. Activation of its substrate D-
luciferin requires the presence of ATP [428], which is only produced in living cells. The 
signal emitted is proportional to the number of living cells [429]. We already performed 
a pilot experiment using this combined technique of optical imaging with MRI, which 
indicated that cell number decreases significantly within two weeks after injection in the 
joint. These experiments should be further extended to see if cell survival is related to, 
for instance, inflammation or other micro environmental circumstances. It could even be 
the case that, in line with other reports, MSCs locally reside in a quiescent state after 
inflammation diminishes, but become active and proliferate once a new episode of in-
flammation occurs [137]. Certain imaging markers could even be linked to a particular 
gene of interest [430], which could teach us whether cells have a merely anabolic role 
via the secretion of growth factors, an anti-catabolic role via the secretion of factors 
counteracting degradative enzymes, or more an anti-inflammatory function by the se-
cretion of anti-inflammatory factors. Likely, different roles are being played at different 
stages of the disease and by different subsets of MSCs. Visualizing this complicated but 
finely tuned interplay would give true insight into cell activity over time. 
Osteoarthritis monitoring
Since OA is a multifactorial disease consisting of many simultaneous processes, as-
sessment of the effect of cellular therapies on structural joint aspects, joint inflamma-
tion as well as pain in various animal OA models and after application in early and later 
















Structural cartilage changes can be determined by micro computed tomography (µCT) 
or MRI. Techniques based on the diffusion of a contrast agent into cartilage have been 
developed, which can be used to visualize the amount of proteoglycans present in the 
cartilage. For small animals µCT arthography can be used and for humans delayed 
gadolinium enhanced MRI of cartilage (dGEMRIC) [279,424]. The amount of proteogly-
cans is an indicator of structural cartilage quality and thereby a good outcome measure 
for therapeutic efficacy. CT can also be used to evaluate subchondral bone changes in 
terms of sclerosis, porosity and osteophyte formation [431]. Regarding MRI, new se-
quences are being developed to visualize structural cartilage characteristics without the 
need for applying a contrast agent, thereby further reducing the exposure of patients to 
potentially harmful interventions [425,432].
Synovitis is another OA aspect which can be evaluated using MRI [433]. For this ap-
plication, new sequences are being developed that could make use of a contrast agent 
redundant as well. Macrophage activity can more specifically be used as a measure of 
inflammation and can be visualized and quantified using probes for positron emission 
tomography (PET), single photon emission computed tomography (SPECT) or optical 
imaging [434]. This can be used to evaluate the effect of inflammation on applied MSCs, 
as well as the subsequent effect of MSCs on inflammation. In addition, histological 
techniques can be used to verify these data and to further distinguish between mac-
rophage subtypes [268]. Currently, macrophages are broadly classified into two main 
groups designated M1 and M2. In short, M1 macrophages represent pro-inflammatory 
cells, whereas M2 macrophages have a more regenerative and immune modulatory 
role. As mentioned before, MSCs are able to influence macrophage subtype differentia-
tion [418].  The distinction between macrophage subtypes can be used to gain further 
insight into the effect of MSCs on joint inflammation. Next to these imaging options, 
various techniques, like enzyme-linked immunosorbent assay (ELISA) or cytometric 
bead array (CBA) based on flow cytometry, exist to measure different cytokines. These 
cytokines can be determined in blood or in synovial fluid, giving further insight in inflam-
matory processes.
Pain can be measured using several methods and is a complicated phenomenon con-
sisting of inflammatory and neuropathic aspects [287,288]. The effect of MSC therapy 
on pain or other clinical outcome measures are difficult to assess in animal OA studies, 
and therefore they are not extensively documented. Nevertheless, pain is the most im-
portant clinical outcome measure and it is known that pain is not clinically associated 
with cartilage damage [435], although correlations between pain levels and the amount 
of synovitis and intra-articular cytokine levels have been demonstrated [436]. Further 
evaluation of multiple pain aspects, including weight bearing, mechanical allodynia and 








Finally, sensitive markers for MSCs or other progenitor cells would allow (histological) 
detection of endogenous repair cells who could also account for various regenerative 
processes [437]. If a large part of the regenerative capacities of MSCs is based on the 
activation of endogenous cells, this knowledge can be used to enhance this feature 
by, for instance, selection of MSC-subtypes. Another option is to determine the factor 
responsible for endogenous repair cell recruitment and activation [221] and integrate or 
add this factor to cellular therapies.
Therapeutic efficacy
To increase therapeutic efficacy various adjustments can be made. Since MSCs com-
prise a heterogeneous cell population, cell selection techniques can be developed to 
isolate the subpopulation with the greatest regenerative potential [438]. This has to 
be based on insight into their specific mode of regenerative action. Potentially, this 
can be combined with a form of pre-treatment of cells prior to application, to ensure 
that they are optimally instructed to fulfil their regenerative action [439]. This could be 
performed by pre-treatment with bioactive factors [439] or even genetic modifications 
[54], although the latter implies many extra hurdles for clinical application. Other adjust-
ments include the timing and mode of application. It could be that injecting a low dose 
of cells for multiple times has advantages over a single injection of a high cell dose for 
instance. Regarding the mode of application many adaptations can be made, including 
the encapsulation of MSCs in alginate beads to improve the survival and retention time 
of cells in the joint, enabling a durable modification of multiple osteoarthritic processes 
by MSCs [426]. Of course, the specific encapsulation material can be endlessly varied, 
and must be tailored to the specific anti-osteoarthritic actions of MSCs.
Beyond cell-based therapies 
As argued before, MSC injection into damaged joints is an approach mimicking and 
enhancing natural repair mechanisms [46]. Nevertheless, if we assume that this repair 
mechanism is not based on the formation of new tissue by differentiated MSCs but by 
the secretion of trophic factors, identification of the responsible factors must be achiev-
able. By exactly finding out what cells secrete at what time point and by what this is 
triggered, we could mimic this process without the need for actual cell application. A 
future perspective could then be to isolate and combine the relevant bioactive factors, 
enabling the production of a so-called anti-osteoarthritic cocktail. Maybe a few different 
cocktails are needed depending on the stage of the disease or certain patient-specific 
















of bioactive factors they can be incorporated in various available slow-release systems 
[440]. The effect might not last as long as actual cell therapy, but due to the off-the-
shelf nature of this approach the treatment could be repeated once cost-effectiveness 
has been established. A disadvantage of this approach is the fact that this therapy will 
inevitably be less tailored than individual autologous cell therapy, but it has the huge ad-
vantages of standardization of the medicinal product (and thereby the expected effects) 
and a much higher chance of broad clinical application in terms of safety, availability 
and costs. Furthermore, the relevant factors could be applied in a supra-physiological 
concentration if desired. At the same time, MSC-secreted factors with a known nega-
tive effect on cartilage, like VEGF for instance [441], could be specifically excluded from 
the cocktail. This way, we could develop biological cell therapy through understanding 
of cellular mechanisms and isolation of the beneficial bioactive factors to evolve into the 

















Richting celtherapie als behandeling voor artrose
Artrose is een veel voorkomende degeneratieve gewrichtsaandoening en wordt geken-
merkt door een catabool en inflammatoir gewrichtsmilieu. Het gehele gewricht speelt 
een rol bij artrose, waaronder het kraakbeen, synovium en het subchondrale bot. Tot op 
heden zijn alleen symptomatische behandelingen beschikbaar voor artrose, zoals pijn-
medicatie, fysiotherapie en levensstijl veranderingen zoals gewichtsverlies. Deze behan-
delingen zijn niet in staat om artrose te genezen en kunnen daarmee geen langdurige 
oplossing brengen. Als deze conservatieve methoden falen, is de definitieve behande-
ling een gewrichtsvervangende operatie. Helaas hebben de gebruikte protheses een 
beperkte levensduur van 10 à 15 jaar, en zijn dus ook niet in staat om een permanente 
oplossing te vormen voor artrose, vooral bij jonge paitenten. In dit proefschrift heben we 
het werkingsmechanisme en de effectiviteit onderzocht van twee biologische therapieen 
en hun capaciteit om artrotische processen te veranderen om daarmee de ziektever-
schijnselen te voorkomen of verminderen. Hiertoe hebben we als eerste therapie plaat-
jes-rijk plasma (PRP) onderzocht. De bloedplaatjes in PRP zijn kleine celfragmenten die 
van megakaryocyten komen. Deze plaatjes kunnen worden geïsoleerd uit bloed door 
middel van centrifugatie en vervolgens worden gestimuleerd om bioactieve factoren uit 
te scheiden. Als tweede optie hebben wij mesenchymale stamcellen uit het beenmerg 
onderzocht. Stamcellen komen in meerdere weefsels voor en spelen een belangrijke 
rol bij natuurlijke homeostase en regeneratie van weefsels. Zij zijn in staat om nieuw 
weefsel te vormen en ook om allerlei factoren uit te scheiden die de lokale omgeving 
beïnvloeden. Onze hypothese bij deze biologische behandelopties was dat door het 
stimuleren van de patient zijn eigen herstel mechanismen, het mogelijk zou zijn om de 
vicieuze degeneratieve cirkel van artrotische processen te doorbreken.
In hoofdstuk 2 hebben we de capaciteit onderzocht van factoren uit PRP om de ef-
fecten van ontsteking op humane artrotische chondrocyten te verminderen. De factoren 
uit PRP waren in staat om de effecten van interleukine-1 beta, een ontstekingsfactor, 
te verminderen op genen gerelateerd aan ontsteking en de opbouw en afbraak van 
kraakbeenmatrix. De factoren uit PRP verminderden de activatie van nucleaire factor 
kappa B, dit zou een mogelijke route kunnen zijn via welke deze factoren hun effecten 
teweeg brengen. Deze studie toonde aan dat een combinatie van bioactieve factoren in 
staat was om pathologische processen in artrotische chondrocyten te veranderen. Een 
beperking van deze mogelijke therapie is het feit dat geinjecteerde stoffen slechts een 
beperkte tijd in de knie aanwezig blijven. Aangezien mesenchymale stamcellen in staat 
zijn om langdurig een breed scala aan bioactieve factoren uit te scheiden, hebben we 













Friedenstein en zijn collega’s hebben als eerste kolonie-vormende cellen beschreven die 
verkregen werden uit beenmerg. Later werden deze cellen tot mesenchymale stamcel-
len (MSCs) benoemd door Caplan en zijn collega’s. In hoofdstuk 3 geven we een lite-
ratuuroverzicht van de karakteristieken van de natuurlijk aanwezige voorlopercellen of 
stamcellen in verschillende weefsels in het gewricht, waaronder het gewrichtsvlies, vet-
weefsel, de pezen, spieren en het bot. Over het algemeen tonen de cellen verkregen uit 
deze verschillende weefsels minimale verschillen, en zijn ze heel vergelijkbaar met stam-
cellen uit het beenmerg wat betreft proliferatie- en differentiatie capaciteiten. Aangezien 
verreweg de meeste kennis en ervaring is verkregen met betrekking tot stamcellen uit 
het beenmerg, is dit het celtype waar we ons verdere onderzoek mee hebben verricht. 
Dit om de eventuele klinische translatie van ons onderzoek zo eenvoudig mogelijk te 
houden. Vanaf nu zullen wij aan deze cellen refereren als MSCs. 
De regeneratieve capaciteit van MSCs is op zijn minst gebaseerd op twee aspecten. 
Ten eerste hebben ze de capaciteit om te differentiëren naar volwassen weefselcel, bij-
voorbeeld een kraakbeencel, om zo nieuwe (kraakbeen)matrix te vormen. Een tweede 
aspect is het feit dat ze een breed scala aan groei- en immunomodulatoire factoren 
kunnen uitscheiden, een paracriene functie die het lokale micro-milieu kan beïnvloeden. 
Eerdere dierstudies die gebruik maken van technieken om MSCs te vervolgen in een be-
schadigd gewricht laten zien dat de MSCs maar beperkt chondrogeen differentiëren en 
nieuwe kraakbeenmatrix vormen. Vanwege die reden hebben wij in hoofdstuk 4 onder-
zocht in hoeverre de paracriene effecten van MSCs een rol spelen bij het beïnvloeden 
van artrotische processen in kraakbeen en synovium. Het gewrichtsvlies, (synovium) 
speelt met name een belangrijke rol in bij ontsteking van een gewricht. Het bleek dat 
de groei- en immunomodulatoire factoren die worden uitgescheiden door MSCs, an-
ti-inflammatoire en anti-catabole effecten hebben op genexpressie niveau in artrotisch 
synovium. In artrotisch kraakbeen werden anti-inflammatoire effecten gezien op genex-
pressie niveau alsmede een remming van opbouw en afbraak van kraakbeen matrix. 
Ook met andere assays werden anti-inflammatoire effecten gezien, met remming van 
nucleaire factor kappa B activatie als een mogelijk werkingsmechanisme. Gebaseerd 
op deze resultaten hebben we geconcludeerd dat MSCs in staat zijn om factoren uit te 
scheiden die meerdere anti-inflammatoire effecten hebben en genen beïnvloeden die 
zijn betrokken bij matrix opbouw en –afbraak in artrotisch synovium en kraakbeen. Ge-
zien het feit dat MSCs ten minste zes weken kunnen overleven in een gewricht, zouden 
zij de ultieme therapie kunnen zijn die voor een langere termijn artrotische processen 
kan beinvloeden.
Als volgende stap hebben we in hoofdstuk 5 de effecten bestudeerd van verschil-
lende celtypen, verkregen uit het beenmerg, op een model voor artrose in ratten. We 
hebben gekeken naar de effecten op pijn, kraakbeen- en botstructuur en ontsteking. 
Als celtypen hebben we ratten MSCs gebruikt, humane MSCs (om de klinische trans-







laatste met als doel om te onderzoeken of het kweken van cellen overbodig zou kunnen 
worden waardoor translatie naar de kliniek makkelijker zou zijn. Wij zagen dat, na het 
induceren van artrose, dieren die met ratten MSCs werden behandeld meer gewicht op 
hun aangedane poot zetten na behandeling met celinjectie dan ervoor. Dit is indicatief 
voor een verminderde pijn sensatie na behandeling. In de overige groepen en de con-
trole groep werd dit effect niet gezien. Wij zagen geen effecten van enige behandeling 
op kraakbeenschade, subchondraal bot of ontsteking in het gewricht. Op basis van 
deze resultaten hebben wij gekozen om verder onderzoek te doen naar het labelen 
en vervolgen van cellen om meer inzicht te krijgen in hun functie in het gewricht en zo 
mogelijk hun effectiviteit te vergroten.
Met het doel om meer inzicht te krijgen in celfunctie en lokalisatie in het gewricht heb-
ben we onze studies gecontinueerd door een cel volg-methode gebaseerd op MRI, 
geschikt te maken voor intra-articulair gebruik. Wederom met het oog op klinische 
translatie hebben we gekozen voor een methode door middel van cel labeling met 
superparamagnetisch ijzer oxide (SPIO), een methode die reeds experimenteel in de 
kliniek gebruikt wordt in andere vakgebieden. In hoofdstuk 6 hebben we twee SPIOs 
vergeleken, ferumoxides en ferucarbotran, voor het intracellulair labelen van cellen. Het 
bleek dat ferumoxides, in combinatie met protamine als transfectie mediator, leidde 
tot meer intracellulair en minder extracellulair SPIO. Deze methode hebben wij dus het 
meest geschikt bevonden om cellen te labelen en te vervolgen in het gewricht, gezien 
het feit dat dit de hoogste betrouwbaarheid geeft dat de signalen gezien op MRI daad-
werkelijk overeenkomen met gelabelde cellen.
Deze methode hebben we verder ontwikkeld door verschillende aspecten te onderzoe-
ken met betrekking tot effectiviteit, veiligheid en visualiseerbaarheid door MRI in hoofd-
stuk 7. Onze studies lieten geen nadelige effecten zien van de labeling methode op 
levensvatbaarheid van de MSCs, hun chondrogene differentiatie en de uitgescheidde 
groei- en immunomodulatoire factoren. SPIO uit dode, gelabelde cellen kon worden op-
genomen door synovium, wat betekent dat gelabelde cellen die worden gevisualiseerd 
door MRI niet automatisch origineel gelabelde cellen zijn. Wij hebben daarom gead-
viseerd om eerst dierstudies te verrichten met een dubbele labeling techniek om het 
MRI signaal te kunnen valideren. Intra-articulair ingebrachte cellen gelabeld met SPIO 
konden adequaat gevisualiseerd worden met de MRI. Wanneer de cellen geimplanteerd 
werden in een lokaal kraakbeendefect was het mogelijk om verschillende hoeveelheden 
cellen te quantificeren. Gebaseerd op deze resultaten hebben wij geconcludeerd dat 
cellabeling met SPIO veilig is, dat de cellen intra-articulair gevisualiseerd kunnen worden 
als zij in het gewricht worden geïnjecteerd en gekwantificeerd als zij worden geïmplan-
teerd in een lokaal kraakbeendefect. De MRI heeft als voordeel dat tegelijkertijd eventu-













Aangezien beperkte cel overleving één van de aspecten is die de lange termijn effecten 
van stamceltherapie kan verminderen, hebben we een methode bestudeerd om hun 
overleving intra-articulair te verbeteren. In hoofdstuk 8 hebben we MSCs in alginaat 
bolletjes ingesloten zodat zij beschermd zijn tegen cellen van het immuunsysteem, maar 
nog steeds hun bioactieve factoren kunnen uitscheiden. We zagen dat MSCs in deze 
alginaat bolletjes hun immunomodulatoire capaciteiten behielden gedurende ten minste 
30 dagen in vitro. Wel moeten er nog aspecten geoptimaliseerd worden, zoals alginaat- 
en MSC concentratie, alsmede de grootte van de bolletjes, om de continue uitscheiding 
van bioactieve factoren door MSCs te verbeteren.
Concluderend hebben we in dit proefschrift aangetoond dat biologische behandelingen, 
in de vorm van bioactieve factoren of celtherapie, een veelbelovend alternatief kan wor-
den voor de huidige symptomatische behandelingen die beschikbaar zijn voor artrose. 
We hebben ontdekt dat bioactieve factoren geisoleerd uit bloed (PRP), zowel als facto-
ren uitgescheiden door MSCs, positieve effecten hebben op verschillende artrotische 
processen in vitro. Het gebruik van MSCs heeft mogelijk als voordeel dat ze gedurende 
een langere periode factoren kunnen uitscheiden, en dus een langduriger artrose mo-
dulerend effect kunnen hebben. Door stamcellen in een artrotisch gewricht te injecteren 
in een proefdiermodel werden slechts bescheiden effecten gezien op pijn en structurele 
uitkomstmaten. Meer onderzoek is nodig om deze effecten te verbeteren. Het labelen 
en vervolgen van cellen met MRI is een methode die gebruikt kan worden om inzicht te 
krijgen in hun werkingsmechnisme, om zo de effectiviteit van stamceltherapie te vergro-
ten. Het insluiten van MSCs in alginaatbolletjes kan hun overleving in het gewricht ver-
groten en daarmee de duur van het therapeutische effect. Deze ontwikkelingen zouden 
intra-articulaire stamceltherapie kunnen maken tot een effectieve therapie die langdurig 
artrotische processen kan modificeren. 
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and voor alles’ manier van wetenschap bedrijven heeft mijn projecten en wetenschap-
pelijke vorming bijzonder positief beïnvloed.
Dr. M.R. Bernsen, beste Monique, ook jij bent als co-promotor bijzonder nauw betrok-
ken geweest bij mij onderzoek en de begeleiding daarvan. Je enthousiasme en inzicht 
tonen veel overeenkomsten met die van Gerjo, maar de werkwijze en een aantal per-
soonlijke kenmerken verschillen dag en nacht. Dit maakte jouw begeleiding voor mij 
bijzonder waardevol; jouw kritische schrijf-aanwijzingen hebben mijn publicaties zonder 
uitzondering flink verbeterd.
Dr. E. Farrell, dear Eric, you were my first daily supervisor, and probably the best I could 
have ever wished for. You taught me a massive amount of useful, and useless, stuff 
during my first year. At the same time, you are socially a tireless centipede, which really 
enlightened my presence in Rotterdam. You’re also responsible for probably the most 
efficient didactic moment during my PhD. After reading the first version of my first man-
uscript you did not bother to go into any detail but simply replied: “Cut every sentence 
in half and just make it better”.  I sincerely hope we will share a bright future in both a 
professional and personal way.  
Prof. Dr. J.A.N. Verhaar, beste professor, de manier waarop u kliniek en wetenschap 
met elkaar combineert heb ik altijd bewonderenswaardig gevonden. Dank voor uw be-
geleiding en de mogelijkheden die u me geboden heeft.
Prof. Dr. Krestin, dank voor uw ondersteuning en aanvullingen op mijn manuscripten. 







starten van mijn promotie heeft mij gedurende de rest van het traject enorme steun en 
vertrouwen gegeven.
Dr. P.K. Bos, beste Koen, jouw visie in klinische translatie is een belangrijke leidraad 
geweest voor de richting van mijn onderzoek. Dank voor je steun en je lange termijnvisie 
op de klinische toepassing van stamceltherapie in de orthopaedie.
Beste Nicole, Kopseflops, Opperdepop, etc. Jij bent zonder twijfel de collega in mijn 
leven waar ik de meeste bijnamen ooit voor heb bedacht. Ik denk dat dit een goede 
reflectie is voor jouw veelzijdigheid als persoon, alsmede de hoeveelheid aan verschillen 
in werkwijze die wij er op nahouden. Onze samenwerking werd exponentieel beter in 
die 4 jaar, en jouw klaterende lach was een verlichting op de werkvloer. Dank voor al het 
werk dat je voor me verzet hebt.
Beste Wendy, Sandra en Gaby, als analisten van de afdelingen orthopaedie en radiolo-
gie hebben jullie mij gedurende mijn gehele promotie geweldig ondersteund. Dank voor 
al jullie hulp en gezellige momenten.
Dear Gyula and Piotr, you were the brains behind the physical and technical part of 
the MR imaging in my thesis, which enabled me to perform cell-tracking at a level that 
would have been way out of my reach without you. Many thanks for your help and for 
sharing your knowledge with me.
Beste collega (onderzoeker)’s, beste Michiel, YBJ, Roberto, Erwin, Maarten, Joost, Jas-
per, Rintje, Sandra, Ruud, Olav, Tom, Anna, Wu, Femke, Robert-Jan, Marloes, Mieke, 
Nienke,  Johan, Job, Belle, Ton, en alle anderen, heel veel dank voor jullie samenwerk-
ing en gezelligheid.
Dirk en Stefan, mijn beide paranimfen. Jullie zijn beiden fantastische (assistent)ortho-
peden en hebben mij beiden in een ander gedeelte van de opleiding meegemaakt. Dirk 
tijdens mijn studie, Stefan tijdens deze promotie, beiden even waardevol. Zowel sociaal 
als qua professionele instelling denk ik dat wij drieën  een grote gelijkenis vertonen. 
Geweldig dat ik samen met jullie een vergelijkbare weg bewandel! Ik dank jullie bij voor-
baat voor de steun die jullie mij op dit toneel gaan bieden.
En dan mijn familie, lieve PaPaul, MaSylvia, grote broer Jasper, schoonzus Marie-Chris-
tine en aan de ander kant Paul, Roos, Marije, Rutger en Floor. Dank voor jullie steun 
en interesse. Jullie zijn een (schoon)familie waar enorm veel warmte van uit gaat en die 
altijd vol belangstelling naar mijn onderzoeksresultaten en avonturen hebben geluisterd. 
Pa en ma, jullie weten precies wat promoveren inhoudt. Jullie lichte verontwaardiging 
toen jullie erachter kwamen dat ik mijn eerste artikel niet ter correctie aan jullie had 
gestuurd alvorens het werd gepubliceerd vond ik schattig en geweldig tegelijk. Dank 
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voor alle support en steun die ik al mijn hele leven van jullie ontvang, dit proefschrift kan 
weer mooi op het “voor een kind niet slecht, ook al is het maar een arts” rijtje worden 
bijgeschreven.
Lieve Felien, als waarachtige Mini-Me vind ik je geweldig en fantastisch. De schuld aan 
je ouders betaal je terug aan je eigen kinderen, en in die geest heb je mij op weten-
schappelijk gebied ruimschoots de gelegenheid geboden om hieraan te voldoen. Ik hou 
van je, en hoop nog heel veel met je te gaan beleven.
Lieve Wendy, als een moderne ‘vrouw van de dokter’ heb jij jezelf gewoon lekker verd-
er ontwikkeld gedurende mijn promotie op zowel persoonlijk als professioneel gebied. 
Inmiddels bij jij zelfs ‘de baas’ geworden, iets wat ik nog niet kan zeggen. Je was altijd 
geïnteresseerd en ondersteunend  in mijn onderzoek, maar vond het heerlijk als ik op 
congres was om je eigen ritme er op na te kunnen houden. Dank voor al jouw liefde, je 











Gerben Matthijs van Buul werd geboren op 28 augustus 1982 te Leiderdorp. Hij werd 
grootgebracht in het waterrijke Woubrugge waar hij naar basisschool “Esselycker-
woude” ging. Hij vervolgde zijn opleiding op het Stedelijk Gymnasium Leiden, waar hij 
in 2000 cum laude zijn diploma behaalde. In datzelfde jaar ging hij geneeskunde stu-
deren in de domstad aan de Universiteit Utrecht. In 2003-2004 heeft hij een studievrij 
jaar gehad om zich in te zetten als praeses van de geneeskundige faculteitsvereniging 
MSFU “Sams”. Hierna zette hij zijn co-schappen voort en combineerde dit waar moge- 
lijk met zijn liefde voor reizen. Zijn co-schap kindergeneeskunde volgde hij in Mauritius 
en zijn co-schap gynaecologie in Aruba. In 2007 volbracht hij zijn semi-arts stage ge-
combineerd met wetenschappelijk onderzoek bij de afdeling orthopaedie van het UMC 
Utrecht onder leiding van prof. W.J.A. Dhert en prof. D.B. Saris. Hier werd de basis 
gelegd voor zijn interesse in basaal wetenschappelijk onderzoek met een translationele 
inslag. Dit vertaalde zich in de start van zijn promotie in 2008 aan de Erasumus Univer-
siteit in Rotterdam onder begeleiding van onder andere zijn promotoren prof. G.J.V.M. 
van Osch en prof. H. Weinans. In 2012 startte hij met zijn vooropleiding chirurgie in het 
Reinier de Graaf Gasthuis in Delft onder leiding van opleider Dr. M. van der Elst. In 2013 
is hij begonnen met zijn opleiding tot orthopaedisch chirurg die hij in het Erasmus MC 
Rotterdam en het Reinier de Graaf Gasthuis zal volgen. In 2010 is hij getrouwd met 
Wendy van Buul-Arah en samen hebben zij Felien als stralende dochter. 
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1. PhD training
Year Workload
General academic skills 
- Biomedical English Writing and Communication






- Literature meeting orthopedic lab





In-depth courses (e.g. Research school, Medical Training)
- 2nd Animal Imaging Workshop: Applied Molecular Imaging Erasmuc 
MC
- Laboratory Skills Course: International Cartilage Repair Society
- Statistics: introduction to data analysis: Erasmus MC
- Statistics: regression analysis: Erasmus MC











(Inter)national conferences: poster presentations
- Clinically applicable cell tracking using Super Paramagnetic Iron 
Oxides (SPIO), International Stem Cell Symposium: Amsterdam, the 
Netherlands 
- Cell labeling using Superparamagnetic Iron Oxide (SPIO) has no effect 
on chondrocyte behavior: implications for clinically applicable cell 
tracking using MRI , European Society of Molecular Imaging: Antalya, 
Turkey
- Clinically applicable hBMSC tracking in cartilage repair using MRIMSC 
in Solid Organ Transplantation: Rotterdam, the Netherlands
- Ferumoxides-protamine sulfate is more effective than ferucarbotran 
for cell labeling: implications for clinically applicable cell tracking using 
MRI, Osteoarthritis Research Society International: Montreal, Canada
- Cell labeling using Superparamagnetic Iron Oxide (SPIO) has no effect 
on chondrocyte behavior: implications for clinically applicable cell 












- Feasibility of superparamagnetic iron oxides for clinical intra-articular 
cell tracking, European Congress of Radiology: Vienna, Austria 
- Clinically applicable cell tracking by MRI in cartilage repair using 
Superparamagnetic Iron Oxide (SPIO), European Molecular Imaging 
Meeting, Warsaw, Poland. 
- Clinically applicable cell tracking in cartilage repair using MRI, Tissue 
Engineering & Regenerative Medicine International Society, Galway, 
Ireland. 
- Cell tracking for cartilage repair using Superparamagnetic Iron Oxides: 
clinical potential, Osteoarthritis Research Society International, 
Brussels, Belgium. 
- Clinically applicable cell tracking in cartilage repair using MRI, 
International Cartilage Repair Society, Barcelona, Spain. 
- Platelet Rich Plasma inhibits IL-1b induced catabolic processes in 
osteoarthritic chondrocytes, Orthopedic Research Society, Long 
Beach, USA. 
- Platelet-rich Plasma releaste inhibits catabolic processes in 
osteoarthritic chondrocytes, Molecular Medicine Day, Rotterdam, the 
Netherlands. 
- Platelet-Rich Plasma has anti-catabolic properties in Osteoarthritic 
Chondrocytes, Tissue Engineering & Regenerative Medicine 
International Society, Granada, Spain.
- Mesenchymal stem cells exert paracrine effects on osteoarthritic 
cartilage and synovium, Tissue Engineering & Regenerative Medicine 
International Society, Granada, Spain.
- Mesenchymal stem cells have anti-catabolic and anti-inflammatory 
effects on osteoarthritic cartilage and synovium, International Society 
for Cellular Therapy, Rotterdam, the Netherlands.  
- Clinical feasibility of cell tracking for cartilage repair using MRI, 
International Society for Cellular Therapy, Rotterdam, the Netherlands.
- Platelet-Rich Plasma has anti-inflammatory properties in Osteoarthritic 
Chondrocytes, Osteoarthritis Research Society International, San 
Diego, USA.
- Mesenchymal stem cell therapy in a monoiodoacetate induced rat 




























(Inter)national conferences: podium presentations
- Clinically applicable cell tracking using super paramagnetic iron oxides 




- Cell tracking using super paramagnetic iron oxides in cell therapy 
for cartilage regeneration, Term symposium: Egmond aan Zee, the 
Netherlands 
- Clinically relevant cell tracking using Superparamagnetic Iron Oxides 
has no effect on chondrocyte behaviour, International Cartilage Repair 
Society: Miami, USA 
- Ferumoxides-protamine sulfate is more effective than ferucarbotran 
for cell labeling: implications for clinically applicable cell tracking using 
MRI, European Society for Magnetic Resonance in Medicine and 
Biology: Barcelona, Spain 
- Clinically applicable cell tracking in cartilage repair using MRI, Molmed 
day: Rotterdam, the Netherlands 
- Clinically applicable cell tracking in cartilage repair; suitability of 
superparamagnetic iron oxide labeling, Orthopedic Research Society: 
New Orleans, USA 
- Clinically applicable cell tracking in cartilage repair using 
Superparamagnetic Iron Oxides (SPIO), Radiological Society of North 
America, Chicago, USA. 
- Clinically applicable cell tracking by MRI in cartilage repair, Biomedical 
Materials & Translational excellence in Regenerative Medicine Meeting, 
Ermelo, the Netherlands
- Mesenchymal stem cells exert paracrine effects on osteoarthritic 
cartilage and synovium, Osteoarthritis Research Society International, 
San Diego, USA.
- Mesenchymale stamcellen remmen ontstekingsprocessen en 
kraakbeen afbraak in artrotisch synovium en kraakbeen, Nederlandse 
Orthopedie Vereniging, the Hague, the Netherlands
- Mesenchymal stem cells exert paracrine effects on osteoarthritic 























- Cell tracking and quantification using SPIO in cartilage repair by MRI, 
Catholic Univerisity Leuven, Leuven, Belgium.  







- Cell tracking using super paramagnetic iron oxides in cell therapy 
for cartilage regeneration, Term symposium: Egmond aan Zee, the 
Netherlands 
- Clinically relevant cell tracking using Superparamagnetic Iron Oxides 
has no effect on chondrocyte behaviour, International Cartilage Repair 
Society: Miami, USA 
- Ferumoxides-protamine sulfate is more effective than ferucarbotran 
for cell labeling: implications for clinically applicable cell tracking using 
MRI, European Society for Magnetic Resonance in Medicine and 
Biology: Barcelona, Spain 
- Clinically applicable cell tracking in cartilage repair using MRI, Molmed 
day: Rotterdam, the Netherlands 
- Clinically applicable cell tracking in cartilage repair; suitability of 
superparamagnetic iron oxide labeling, Orthopedic Research Society: 
New Orleans, USA 
- Clinically applicable cell tracking in cartilage repair using 
Superparamagnetic Iron Oxides (SPIO), Radiological Society of North 
America, Chicago, USA. 
- Clinically applicable cell tracking by MRI in cartilage repair, Biomedical 
Materials & Translational excellence in Regenerative Medicine Meeting, 
Ermelo, the Netherlands
- Mesenchymal stem cells exert paracrine effects on osteoarthritic 
cartilage and synovium, Osteoarthritis Research Society International, 
San Diego, USA.
- Mesenchymale stamcellen remmen ontstekingsprocessen en 
kraakbeen afbraak in artrotisch synovium en kraakbeen, Nederlandse 
Orthopedie Vereniging, the Hague, the Netherlands
- Mesenchymal stem cells exert paracrine effects on osteoarthritic 























- Cell tracking and quantification using SPIO in cartilage repair by MRI, 
Catholic Univerisity Leuven, Leuven, Belgium.  








Supervising practicals and excursions
- Teaching cartilage/OA histology ’08 – ‘12 1.0
Supervising Master’s theses
- Supervising medical students (Jasper van de Slegt and Maarten Leijs) 
in scientific period
’09 & ‘11 8.0
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List of Publications 
Leijs MJ, van Buul GM, Lubberts E, Bos PK, Verhaar JA, Hoogduijn MJ, van Osch 
GJ. Effect of Arthritic Synovial Fluids on the Expression of Immunomodulatory Factors 
by Mesenchymal Stem Cells: An Explorative in vitro Study. Frontiers in Immunology 
2012;3:231. 
van Buul GM, Villafuertes E, Bos PK, Waarsing JH, Kops N, Narcisi R, Weinans H, Ver-
haar JA, Bernsen MR, van Osch GJ. Mesenchymal stem cells secrete factors that inhibit 
inflammatory processes in short-term osteoarthritic synovium and cartilage explant cul-
ture. Osteoarthritis and Cartilage 2012 Oct;20(10):1186-96. 
van Buul GM, Koevoet WL, Kops N, Bos PK, Verhaar JA, Weinans H, Bernsen MR, van 
Osch GJ. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic 
chondrocytes. American Journal of Sports Medicine. 2011 Nov;39(11):2362-70. 
van Buul GM, Kotek G, Wielopolski PA, Farrell E, Bos PK, Weinans H, Grohnert AU, Jahr 
H, Verhaar JA, Krestin GP, van Osch GJ, Bernsen MR. Clinically translatable cell track-
ing and quantification by MRI in cartilage repair using superparamagnetic iron oxides. 
PLoS One. 2011 Feb 23;6(2):e17001. 
van Buul GM, van Osch GJ. Musculoskeletal stem cells. Bookchapter in Regenerative 
Medicine: From Protocol to Patient. 1st edition, Springer 2011.
van Buul GM, Farrell E, Kops N, van Tiel ST, Bos PK, Weinans H, Krestin GP, van Osch 
GJ, Bernsen MR. Ferumoxides-protamine sulfate is more effective than ferucarbotran 
for cell labeling: implications for clinically applicable cell tracking using MRI. Contrast 
Media and Molecular Imaging. 2009 Sep-Oct;4(5):230-6. 
Van Buul GM, Oner FC. Thoracic spinal cord injury without radiographic abnormality in 
an adult patient. Spine Journal 2009 Mar;9(3):e5-8. 
van Tiel J, Reijman M, Bos PK, Hermans J, van Buul GM, Bron EE, Klein S, Verhaar JA, 
Krestin GP, Bierma-Zeinstra SM, Weinans H, Kotek G, Oei EH. Delayed gadolinium-en-
hanced MRI of cartilage (dGEMRIC) shows no change in cartilage structural composi-
tion after viscosupplementation in patients with early-stage knee osteoarthritis. Accept-
ed for publication in: PLoS One.
 van Buul GM, Siebelt M, Leijs MJ, Bos PK, Waarsing JH, Kops N, Weinans H, Verhaar 
JA, Bernsen MR, van Osch GJ. Effects of rat and human bone marrow derived cells on 












Villafuertes E, van Buul GM, Koevoet WL, Fernandez-Gutierrez B, Verhaar JA, Hoogdui-
jn MJ, van Osch GJ. Human bone marrow mesenchymal stem cells embedded in algi-
nate beads retain long-term immunomodulatory properties. Manuscript in preparation.
van der Werf R, van Buul GM, Smit H, Houston G, Leijs MJ, van Tiel ST, Doeswijk GN, 
van Osch GJ, Klein S, Bernsen MR, Kotek G.  Reproducible MR imaging method to 
monitor superparamagnetic iron oxide labeled cells in regions of low proton density at 
7T. Manuscript in preparation
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